INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67001, 'Citalopram', 'Paraldehyde', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67088/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67002, 'Citalopram', 'Paramethadione', 'Moderate', 'The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.', 'Antagonism', 'Oxitriptan, Bupropion, Viloxazine, Tryptophan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67089/', '[1] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al "Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies." Epilepsia 57 (2016): 2067-79[4] "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[6] "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al "Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study." Seizure 59 (2018): 28-33[10] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A "Hyponatremia associated with sodium valproate in a 22-year-old male." Nephrol Dial Transplant 23 (2008): epub[12] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[13] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[16] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[17] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[18] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK "Sodium valproate-induced hyponatremia: a case report." Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[22] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[24] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[26] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[28] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67003, 'Citalopram', 'Pasireotide', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More', 'Nafarelin, Elagolix, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67090/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67004, 'Citalopram', 'Pazopanib', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, More', 'Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67091/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67005, 'Citalopram', 'Pentamidine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More', 'Miltefosine, Nifurtimox, Benznidazole', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67092/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67006, 'Citalopram', 'Pentazocine', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'Viloxazine', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67093/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67007, 'Citalopram', 'Pentobarbital', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67094/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67008, 'Citalopram', 'Perampanel', 'Moderate', 'The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.', 'Antagonism', 'Oxitriptan, Bupropion, Viloxazine, Tryptophan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67095/', '[1] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al "Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies." Epilepsia 57 (2016): 2067-79[4] "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[6] "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al "Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study." Seizure 59 (2018): 28-33[10] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A "Hyponatremia associated with sodium valproate in a 22-year-old male." Nephrol Dial Transplant 23 (2008): epub[12] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[13] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[16] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[17] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[18] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK "Sodium valproate-induced hyponatremia: a case report." Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[22] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[24] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[26] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[28] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67009, 'Citalopram', 'Perflutren', 'Major', 'Perflutren lipid microsphere suspension (Definity)has been reported to cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Concomitant use of perflutren lipid microsphere suspension with other agents that can prolong the QT interval should be avoided in some cases.', NULL, 'Concomitant use of perflutren lipid microsphere suspension with other agents that can prolong the QT interval should be avoided in some cases. Please refer to the prescribing information for these drugs for more information. No data are available regarding the effect of perflutren protein-type A microsphere suspension (Optison) on the QT interval of the electrocardiogram.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67096/', '[1] "Product Information. Optison (perflutren)." Mallinckrodt Medical Inc, St. Louis, MO.[2] "Product Information. Definity (perflutren)." Lantheus Medical Imaging Inc, North Billerica, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67010, 'Citalopram', 'Pergolide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67097/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67011, 'Citalopram', 'Perphenazine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Oxitriptan, Vilazodone, Vortioxetine, Tryptophan', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67098/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67012, 'Citalopram', 'Pexidartinib', 'Major', 'Coadministration with CYP450 2C19 inhibitors may increase the plasma concentrations of citalopram, which is partially metabolized by the isoenzyme. Cases of QT interval prolongation and torsade de pointes have been reported during postmarketing use. In general, the risk of ventricular arrhythmia in association with QT prolongation is largely unpredictable, but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia).', NULL, 'Given the risk of dose-dependent QT prolongation, citalopram dosage should not exceed 20 mg/day when prescribed in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole.', NULL, 'Given the risk of dose-dependent QT prolongation, citalopram dosage should not exceed 20 mg/day when prescribed in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole. Alternatives should be considered when possible, and hypokalemia or hypomagnesemia should be corrected prior to initiation of citalopram treatment and periodically monitored. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Metabolism', 'Sertraline, Maprotiline, Fluoxetine, Levomilnacipran, Doxepin, Isocarboxazid, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, More', 'Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67099/', '[1] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[2] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[3] Priskorn M, Larsen F, Segonzac A, Moulin M "Pharmacokinetic interaction study of citalopram and cimetidine in healhy subjects." Eur J Clin Pharmacol 52 (1997): 241-2[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[9] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67013, 'Citalopram', 'Phenacemide', 'Moderate', 'The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.', 'Antagonism', 'Oxitriptan, Bupropion, Viloxazine, Tryptophan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67100/', '[1] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al "Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies." Epilepsia 57 (2016): 2067-79[4] "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[6] "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al "Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study." Seizure 59 (2018): 28-33[10] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A "Hyponatremia associated with sodium valproate in a 22-year-old male." Nephrol Dial Transplant 23 (2008): epub[12] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[13] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[16] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[17] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[18] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK "Sodium valproate-induced hyponatremia: a case report." Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[22] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[24] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[26] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[28] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67014, 'Citalopram', 'Phendimetrazine', 'Major', 'Serotonin reuptake inhibitors may potentiate the pharmacologic response to sympathomimetic agents.', NULL, 'In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).', NULL, 'In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Close monitoring for enhanced sympathomimetic effects and possible serotonin syndrome is recommended if these agents must be used together.', 'Synergism', 'Maprotiline, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67101/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] Barrett J, Meehan O, Fahy T "SSRI and sympathomimetic interaction." Br J Psychiatry 168 (1996): 253[3] Prior FH, Isbister GK, Dawson AH, Whyte IM "Serotonin toxicity with therapeutic doses of dexamphetamine and venlafaxine." Med J Aust 176 (2002): 240-1[4] Walters AM "Sympathomimetic-fluoxetine interaction." J Am Acad Child Adolesc Psychiatry 31 (1992): 565-6[5] Bostwick JM, Brown TM "A toxic reaction from combining fluoxetine and phentermine." J Clin Psychopharmacol 16 (1996): 189-90[6] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[7] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[8] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[9] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[13] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67015, 'Citalopram', 'Phenelzine', 'Major', 'By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of selective serotonin reuptake inhibitors (SSRIs) and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', NULL, 'In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.', NULL, 'In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with SSRIs, and vice versa.', 'Metabolism', 'Phenelzine', 'Citalopram, Esketamine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67102/', '[1] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20[2] Kline SS, Mauro LS, Scala-Bennett DM, Zick D "Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death." Clin Pharm 8 (1989): 510-4[3] Bhatara VS, Bandettini FC "Possible interaction between sertraline and tranylcypromine." Clin Pharm 12 (1993): 222-5[4] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[7] Suchowersky O, deVries JD "Interaction of fluoxetine and selegiline." Can J Psychiatry 35 (1990): 571-2[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[9] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[10] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[11] Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):[12] Suchowersky O, deVries J "Possible interactions between deprenyl and prozac." Can J Neurol Sci 17 (1990): 352-3[13] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[14] Sternbach H "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 850-1[15] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[16] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[17] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[18] Phillips SD, Ringo P "Phenelzine and venlafaxine interaction." Am J Psychiatry 152 (1995): 1400-1[19] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ "Adverse consequences of fluoxetine-MAOI combination therapy." J Clin Psychiatry 51 (1990): 222-5[20] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[21] Jimenez-Genchi A "Immediate switching from moclobemide to duloxetine may induce serotonin syndrome." J Clin Psychiatry 67 (2006): 1821-1822[22] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[23] Graber MA, Hoehns TB, Perry PJ "Sertraline-phenelzine drug interaction: a serotonin syndrome reaction." Ann Pharmacother 28 (1994): 732-5[24] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[25] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[26] Graham PM, Ilett KF "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 1255-6[27] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[28] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[29] Brannan SK, Talley BJ, Bowden CL "Sertraline and isocarboxazid cause a serotonin syndrome." J Clin Psychopharmacol 14 (1994): 144-5[30] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[31] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[32] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[33] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[34] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[35] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[36] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[37] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[38] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[39] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[40] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[41] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[42] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[43] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[44] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[45] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[46] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[47] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[48] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[49] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[50] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[51] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[52] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[53] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[54] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80[55] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[56] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[57] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[58] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67016, 'Citalopram', 'Phenindamine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Vilazodone, Sertraline, Paroxetine, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, More', 'Azelastine, Ketotifen', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67103/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67017, 'Citalopram', 'Phenobarbital', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67104/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67018, 'Citalopram', 'Phenolphthalein', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Maprotiline, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, More', 'Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67105/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67019, 'Citalopram', 'Phensuximide', 'Moderate', 'The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.', 'Antagonism', 'Oxitriptan, Bupropion, Viloxazine, Tryptophan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67106/', '[1] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al "Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies." Epilepsia 57 (2016): 2067-79[4] "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[6] "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al "Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study." Seizure 59 (2018): 28-33[10] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A "Hyponatremia associated with sodium valproate in a 22-year-old male." Nephrol Dial Transplant 23 (2008): epub[12] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[13] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[16] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[17] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[18] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK "Sodium valproate-induced hyponatremia: a case report." Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[22] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[24] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[26] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[28] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67020, 'Citalopram', 'Phentermine', 'Major', 'Serotonin reuptake inhibitors may potentiate the pharmacologic response to sympathomimetic agents.', NULL, 'In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).', NULL, 'In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Close monitoring for enhanced sympathomimetic effects and possible serotonin syndrome is recommended if these agents must be used together.', 'Synergism', 'Ephedrine', 'Maprotiline, St. John''s Wort, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67107/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] Barrett J, Meehan O, Fahy T "SSRI and sympathomimetic interaction." Br J Psychiatry 168 (1996): 253[3] Prior FH, Isbister GK, Dawson AH, Whyte IM "Serotonin toxicity with therapeutic doses of dexamphetamine and venlafaxine." Med J Aust 176 (2002): 240-1[4] Walters AM "Sympathomimetic-fluoxetine interaction." J Am Acad Child Adolesc Psychiatry 31 (1992): 565-6[5] Bostwick JM, Brown TM "A toxic reaction from combining fluoxetine and phentermine." J Clin Psychopharmacol 16 (1996): 189-90[6] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[7] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[8] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[9] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[13] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67021, 'Citalopram', 'Phenylbutazone', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 'Chondroitin sulfate, Glucosamine, Tolazoline, Dimethyl sulfoxide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67108/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67022, 'Citalopram', 'Phenylpropanolamine', 'Major', 'Serotonin reuptake inhibitors may potentiate the pharmacologic response to sympathomimetic agents.', NULL, 'In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).', NULL, 'In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Close monitoring for enhanced sympathomimetic effects and possible serotonin syndrome is recommended if these agents must be used together.', 'Synergism', 'Maprotiline, Nefazodone, St. John''s Wort, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan, Esketamine', 'Pseudoephedrine, Phenylephrine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67109/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] Barrett J, Meehan O, Fahy T "SSRI and sympathomimetic interaction." Br J Psychiatry 168 (1996): 253[3] Prior FH, Isbister GK, Dawson AH, Whyte IM "Serotonin toxicity with therapeutic doses of dexamphetamine and venlafaxine." Med J Aust 176 (2002): 240-1[4] Walters AM "Sympathomimetic-fluoxetine interaction." J Am Acad Child Adolesc Psychiatry 31 (1992): 565-6[5] Bostwick JM, Brown TM "A toxic reaction from combining fluoxetine and phentermine." J Clin Psychopharmacol 16 (1996): 189-90[6] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[7] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[8] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[9] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[13] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67023, 'Citalopram', 'Phenytoin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Nefazodone, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67110/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67024, 'Citalopram', 'Pimavanserin', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67111/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67025, 'Citalopram', 'Pimozide', 'Major', 'Coadministration with citalopram has been shown to potentiate the effects of pimozide on the QT interval. The mechanism of interaction is unknown.', NULL, 'The use of pimozide in combination with citalopram or escitalopram is considered contraindicated.', NULL, 'The use of pimozide in combination with citalopram or escitalopram is considered contraindicated.', 'Synergism', 'Oxitriptan, Vilazodone, Vortioxetine, Tryptophan', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67112/', '[1] "Product Information. Orap Tablets (pimozide)." Gate Pharmaceuticals, Sellersville, PA.[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[7] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[8] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[9] "Product Information. Orap Tablets (pimozide)." Gate Pharmaceuticals, Sellersville, PA.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[13] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67026, 'Citalopram', 'Pirbuterol', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Ephedrine, Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Beclomethasone dipropionate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67113/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67027, 'Citalopram', 'Piroxicam', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Phenelzine, Desipramine, Tranylcypromine, Trimipramine, Maprotiline, St. John''s Wort, Isocarboxazid, Oxitriptan, Viloxazine, Tryptophan, Amoxapine, More', 'Chondroitin sulfate, Glucosamine, Tolazoline, Dimethyl sulfoxide, Cortisone, Betamethasone, Fluorometholone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67114/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67028, 'Citalopram', 'Pitolisant', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 'Dalfampridine, Tafamidis', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67115/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67029, 'Citalopram', 'Plicamycin', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 'Valrubicin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67116/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67030, 'Citalopram', 'Polyethylene glycol (3350)', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Maprotiline, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67117/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67031, 'Citalopram', 'Polyethylene glycol (3350 with electrolytes)', 'Moderate', 'The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).', NULL, 'Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.', NULL, 'Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67118/', '[1] Salik JM, Kurtin P "Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome." Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] "Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate)." Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Suclear (polyethylene glycol 3350 with electrolytes)." Braintree Laboratories, Braintree, MA.[9] "Product Information. Visicol (sodium biphosphate-sodium phosphate)." Salix Pharmaceuticals, Raleigh, NC.[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[13] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] "Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate)." Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] "Product Information. Golytely (polyethylene glycol electrolyte solution)." Braintree, Braintree, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67032, 'Citalopram', 'Polythiazide', 'Moderate', 'Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.', NULL, 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.', NULL, 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Desipramine, St. John''s Wort, Oxitriptan, Viloxazine, Nortriptyline, Tryptophan, Protriptyline, Esketamine', 'Tinidazole, Mitapivat, Ascorbic acid, Oxytetracycline, Ciclopirox, Sulfamethizole, Simeprevir, Diazoxide, Econazole, Povidone-iodine, Sulfisoxazole, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67119/', '[1] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995): 809-10[3] Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996): 885[4] Odeh M, Beny A, Oliven A "Severe symptomatic hyponatremia during citalopram therapy." Am J Med Sci 321 (2001): 159-60[5] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991): 542-3[6] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[7] Jacob S, Spinler SA "Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults." Ann Pharmacother 40 (2006): 1618-22[8] Fitzgerald MA "Hyponatremia associated with SSRI use in a 65-year-old woman." Nurse Pract 33 (2008): 11-2[9] van Campen JP, Voets AJ "SIADH caused by paroxetine." Ann Pharmacother 30 (1996): 1499[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996): 524[12] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[13] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[14] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997): 93-5[15] Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993): 1564[16] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[17] Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996): 680-3[18] Odeh M, Seligmann H, Oliven A "Severe life-threatening hyponatremia during paroxetine therapy." J Clin Pharmacol 39 (1999): 1290-1[19] Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995): 809[20] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[21] "Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996): 562[22] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997): 580[23] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[24] Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992): 1332[25] Barclay TS, Lee AJ "Citalopram-associated SIADH." Ann Pharmacother 36 (2002): 1558-63[26] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[27] Covyeou JA, Jackson CW "Hyponatremia associated with escitalopram." N Engl J Med 356 (2007): 94-5[28] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[29] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[30] Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996): 1413[31] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[32] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[33] Spigset O, hedenmalm K "Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions." Pharmacotherapy 17 (1997): 348-52[34] Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990): 1569-70[35] Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993): 723-4[36] Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994): 543-4[37] Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993): 62-3[38] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[39] Hwang AS, Magraw RM "Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine." Am J Psychiatry 146 (1989): 399[40] Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990): 948-9[41] Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997): 306-7[42] Kazal LA, Jr Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993): 341-3[43] Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995): 390[44] Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993): 143[45] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[46] Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997): 108-10[47] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[48] Rosner MH "Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors." Am J Med Sci 327 (2004): 109-11[49] Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994): 779-80[50] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[51] Madhusoodanan S, Brenner R, Brafman I, Bogunovic O "Hyponatremia associated with paroxetine use." South Med J 92 (1999): 843[52] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[53] Esposito P, Rampino T, Gregorini M, et al. "Severe symptomatic hyponatremia during sibutramine therapy: a case report." Am J Kidney Dis 52 (2008): 137-9[54] Spier SA, Frontera MA "Unexpected deaths in depressed medical inpatients treated with fluoxetine." J Clin Psychiatry 52 (1991): 377-82[55] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[56] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[57] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67033, 'Citalopram', 'Ponatinib', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Maprotiline, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More', 'Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67120/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67034, 'Citalopram', 'Porfimer sodium', 'Moderate', 'Concomitant use of porfimer with drugs known to cause photosensitivity may increase the risk of a photosensitivity reaction. Photosensitivity with porfimer is due to residual drug being present in the skin. Patients treated with porfimer will be photosensitive for at least 30 days.', NULL, 'Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient''s hepatic and/or renal function.', NULL, 'Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient''s hepatic and/or renal function.', 'Synergism', 'Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Maprotiline, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More', 'Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67121/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Photofrin (porfimer)." Sanofi Winthrop Pharmaceuticals, New York, NY.[3] Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivityan update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47[4] Hoffman GA, Gradl G, Schulz M, Haidinger G, Tanew A, Weber B "The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature." J Eur Acad Dermatol Venereol 34 (2020): 589-600[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[6] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67035, 'Citalopram', 'Posaconazole', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'St. John''s Wort, Vortioxetine, Milnacipran, Isocarboxazid, Viloxazine, Imipramine, Esketamine, Fluvoxamine, Phenelzine, Tranylcypromine, Trimipramine, More', 'Flucytosine, Anidulafungin, Micafungin, Oteseconazole', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67122/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67036, 'Citalopram', 'Pramipexole', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67123/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67037, 'Citalopram', 'Prasugrel', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 'Protein C, Selexipag', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67124/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67038, 'Citalopram', 'Pregabalin', 'Moderate', 'The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.', 'Antagonism', 'Oxitriptan, Viloxazine, Tryptophan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67125/', '[1] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al "Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies." Epilepsia 57 (2016): 2067-79[4] "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[6] "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al "Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study." Seizure 59 (2018): 28-33[10] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A "Hyponatremia associated with sodium valproate in a 22-year-old male." Nephrol Dial Transplant 23 (2008): epub[12] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[13] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[16] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[17] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[18] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK "Sodium valproate-induced hyponatremia: a case report." Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[22] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[24] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[26] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[28] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67039, 'Citalopram', 'Primaquine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, More', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67126/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67040, 'Citalopram', 'Primidone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67127/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67041, 'Citalopram', 'Probucol', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More', 'Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Cerivastatin, Colestipol, Bempedoic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67128/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67042, 'Citalopram', 'Procainamide', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Duloxetine, Vilazodone, Paroxetine, Desvenlafaxine, St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More', 'Moricizine, Tocainide, Bretylium, Mexiletine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67129/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67043, 'Citalopram', 'Procarbazine', 'Major', 'By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of selective serotonin reuptake inhibitors (SSRIs) and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', NULL, 'In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.', NULL, 'In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with SSRIs, and vice versa.', 'Metabolism', 'Esketamine', 'Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67130/', '[1] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20[2] Kline SS, Mauro LS, Scala-Bennett DM, Zick D "Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death." Clin Pharm 8 (1989): 510-4[3] Bhatara VS, Bandettini FC "Possible interaction between sertraline and tranylcypromine." Clin Pharm 12 (1993): 222-5[4] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[7] Suchowersky O, deVries JD "Interaction of fluoxetine and selegiline." Can J Psychiatry 35 (1990): 571-2[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[9] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[10] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[11] Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):[12] Suchowersky O, deVries J "Possible interactions between deprenyl and prozac." Can J Neurol Sci 17 (1990): 352-3[13] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[14] Sternbach H "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 850-1[15] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[16] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[17] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[18] Phillips SD, Ringo P "Phenelzine and venlafaxine interaction." Am J Psychiatry 152 (1995): 1400-1[19] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ "Adverse consequences of fluoxetine-MAOI combination therapy." J Clin Psychiatry 51 (1990): 222-5[20] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[21] Jimenez-Genchi A "Immediate switching from moclobemide to duloxetine may induce serotonin syndrome." J Clin Psychiatry 67 (2006): 1821-1822[22] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[23] Graber MA, Hoehns TB, Perry PJ "Sertraline-phenelzine drug interaction: a serotonin syndrome reaction." Ann Pharmacother 28 (1994): 732-5[24] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[25] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[26] Graham PM, Ilett KF "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 1255-6[27] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[28] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[29] Brannan SK, Talley BJ, Bowden CL "Sertraline and isocarboxazid cause a serotonin syndrome." J Clin Psychopharmacol 14 (1994): 144-5[30] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[31] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[32] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[33] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[34] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[35] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[36] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[37] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[38] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[39] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[40] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[41] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[42] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[43] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[44] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[45] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[46] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[47] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[48] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[49] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[50] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[51] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[52] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[53] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[54] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80[55] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[56] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[57] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[58] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67044, 'Citalopram', 'Prochlorperazine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67131/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67045, 'Citalopram', 'Procyclidine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Vilazodone, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67132/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67046, 'Citalopram', 'Promazine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67133/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67047, 'Citalopram', 'Promethazine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', 'Azelastine, Ketotifen, Tetracaine, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67134/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67048, 'Citalopram', 'Propafenone', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Tranylcypromine, Desvenlafaxine, St. John''s Wort, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 'Moricizine, Tocainide, Bretylium, Mexiletine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67135/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67049, 'Citalopram', 'Propiomazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67136/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67050, 'Dextropropoxyphene', 'Citalopram', 'Major', 'Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS- and/or respiratory-depressant effects with propoxyphene. Misuse of propoxyphene, either alone or in combination with other CNS depressants, has been a major cause of drug-related deaths, particularly in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Pharmacokinetically, propoxyphene is an inhibitor of CYP450 2D6 and may increase the plasma concentrations of many psychotropic agents that are metabolized by the isoenzyme such as phenothiazines, haloperidol, risperidone, phenobarbital, and some tricyclic antidepressants and serotonin reuptake inhibitors.', NULL, 'Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse.', NULL, 'Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Dosage reductions may be appropriate. Patients should be monitored for potentially excessive or prolonged CNS and respiratory depression and other CNS adverse effects. Patients should be warned not to exceed recommended dosages, to avoid alcohol, and to avoid activities requiring mental alertness until they know how these agents affect them.', 'Metabolism, Synergism', 'Viloxazine', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67137/', '[1] Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67[2] Peterson GR, Covault HP, Hostetler RM "Acute inhibition of microsomal drug metabolism by propoxphene in narcotic tolerant/dependent mice." Life Sci 22 (1978): 2087-96[3] Abernethy DR, Greenblatt DJ, Morse DS, Shader RI "Interaction of propoxyphene with diazepam, alprazolam and lorazepam." Br J Clin Pharmacol 19 (1985): 51-7[4] Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4[5] Puckett WH Jr, Visconti JA "Orphenadrine and propoxyphene." N Engl J Med 283 (1970): 544[6] Pearson RE, Salter FJ "Drug interaction? Orphenadrine with propoxyphene." N Engl J Med 282 (1970): 1215[7] Shorr RI, Griffin MR, Daugherty JR, Ray WA "Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene." J Gerontol 47 (1992): m111-5[8] "Product Information. Darvon (propoxyphene)." Lilly, Eli and Company, Indianapolis, IN.[9] "Product Information. Darvon (propoxyphene)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[13] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67051, 'Citalopram', 'Propranolol', 'Moderate', 'Limited clinical data suggest that selective serotonin reuptake inhibitors (SSRIs) may potentiate the pharmacologic effects of some beta-blockers. The proposed mechanism is SSRI inhibition (competitive and/or noncompetitive) of CYP450 2D6, the isoenzyme responsible for the metabolic clearance of beta-blockers such as carvedilol, labetalol, metoprolol, nebivolol, propranolol, and timolol. Paroxetine and norfluoxetine (the active metabolite of fluoxetine), in particular, are potent inhibitors of CYP450 2D6 and may be more likely than other SSRIs to cause the interaction. On the other hand, fluvoxamine is a potent inhibitor of CYP450 1A2 and may significantly interact with propranolol, which is a substrate of both CYP450 2D6 and 1A2.', NULL, 'During concomitant therapy with SSRIs, a lower initial dosage and more cautious titration of the beta-blocker may be appropriate.', NULL, 'During concomitant therapy with SSRIs, a lower initial dosage and more cautious titration of the beta-blocker may be appropriate. Cardiac function should be closely monitored and the beta-blocker dosage adjusted accordingly, particularly following initiation, discontinuation or change of dosage of SSRI in patients who are stabilized on their beta-blocker regimen. Due to the long half-life of fluoxetine and its active metabolite, norfluoxetine, the risk of an interaction may exist for an extended period (up to several weeks) after discontinuation of fluoxetine. To avoid the interaction, use of beta-blockers that are primarily eliminated by the kidney such as atenolol, acebutolol, betaxolol, carteolol, and nadolol may be considered.', 'Metabolism', 'St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine, Escitalopram', 'Esmolol, Betaxolol, Carteolol, Penbutolol', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67138/', '[1] Walley T, Pirmohamed M, Proudlove C, Maxwell D "Interaction of metoprolol and fluoxetine." Lancet 341 (1993): 967-8[2] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5[3] Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML, Kulawy RW, Beck DJ, Bertino JS "Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping." Clin Pharmacol Ther 64 (1998): 257-68[4] Riesenman C "Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal." Pharmacotherapy 15 (1995): s84-99[5] Ereshefsky L "Treating depression: potential drug-drug interactions: commentary." J Clin Psychopharmacol 16 (suppl (1996): s50-3[6] Hemeryck A, Lefebvre RA, DeVriendt C, Belpaire FM "Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers." Clin Pharmacol Ther 67 (2000): 283-91[7] Perucca E, Gatti G, Spina E "Clinical pharmacokinetics of fluvoxamine." Clin Pharmacokinet 27 (1994): 175-90[8] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51[9] Nemeroff CB, Devane CL, Pollock BG "Newer antidepressants and the cytochrome p450 system." Am J Psychiatry 153 (1996): 311-20[10] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM "Inhibition by fluoxetine of cytochrome P450 2D6 activity." Clin Pharmacol Ther 53 (1993): 401-9[13] Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S "Fluvoxamine is a potent inhibitor of cytochrome P4501A2." Biochem Pharmacol 45 (1993): 1211-4[14] Drake WM, Gordon GD "Heart block in a patient on propranolol and fluoxetine." Lancet 343 (1994): 425-6[15] Hemeryck A, DeVriendt CA, Belpaire FM "Metoprolol-paroxetine interaction in human liver microsomes: Stereoselective aspects and prediction of the in vivo interaction." Drug Metab Disposition 29 (2001): 656-63[16] Richelson E "Pharmacokinetic interactions of antidepressants." J Clin Psychiatry 59 (1998): 22-6[17] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[20] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67052, 'Citalopram', 'Protriptyline', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval including tricyclic antidepressants and other antidepressants (e.g., trazodone) may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death. Concomitant use of agents with serotonergic activity including selective serotonin reuptake inhibitors, tricyclic antidepressants, and other antidepressants may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure. However, if treatment with citalopram is required in these patients, the labeling recommends that the dosage not exceed 40 mg/day, as higher dosages may have an excessive effect on the QT interval and confer no additional benefit in the treatment of depression. In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).', 'Synergism', 'Protriptyline, Viloxazine', 'Citalopram, Esketamine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67139/', '[1] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[2] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[3] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[4] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[5] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[6] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[7] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[8] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[9] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[10] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[11] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[12] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[13] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[14] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[15] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[17] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[18] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[19] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[20] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[21] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[22] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67053, 'Citalopram', 'Mepyramine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion', 'Tetracaine, Azelastine, Ketotifen', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67140/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67054, 'Citalopram', 'Quazepam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67141/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67055, 'Citalopram', 'Quetiapine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Oxitriptan, Vilazodone, Vortioxetine, Tryptophan', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67142/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67056, 'Citalopram', 'Quinidine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 'Moricizine, Tocainide, Bretylium, Mexiletine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67143/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67057, 'Citalopram', 'Quinine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More', 'Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67144/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67058, 'Citalopram', 'Ramelteon', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67145/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67059, 'Citalopram', 'Ramucirumab', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67146/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67060, 'Citalopram', 'Ranolazine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine', 'Regadenoson, Ubidecarenone', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67147/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67061, 'Citalopram', 'Rasagiline', 'Major', 'By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of selective serotonin reuptake inhibitors (SSRIs) and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. The extent to which rasagiline, a selective MAO-B inhibitor, may interact with SSRIs is unknown.', NULL, 'In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity.', NULL, 'In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with SSRIs, and vice versa. Due to the long half-life of fluoxetine and its active metabolite, norfluoxetine, a washout period of 5 weeks minimum is recommended when switching from fluoxetine to an MAOI. Similarly, a washout period of 3 weeks is recommended when switching from vortioxetine to an MAOI.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67148/', '[1] Suchowersky O, deVries J "Possible interactions between deprenyl and prozac." Can J Neurol Sci 17 (1990): 352-3[2] Suchowersky O, deVries JD "Interaction of fluoxetine and selegiline." Can J Psychiatry 35 (1990): 571-2[3] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[4] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[5] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[6] Graham PM, Ilett KF "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 1255-6[7] "Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA, North Wales, PA.[8] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[9] Sternbach H "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 850-1[10] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[11] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ "Adverse consequences of fluoxetine-MAOI combination therapy." J Clin Psychiatry 51 (1990): 222-5[12] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[13] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[14] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20[15] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[16] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[17] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[18] McGrath PJ, Stewart JW, Quitkin FM "A possible L-deprenyl induced hypertensive reaction." J Clin Psychopharmacol 9 (1989): 310-1[19] "Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA, North Wales, PA.[20] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[21] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[22] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[25] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[26] Ito D, Amano T, Sato H, Fukuuchi Y "Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson''s disease." J Neurol 248 (2001): 533-4[27] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[28] Lefebvre H, Noblet C, Morre N, Wolf LM "Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline." Clin Endocrinol (Oxf) 42 (1995): 95-8[29] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[30] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[32] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67062, 'Citalopram', 'Regorafenib', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Maprotiline, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More', 'Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67149/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67063, 'Citalopram', 'Relugolix', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, More', 'Nafarelin, Elagolix, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Aminoglutethimide', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67150/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67064, 'Citalopram', 'Remifentanil', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'Viloxazine', 'Desflurane, Enflurane, Esketamine, Nitrous oxide', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67151/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67065, 'Citalopram', 'Remimazolam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67152/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67066, 'Citalopram', 'Repaglinide', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', 'Desipramine, Trimipramine, Desvenlafaxine, Maprotiline, Clomipramine, Oxitriptan, Trazodone, Milnacipran, Tryptophan, Amitriptyline, Levomilnacipran, More', 'Lixisenatide, Albiglutide, Guar gum, Canagliflozin, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Ertugliflozin, Semaglutide, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67153/', '[1] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[2] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[3] Field JB, Ohta M, Boyle C, Remer A "Potentiation of acetohexamide hypoglycemia by phenylbutazone." N Engl J Med 277 (1967): 889-94[4] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[5] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[6] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J "Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole." Diabet Med 4 (1987): 245-7[7] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[8] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT "Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride." Clin Pharmacol Ther 69 (2001): 194-200[9] Ravic M, Johnston A, Turner P "Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs." Postgrad Med J 66 (1990): s30-4[10] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[11] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[12] Tran PO, Gleason CE, Robertson RP "Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function." Diabetes 51 (2002): 1772-8[13] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[14] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[15] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[16] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[17] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[18] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[19] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[20] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[21] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA "Effect of pirprofen on glibenclamide kinetics and response." Br J Clin Pharmacol 14 (1982): 123-6[22] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[23] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[24] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[25] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[26] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[28] Sawka AM, Burgart V, Zimmerman D "Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors." Diabetes Care 24 (2001): 1845-6[29] Wing LM, Miners JO "Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition." Br J Clin Pharmacol 20 (1985): 482-5[30] Tremaine LM, Wilner KD, Preskorn SH "A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide." Clin Pharmacokinet 32(Suppl 1) (1997): 31-36[31] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Tannenbaum H, Anderson LG, Soeldner JS "Phenylbutazone-tolbutamide drug interaction." N Engl J Med 290 (1974): 344[33] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[34] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[35] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB "Aspirin-induced hypoglycaemia in a patient on haemodialysis." Lancet 2 (1971): 1092-3[36] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[37] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[38] Kradjan WA, Witt DM, Opheim KE, Wood FC "Lack of interaction between glipizide and co-trimoxazole." J Clin Pharmacol 34 (1994): 997-1002[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[41] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[42] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[43] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[44] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[45] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[46] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[47] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[48] Lozada A, Dujovne CA "Drug interactions with fibric acids." Pharmacol Ther 63 (1994): 163-76[49] Shah SJ, Bhandarkar SD, Satoskar RS "Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone." Int J Clin Pharmacol Ther Toxicol 22 (1984): 470-2[50] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[51] Nikkila EA, Ylikahri R, Huttunen JK "Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia." Proc R Soc Med 69 (1976): 58-63[52] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[53] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[54] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[55] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[56] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[57] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[58] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[59] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[60] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[61] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[64] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[65] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[66] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[67] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[68] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[69] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[70] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[71] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[72] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[73] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[74] "Product Information. Micronase (glyburide)." Pharmacia and Upjohn, Kalamazoo, MI.[75] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[76] Petitpierre B, Perrin L, Rudhardt M, et al "Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy." Int J Clin Pharmacol 6 (1972): 120-4[77] Pond SM, Birkett DJ, Wade DN "Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole." Clin Pharmacol Ther 22 (1977): 573-9[78] Sone H, Takahashi A, Yamada N "Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea." Ann Intern Med 134 (2001): 344[79] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[80] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[81] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[82] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[83] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[84] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[85] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[86] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[87] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[88] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[89] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[90] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[91] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[92] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[93] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[94] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM "Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism." Clin Pharmacol Ther 17 (1975): 731-4[95] Diwan PV, Sastry MS, Satyanarayana NV "Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans." Indian J Exp Biol 30 (1992): 317-9[96] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[97] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[98] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[99] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[100] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[101] Harris EL "Adverse reactions to oral antidiabetic agents." Br Med J 3 (1971): 29-30[102] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK "Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide." Br J Clin Pharmacol 30 (1990): 245-52[103] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[104] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[105] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[106] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[107] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[108] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[109] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[110] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[111] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[112] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67067, 'Citalopram', 'Reteplase', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Protein C, Selexipag', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67154/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67068, 'Citalopram', 'Ribociclib', 'Major', 'Ribociclib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Coadministration with ribociclib may increase the plasma concentrations and pharmacologic effects of drugs that are substrates of CYP450 3A4. The proposed mechanism is decreased clearance due to ribociclib-mediated inhibition of CYP450 3A4 metabolism.', NULL, 'Coadministration of ribociclib with other drugs that can prolong the QT interval and are substrates of CYP450 3A4, particularly those with a narrow therapeutic range, should generally be avoided.', NULL, 'Coadministration of ribociclib with other drugs that can prolong the QT interval and are substrates of CYP450 3A4, particularly those with a narrow therapeutic range, should generally be avoided. Since the magnitude of QT prolongation may increase with increasing plasma concentrations of these drugs, caution and close clinical monitoring are recommended if concomitant use with these drugs is unavoidable. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ribociclib is added to or withdrawn from therapy.', 'Metabolism, Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More', 'Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67155/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[4] Abbas R, Hug BA, Leister C, Sonnichsen D "A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects." Int J Cancer 131 (2012): Epub[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] "Product Information. Uroxatral (alfuzosin)." sanofi-aventis , Bridgewater, NJ.[7] "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.[8] "Product Information. Fareston (toremifene)." Schering Laboratories, Kenilworth, NJ.[9] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[10] "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67069, 'Citalopram', 'Rifampicin', 'Moderate', 'Coadministration with potent inducers of CYP450 2C19 and/or 3A4, such as rifampin and St. John''s wort, may significantly decrease the plasma concentrations of drugs which are primarily metabolized by these isoenzymes.', NULL, 'Caution is advised when potent inducers of CYP450 2C19 and/or 3A4 are used concomitantly with medications that are substrates of these CYP450 isoenzymes.', NULL, 'Caution is advised when potent inducers of CYP450 2C19 and/or 3A4 are used concomitantly with medications that are substrates of these CYP450 isoenzymes. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever St. John''s wort or rifampin is added to or withdrawn from therapy.', 'Metabolism', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Maprotiline, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, More', 'Capreomycin, Rifamycin, Rifapentine, Streptomycin, Cycloserine, Rifabutin, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67156/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Rifadin (rifampin)." Hoechst Marion-Roussel Inc, Kansas City, MO.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67070, 'Citalopram', 'Rilpivirine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Brincidofovir, Remdesivir, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67157/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67071, 'Citalopram', 'Risperidone', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Oxitriptan, Vilazodone, Vortioxetine, Tryptophan', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67158/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67072, 'Citalopram', 'Ritodrine', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Paroxetine, St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Bremelanotide, Black cohosh', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67159/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67073, 'Citalopram', 'Ritonavir', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.', NULL, '-', NULL, '-', 'Metabolism', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Esketamine', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Brincidofovir, Remdesivir, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67160/', '[1] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[2] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67074, 'Citalopram', 'Rivaroxaban', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Maprotiline, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More', 'Protein C, Selexipag', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67161/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67075, 'Citalopram', 'Rivastigmine', 'Moderate', 'Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.', NULL, 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.', NULL, 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.', 'Synergism', 'Phenelzine, Tranylcypromine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More', 'Aducanumab', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67162/', '[1] "Product Information. Razadyne (galantamine)." Johnson and Johnson Medical Inc, Arlington, TX.[2] "Product Information. Exelon (rivastigmine)" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Aricept (donepezil)." Pfizer US Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67076, 'Citalopram', 'Rizatriptan', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'Viloxazine, Esketamine', 'Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Erenumab, Fremanezumab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67163/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67077, 'Citalopram', 'Romidepsin', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More', 'Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67164/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67078, 'Citalopram', 'Ropinirole', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67165/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67079, 'Citalopram', 'Rotigotine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67166/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67080, 'Citalopram', 'Rucaparib', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Tranylcypromine, Paroxetine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More', 'Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67167/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67081, 'Citalopram', 'Rufinamide', 'Moderate', 'The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.', 'Antagonism', 'Oxitriptan, Viloxazine, Tryptophan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67168/', '[1] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al "Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies." Epilepsia 57 (2016): 2067-79[4] "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[6] "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al "Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study." Seizure 59 (2018): 28-33[10] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A "Hyponatremia associated with sodium valproate in a 22-year-old male." Nephrol Dial Transplant 23 (2008): epub[12] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[13] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[16] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[17] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[18] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK "Sodium valproate-induced hyponatremia: a case report." Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[22] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[24] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[26] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[28] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67082, 'Citalopram', 'Ruxolitinib', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Phenelzine, Desipramine, Tranylcypromine, Trimipramine, Maprotiline, Isocarboxazid, Oxitriptan, Mirtazapine, Bupropion, Trazodone, Tryptophan, More', 'Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67169/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67083, 'Citalopram', 'Safinamide', 'Moderate', 'By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs), including the selective MAO-B inhibitor safinamide, may potentiate the pharmacologic activity of serotonergic agents such as the serotonin reuptake inhibitors (SSRIs). The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', NULL, 'Caution is advised if safinamide is used concomitantly with SSRIs and the SSRI should be administered at the lowest effective dose.', NULL, 'Caution is advised if safinamide is used concomitantly with SSRIs and the SSRI should be administered at the lowest effective dose. Clinical and laboratory monitoring should be considered when these drugs are used concomitantly.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67170/', '[1] Weiner LA, Smythe M, Cisek J "Serotonin syndrome secondary to phenelzine-venlafaxine interaction." Pharmacotherapy 18 (1998): 399-403[2] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[3] Diamond S "The use of sumatriptan in patients on monoamine oxidase inhibitors." Neurology 45 (1995): 1039-40[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):[6] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[9] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[10] Graham PM, Ilett KF "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 1255-6[11] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[12] Jimenez-Genchi A "Immediate switching from moclobemide to duloxetine may induce serotonin syndrome." J Clin Psychiatry 67 (2006): 1821-1822[13] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD "Toxic interaction of venlafaxine and isocarboxazide." Lancet 346 (1995): 1298-9[14] Brubacher JR, Hoffman RS, Lurin MJ "Serotonin syndrome from venlafaxine-tranylcypromine interaction." Vet Hum Toxicol 38 (1996): 358-61[15] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[16] White K, Simpson G "Combined MAOI-tricyclic antidepressant treatment: a reevaluation." J Clin Psychopharmacol 1 (1981): 264-82[17] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[18] "Product Information. Xadago (safinamide)." US WorldMeds LLC, Louisville , KY.[19] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ "Adverse consequences of fluoxetine-MAOI combination therapy." J Clin Psychiatry 51 (1990): 222-5[20] Phillips SD, Ringo P "Phenelzine and venlafaxine interaction." Am J Psychiatry 152 (1995): 1400-1[21] Sternbach H "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 850-1[22] Spiker DG, Pugh DD "Combining tricyclic and monoamine oxidase inhibitor antidepressants." Arch Gen Psychiatry 33 (1976): 828-30[23] Graber MA, Hoehns TB, Perry PJ "Sertraline-phenelzine drug interaction: a serotonin syndrome reaction." Ann Pharmacother 28 (1994): 732-5[24] Bem JL, Peck R "Dextromethorphan. An overview of safety issues." Drug Saf 7 (1992): 190-9[25] Sovner R, Wolfe J "Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid ." N Engl J Med 319 (1988): 1671[26] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20[27] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK "Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports." Neurology 51 (1998): 274-6[28] Jacob JE, Wagner ML, Sage JI "Safety of selegiline with cold medications." Ann Pharmacother 37 (2003): 438-41[29] Staufenberg EF, Tantam D "Malignant hyperpyrexia syndrome in combined treatment." Br J Psychiatry 154 (1989): 577-8[30] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[31] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[32] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[33] Bhatara VS, Bandettini FC "Possible interaction between sertraline and tranylcypromine." Clin Pharm 12 (1993): 222-5[34] Heisler MA, Guidry JR, Arnecke B "Serotonin syndrome induced by administration of venlafaxine and phenelzine." Ann Pharmacother 30 (1996): 84[35] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP "Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan." Am J Psychiatry 142 (1985): 491-2[36] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[37] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[38] Bodner RA, Lynch T, Lewis L, Kahn D "Serotonin syndrome." Neurology 45 (1995): 219-23[39] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[40] "Product Information. Manerix (moclobemide)." Hoffmann-La Roche Limited, Mississauga, IA.[41] Suchowersky O, deVries JD "Interaction of fluoxetine and selegiline." Can J Psychiatry 35 (1990): 571-2[42] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[43] Brannan SK, Talley BJ, Bowden CL "Sertraline and isocarboxazid cause a serotonin syndrome." J Clin Psychopharmacol 14 (1994): 144-5[44] Thomas JM, Rubin EH "Case report of a toxic reaction from a combination of tryptophan and phenelzine." Am J Psychiatry 141 (1984): 281-3[45] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[46] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[47] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[48] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[49] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[50] Levy AB, Bucher P, Votolato N "Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment." Can J Psychiatry 30 (1985): 434-6[51] Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311[52] Graham PM, Potter JM, Paterson J "Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction." Lancet 2 (1982): 440[53] Rivers N, Horner B "Possible lethal reaction between nardil and dextromethorphan." Can Med Assoc J 103 (1970): 85[54] White K, Pistole T, Boyd JL "Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study." Am J Psychiatry 137 (1980): 1422-5[55] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[56] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[57] Cetaruk EW, Aaron CK "Hazards of nonprescription medications." Emerg Med Clin North Am 12 (1994): 483-510[58] "Product Information. Xadago (safinamide)." US WorldMeds LLC, Louisville , KY.[59] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[60] Ueda N, Yoshimura R, Umene-Nakano W, et al. "Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers." World J Biol Psychiatry 10(4 Pt 3) (2009): 832-5[61] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[62] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67084, 'Citalopram', 'Salmeterol', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Beclomethasone dipropionate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67171/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67085, 'Citalopram', 'Saquinavir', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Brincidofovir, Remdesivir, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67172/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67086, 'Citalopram', 'Secobarbital', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67173/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67087, 'Citalopram', 'Selegiline', 'Major', 'By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of selective serotonin reuptake inhibitors (SSRIs) and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', NULL, 'In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.', NULL, 'In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with SSRIs, and vice versa.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67174/', '[1] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20[2] Kline SS, Mauro LS, Scala-Bennett DM, Zick D "Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death." Clin Pharm 8 (1989): 510-4[3] Bhatara VS, Bandettini FC "Possible interaction between sertraline and tranylcypromine." Clin Pharm 12 (1993): 222-5[4] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[7] Suchowersky O, deVries JD "Interaction of fluoxetine and selegiline." Can J Psychiatry 35 (1990): 571-2[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[9] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[10] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[11] Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):[12] Suchowersky O, deVries J "Possible interactions between deprenyl and prozac." Can J Neurol Sci 17 (1990): 352-3[13] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[14] Sternbach H "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 850-1[15] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[16] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[17] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[18] Phillips SD, Ringo P "Phenelzine and venlafaxine interaction." Am J Psychiatry 152 (1995): 1400-1[19] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ "Adverse consequences of fluoxetine-MAOI combination therapy." J Clin Psychiatry 51 (1990): 222-5[20] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[21] Jimenez-Genchi A "Immediate switching from moclobemide to duloxetine may induce serotonin syndrome." J Clin Psychiatry 67 (2006): 1821-1822[22] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[23] Graber MA, Hoehns TB, Perry PJ "Sertraline-phenelzine drug interaction: a serotonin syndrome reaction." Ann Pharmacother 28 (1994): 732-5[24] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[25] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[26] Graham PM, Ilett KF "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 1255-6[27] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[28] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[29] Brannan SK, Talley BJ, Bowden CL "Sertraline and isocarboxazid cause a serotonin syndrome." J Clin Psychopharmacol 14 (1994): 144-5[30] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[31] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[32] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[33] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[34] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[35] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[36] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[37] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[38] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[39] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[40] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[41] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[42] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[43] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[44] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[45] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[46] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[47] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[48] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[49] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[50] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[51] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[52] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[53] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[54] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80[55] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[56] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[57] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[58] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67088, 'Citalopram', 'Selpercatinib', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More', 'Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67175/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67089, 'Citalopram', 'Sertraline', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval including tricyclic antidepressants and other antidepressants (e.g., trazodone) may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death. Concomitant use of agents with serotonergic activity including selective serotonin reuptake inhibitors, tricyclic antidepressants, and other antidepressants may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure. However, if treatment with citalopram is required in these patients, the labeling recommends that the dosage not exceed 40 mg/day, as higher dosages may have an excessive effect on the QT interval and confer no additional benefit in the treatment of depression. In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).', 'Synergism', 'Viloxazine, Sertraline, Esketamine', 'Citalopram, Esketamine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67176/', '[1] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[2] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[3] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[4] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[5] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[6] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[7] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[8] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[9] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[10] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[11] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[12] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[13] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[14] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[15] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[17] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[18] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[19] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[20] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[21] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[22] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67090, 'Citalopram', 'Sevoflurane', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Duloxetine, Vilazodone, Desvenlafaxine, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion, Fluvoxamine', 'Desflurane, Enflurane, Esketamine, Nitrous oxide', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67177/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67091, 'Citalopram', 'Sibutramine', 'Major', 'Concomitant use of sibutramine with other serotonin reuptake inhibitors or other agents that possess or enhance serotonergic activity such as monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, phenylpiperidine opioids, bupropion, dextromethorphan, linezolid, lithium, St. John''s wort, tramadol, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', NULL, 'In general, the concomitant use of sibutramine with other agents that affect the serotonergic neurotransmitter system should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, 'In general, the concomitant use of sibutramine with other agents that affect the serotonergic neurotransmitter system should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when initiating or increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life. For example, a 5-week washout period is recommended following use of fluoxetine and 3 weeks following use of vortioxetine before administering another serotonergic agent such as sibutramine. At least 14 days should elapse between discontinuation of other serotonergic agents and initiation of treatment with sibutramine. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine). Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.', 'Synergism', 'Esketamine', 'Ephedrine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67178/', '[1] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[2] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[3] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[6] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[7] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[8] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[10] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[11] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[12] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67092, 'Citalopram', 'Siponimod', 'Major', 'Due to its significant bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of siponimod treatment in patients receiving drugs that prolong the QT interval.', NULL, 'Siponimod has not been studied in patients receiving drugs that can prolong the QT interval.', NULL, 'Siponimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with siponimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67179/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Mayzent (siponimod)." Novartis Pharmaceuticals, East Hanover, NJ.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67093, 'Citalopram', 'Sirolimus', 'Moderate', 'Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.', NULL, 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', NULL, 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Isocarboxazid, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 'Vitamin A, Ascorbic acid, Nandrolone, Potassium Iodide, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67180/', '[1] "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.[2] "Product Information. Rapamune (sirolimus)" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67094, 'Citalopram', 'Sodium oxybate', 'Major', 'The central nervous system and respiratory depressant effects of sodium oxybate, which is the sodium salt of gamma hydroxybutyrate (GHB), may be potentiated by concomitant use of other agents with CNS depressant effects. An increased risk of serious adverse reactions such as respiratory depression, hypotension, profound sedation, syncope, coma, and even death should be considered.', NULL, 'Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible.', NULL, 'Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible. Otherwise, close monitoring and/or dosage reductions should be considered. If short-term use of a CNS depressant is required (e.g., post- or perioperative opioid), a temporary interruption of sodium oxybate therapy may be appropriate.', 'Synergism', 'Duloxetine, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran', 'Desflurane, Enflurane, Esketamine, Nitrous oxide, Dalfampridine, Tafamidis', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67181/', '[1] "Product Information. Xyrem (sodium oxybate)." Orphan Medical, Minnetonka, MN.[2] "Product Information. Xywav (calcium/magnesium/potass/sodium oxybates)." Jazz Pharmaceuticals, Palo Alto, CA.[3] "Product Information. Xyrem (sodium oxybate)." Orphan Medical, Minnetonka, MN.[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67095, 'Citalopram', 'Salicylic acid (sodium)', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Maprotiline, St. John''s Wort, Vortioxetine, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67182/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67096, 'Citalopram', 'Solifenacin', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Duloxetine, Vilazodone, Desvenlafaxine, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, Esketamine, Paroxetine', 'Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Avanafil, Ammonium chloride, Dimethyl sulfoxide, Silodosin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67183/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67097, 'Citalopram', 'Sorafenib', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More', 'Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67184/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67098, 'Citalopram', 'Sotalol', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Fluvoxamine', 'Esmolol, Betaxolol, Carteolol, Penbutolol', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67185/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67099, 'Citalopram', 'Sparfloxacin', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Paroxetine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, More', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67186/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67100, 'Citalopram', 'St. John''s Wort', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'Viloxazine, Bupropion, St. John''s Wort, Esketamine', 'Citalopram, Esketamine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67187/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67101, 'Citalopram', 'Stiripentol', 'Moderate', 'The concomitant administration of stiripentol may significantly increase plasma concentrations, pharmacologic effects, and toxicities of drugs that are substrates of CYP450 2C19, 3A4, and/or 2D6. The mechanism is inhibition of cytochrome P-450 metabolism by stiripentol.', NULL, 'Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use.', NULL, 'Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use. Dosage adjustments may be required if increased plasma levels or effects are observed.', 'Metabolism', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67188/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[3] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[4] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[5] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[6] "Product Information. Diacomit (stiripentol)." Biocodex Inc, Creswell, OR.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67102, 'Citalopram', 'Streptokinase', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Protein C, Selexipag, Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67189/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67103, 'Citalopram', 'Sufentanil', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'Viloxazine', 'Desflurane, Enflurane, Esketamine, Nitrous oxide', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67190/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67104, 'Citalopram', 'Sulfamethoxazole', 'Minor', 'Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', NULL, '-', NULL, '-', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More', 'Capreomycin, Rifamycin, Rifapentine, Streptomycin, Cycloserine, Rifabutin, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, Sulfamethizole, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67191/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Crouch MA, Limon L, Cassano AT "Clinical relevance and management of drug-related QT interval prolongation." Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wiener I, Rubin D, Martinez E, et al "QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration." Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T "QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole." Am J Cardiol 59 (1987): 376-7[6] Darpo B "Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes." Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67105, 'Citalopram', 'Sulfinpyrazone', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 'Lesinurad, Febuxostat, Pegloticase, Colchicine, Rasburicase', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67192/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67106, 'Citalopram', 'Sulindac', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 'Chondroitin sulfate, Glucosamine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67193/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67107, 'Citalopram', 'Sunitinib', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More', 'Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67194/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67108, 'Citalopram', 'Suvorexant', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67195/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67109, 'Citalopram', 'Tacrine', 'Moderate', 'Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.', NULL, 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.', NULL, 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, More', 'Aducanumab', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67196/', '[1] "Product Information. Razadyne (galantamine)." Johnson and Johnson Medical Inc, Arlington, TX.[2] "Product Information. Exelon (rivastigmine)" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Aricept (donepezil)." Pfizer US Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67110, 'Citalopram', 'Tacrolimus', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 'Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Aminobenzoic acid, Ivermectin, Dupilumab, Tralokinumab, Povidone-iodine, Golimumab, Ustekinumab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67197/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67111, 'Citalopram', 'Tamoxifen', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine', 'Darolutamide, Aminoglutethimide', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67198/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67112, 'Citalopram', 'Tapentadol', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'Viloxazine', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67199/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67113, 'Citalopram', 'Tasimelteon', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67200/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67114, 'Citalopram', 'Tazemetostat', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Phenelzine, Desipramine, Tranylcypromine, Trimipramine, Maprotiline, Isocarboxazid, Oxitriptan, Bupropion, Tryptophan, Amitriptyline, Nortriptyline, More', 'Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67201/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67115, 'Citalopram', 'Telaprevir', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.', NULL, '-', NULL, '-', 'Metabolism', 'Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Brincidofovir, Remdesivir, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67202/', '[1] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[2] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67116, 'Citalopram', 'Telavancin', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More', 'Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67203/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67117, 'Citalopram', 'Telithromycin', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Esketamine, Fluvoxamine', 'Lincomycin, Dirithromycin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67204/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67118, 'Citalopram', 'Telotristat ethyl', 'Moderate', 'Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.', NULL, 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.', NULL, 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.', 'Metabolism', 'Maprotiline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67205/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67119, 'Citalopram', 'Temazepam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67206/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67120, 'Citalopram', 'Temsirolimus', 'Moderate', 'Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.', NULL, 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', NULL, 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Esketamine, Phenelzine, More', 'Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67207/', '[1] "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.[2] "Product Information. Rapamune (sirolimus)" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67121, 'Citalopram', 'Tenecteplase', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Protein C, Selexipag', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67208/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67122, 'Citalopram', 'Terbutaline', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Paroxetine, St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Ephedrine, Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Beclomethasone dipropionate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67209/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67123, 'Citalopram', 'Terfenadine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John''s Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More', 'Azelastine, Ketotifen', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67210/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67124, 'Citalopram', 'Tetrabenazine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', 'Dalfampridine, Tafamidis', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67211/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67125, 'Citalopram', 'Thalidomide', 'Moderate', 'Thalidomide can commonly cause drowsiness/sedation and may have additive effects with other drugs that cause central nervous system (CNS) depression. Thalidomide can cause bradycardia and may have additive effects with other drugs that decrease heart rate. Cases of bradycardia have been associated with thalidomide use, some requiring medical interventions.', NULL, 'Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics.', NULL, 'Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics. Caution is advised when thalidomide is used with drugs that can slow the heart rate or induce torsade de pointes arrhythmia. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67212/', '[1] "Product Information. Thalomid (thalidomide)." Celgene Corporation, Warren, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[7] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67126, 'Citalopram', 'Thiethylperazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Sertraline, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, Levomilnacipran, Vilazodone, More', 'Azelastine, Ketotifen', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67213/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67127, 'Citalopram', 'Thiopental', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Vilazodone, Sertraline, Maprotiline, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Vortioxetine, Trazodone, Levomilnacipran, More', 'Desflurane, Enflurane, Esketamine, Nitrous oxide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67214/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67128, 'Citalopram', 'Thioridazine', 'Major', 'Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, all of which are substrates of the isoenzyme.', NULL, 'The use of thioridazine with drugs that inhibit CYP450 2D6 is considered contraindicated.', NULL, 'The use of thioridazine with drugs that inhibit CYP450 2D6 is considered contraindicated. Depending on the elimination half-life of these drugs, a considerable waiting period may be appropriate following their discontinuation before thioridazine is initiated. For example, the manufacturer of fluoxetine recommends that thioridazine not be administered within 5 weeks after discontinuing fluoxetine because of the drug''s long half-life.', 'Metabolism', 'Oxitriptan, Vilazodone, Vortioxetine, Tryptophan', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67215/', '[1] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[2] Greendyke RM, Gulya A "Effect of pindolol administration on serum levels of thioridazine, haloperidol, phenytoin, and phenobarbital." J Clin Psychiatry 49 (1988): 105-7[3] Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JAG, Berecz R, Duran M, Benitez J "Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients." J Clin Psychopharmacol 19 (1999): 494-9[4] Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4[5] Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969): 135-8[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] "Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[9] Silver JM, Yudofsky SC, Kogan M, Katz BL "Elevation of thioridazine plasma levels by propranolol." Am J Psychiatry 143 (1986): 1290-2[10] Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SHL "Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans." Clin Pharmacol Ther 60 (1996): 543-53[11] Greendyke RM, Kanter DR "Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations." J Clin Psychopharmacol 7 (1987): 178-82[12] Thomas M, Maconochie JG, Fletcher E "The dilemma of the prolonged QT interval in early drug studies." Br J Clin Pharmacol 41 (1996): 77-81[13] Cerner Multum, Inc. "Australian Product Information." O 0[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Gleevec (imatinib mesylate)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67129, 'Citalopram', 'Thiothixene', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67216/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67130, 'Citalopram', 'Tiagabine', 'Moderate', 'The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.', 'Antagonism', 'Oxitriptan, Viloxazine, Tryptophan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67217/', '[1] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al "Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies." Epilepsia 57 (2016): 2067-79[4] "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[6] "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al "Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study." Seizure 59 (2018): 28-33[10] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A "Hyponatremia associated with sodium valproate in a 22-year-old male." Nephrol Dial Transplant 23 (2008): epub[12] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[13] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[16] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[17] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[18] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK "Sodium valproate-induced hyponatremia: a case report." Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[22] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[24] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[26] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[28] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67131, 'Citalopram', 'Ticagrelor', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Maprotiline, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More', 'Protein C, Selexipag', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67218/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67132, 'Citalopram', 'Ticlopidine', 'Major', 'Coadministration with CYP450 2C19 inhibitors may increase the plasma concentrations of citalopram, which is partially metabolized by the isoenzyme. Cases of QT interval prolongation and torsade de pointes have been reported during postmarketing use. In general, the risk of ventricular arrhythmia in association with QT prolongation is largely unpredictable, but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia).', NULL, 'Given the risk of dose-dependent QT prolongation, citalopram dosage should not exceed 20 mg/day when prescribed in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole.', NULL, 'Given the risk of dose-dependent QT prolongation, citalopram dosage should not exceed 20 mg/day when prescribed in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole. Alternatives should be considered when possible, and hypokalemia or hypomagnesemia should be corrected prior to initiation of citalopram treatment and periodically monitored. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Metabolism', 'Protein C, Selexipag', 'Phenelzine, Desipramine, Tranylcypromine, Trimipramine, Maprotiline, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Mirtazapine, Viloxazine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67219/', '[1] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[2] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[3] Priskorn M, Larsen F, Segonzac A, Moulin M "Pharmacokinetic interaction study of citalopram and cimetidine in healhy subjects." Eur J Clin Pharmacol 52 (1997): 241-2[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[9] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67133, 'Citalopram', 'Timolol', 'Moderate', 'Limited clinical data suggest that selective serotonin reuptake inhibitors (SSRIs) may potentiate the pharmacologic effects of some beta-blockers. The proposed mechanism is SSRI inhibition (competitive and/or noncompetitive) of CYP450 2D6, the isoenzyme responsible for the metabolic clearance of beta-blockers such as carvedilol, labetalol, metoprolol, nebivolol, propranolol, and timolol. Paroxetine and norfluoxetine (the active metabolite of fluoxetine), in particular, are potent inhibitors of CYP450 2D6 and may be more likely than other SSRIs to cause the interaction. On the other hand, fluvoxamine is a potent inhibitor of CYP450 1A2 and may significantly interact with propranolol, which is a substrate of both CYP450 2D6 and 1A2.', NULL, 'During concomitant therapy with SSRIs, a lower initial dosage and more cautious titration of the beta-blocker may be appropriate.', NULL, 'During concomitant therapy with SSRIs, a lower initial dosage and more cautious titration of the beta-blocker may be appropriate. Cardiac function should be closely monitored and the beta-blocker dosage adjusted accordingly, particularly following initiation, discontinuation or change of dosage of SSRI in patients who are stabilized on their beta-blocker regimen. Due to the long half-life of fluoxetine and its active metabolite, norfluoxetine, the risk of an interaction may exist for an extended period (up to several weeks) after discontinuation of fluoxetine. To avoid the interaction, use of beta-blockers that are primarily eliminated by the kidney such as atenolol, acebutolol, betaxolol, carteolol, and nadolol may be considered.', 'Metabolism', 'Desipramine, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Escitalopram', 'Esmolol, Betaxolol, Carteolol, Penbutolol, Neostigmine, Acetylcholine, Physostigmine, Betaxolol, Carteolol, Apraclonidine, Guanethidine, Levobunolol', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67220/', '[1] Walley T, Pirmohamed M, Proudlove C, Maxwell D "Interaction of metoprolol and fluoxetine." Lancet 341 (1993): 967-8[2] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5[3] Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML, Kulawy RW, Beck DJ, Bertino JS "Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping." Clin Pharmacol Ther 64 (1998): 257-68[4] Riesenman C "Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal." Pharmacotherapy 15 (1995): s84-99[5] Ereshefsky L "Treating depression: potential drug-drug interactions: commentary." J Clin Psychopharmacol 16 (suppl (1996): s50-3[6] Hemeryck A, Lefebvre RA, DeVriendt C, Belpaire FM "Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers." Clin Pharmacol Ther 67 (2000): 283-91[7] Perucca E, Gatti G, Spina E "Clinical pharmacokinetics of fluvoxamine." Clin Pharmacokinet 27 (1994): 175-90[8] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51[9] Nemeroff CB, Devane CL, Pollock BG "Newer antidepressants and the cytochrome p450 system." Am J Psychiatry 153 (1996): 311-20[10] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[12] Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM "Inhibition by fluoxetine of cytochrome P450 2D6 activity." Clin Pharmacol Ther 53 (1993): 401-9[13] Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S "Fluvoxamine is a potent inhibitor of cytochrome P4501A2." Biochem Pharmacol 45 (1993): 1211-4[14] Drake WM, Gordon GD "Heart block in a patient on propranolol and fluoxetine." Lancet 343 (1994): 425-6[15] Hemeryck A, DeVriendt CA, Belpaire FM "Metoprolol-paroxetine interaction in human liver microsomes: Stereoselective aspects and prediction of the in vivo interaction." Drug Metab Disposition 29 (2001): 656-63[16] Richelson E "Pharmacokinetic interactions of antidepressants." J Clin Psychiatry 59 (1998): 22-6[17] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[20] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67134, 'Citalopram', 'Tinzaparin', 'Moderate', 'Serotonin reuptake inhibitors may potentiate the risk of bleeding in patients receiving heparin therapy. The exact mechanism is unknown but may involve a pharmacodynamic interaction, as serotonin reuptake inhibitors have been reported to interfere with platelet function.', NULL, 'Caution is recommended if a serotonin reuptake inhibitor is administered with heparin therapy, especially in the elderly and patients with renal impairment.', NULL, 'Caution is recommended if a serotonin reuptake inhibitor is administered with heparin therapy, especially in the elderly and patients with renal impairment. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 'Protein C, Selexipag', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67221/', '[1] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[2] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[3] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[4] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[5] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[6] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[7] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[8] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[9] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[10] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[11] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[12] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[14] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[15] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[18] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[19] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[20] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[21] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[22] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[23] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[24] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[25] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[26] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[27] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[28] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[29] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[30] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67135, 'Citalopram', 'Tirofiban', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 'Protein C, Selexipag', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67222/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67136, 'Citalopram', 'Tizanidine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Oxitriptan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67223/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67137, 'Citalopram', 'Tolazamide', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', 'Duloxetine, Desvenlafaxine, Maprotiline, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Trazodone, Tryptophan, More', 'Lixisenatide, Albiglutide, Guar gum, Canagliflozin, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Ertugliflozin, Semaglutide, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67224/', '[1] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[2] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[3] Field JB, Ohta M, Boyle C, Remer A "Potentiation of acetohexamide hypoglycemia by phenylbutazone." N Engl J Med 277 (1967): 889-94[4] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[5] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[6] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J "Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole." Diabet Med 4 (1987): 245-7[7] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[8] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT "Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride." Clin Pharmacol Ther 69 (2001): 194-200[9] Ravic M, Johnston A, Turner P "Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs." Postgrad Med J 66 (1990): s30-4[10] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[11] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[12] Tran PO, Gleason CE, Robertson RP "Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function." Diabetes 51 (2002): 1772-8[13] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[14] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[15] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[16] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[17] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[18] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[19] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[20] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[21] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA "Effect of pirprofen on glibenclamide kinetics and response." Br J Clin Pharmacol 14 (1982): 123-6[22] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[23] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[24] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[25] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[26] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[28] Sawka AM, Burgart V, Zimmerman D "Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors." Diabetes Care 24 (2001): 1845-6[29] Wing LM, Miners JO "Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition." Br J Clin Pharmacol 20 (1985): 482-5[30] Tremaine LM, Wilner KD, Preskorn SH "A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide." Clin Pharmacokinet 32(Suppl 1) (1997): 31-36[31] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Tannenbaum H, Anderson LG, Soeldner JS "Phenylbutazone-tolbutamide drug interaction." N Engl J Med 290 (1974): 344[33] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[34] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[35] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB "Aspirin-induced hypoglycaemia in a patient on haemodialysis." Lancet 2 (1971): 1092-3[36] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[37] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[38] Kradjan WA, Witt DM, Opheim KE, Wood FC "Lack of interaction between glipizide and co-trimoxazole." J Clin Pharmacol 34 (1994): 997-1002[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[41] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[42] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[43] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[44] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[45] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[46] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[47] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[48] Lozada A, Dujovne CA "Drug interactions with fibric acids." Pharmacol Ther 63 (1994): 163-76[49] Shah SJ, Bhandarkar SD, Satoskar RS "Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone." Int J Clin Pharmacol Ther Toxicol 22 (1984): 470-2[50] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[51] Nikkila EA, Ylikahri R, Huttunen JK "Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia." Proc R Soc Med 69 (1976): 58-63[52] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[53] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[54] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[55] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[56] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[57] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[58] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[59] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[60] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[61] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[64] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[65] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[66] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[67] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[68] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[69] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[70] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[71] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[72] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[73] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[74] "Product Information. Micronase (glyburide)." Pharmacia and Upjohn, Kalamazoo, MI.[75] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[76] Petitpierre B, Perrin L, Rudhardt M, et al "Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy." Int J Clin Pharmacol 6 (1972): 120-4[77] Pond SM, Birkett DJ, Wade DN "Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole." Clin Pharmacol Ther 22 (1977): 573-9[78] Sone H, Takahashi A, Yamada N "Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea." Ann Intern Med 134 (2001): 344[79] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[80] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[81] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[82] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[83] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[84] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[85] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[86] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[87] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[88] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[89] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[90] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[91] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[92] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[93] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[94] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM "Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism." Clin Pharmacol Ther 17 (1975): 731-4[95] Diwan PV, Sastry MS, Satyanarayana NV "Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans." Indian J Exp Biol 30 (1992): 317-9[96] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[97] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[98] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[99] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[100] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[101] Harris EL "Adverse reactions to oral antidiabetic agents." Br Med J 3 (1971): 29-30[102] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK "Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide." Br J Clin Pharmacol 30 (1990): 245-52[103] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[104] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[105] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[106] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[107] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[108] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[109] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[110] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[111] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[112] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67138, 'Citalopram', 'Tolbutamide', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', 'Duloxetine, Desvenlafaxine, Maprotiline, St. John''s Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Trazodone, Tryptophan, More', 'Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, Magnesium sulfate, Vitamin A, Metyrapone, Edrophonium, Histamine, Corticorelin, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67225/', '[1] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301[2] Turtle JR, Burgess JA "Hypoglycemic action of fenfluramine in diabetes mellitus." Diabetes 22 (1973): 858-67[3] Field JB, Ohta M, Boyle C, Remer A "Potentiation of acetohexamide hypoglycemia by phenylbutazone." N Engl J Med 277 (1967): 889-94[4] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V "Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia." Eur J Clin Nutr 57 (2003): 243-8[5] Deeg MA, Lipkin EW "Hypoglycemia associated with the use of fluoxetine." West J Med 164 (1996): 262-3[6] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J "Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole." Diabet Med 4 (1987): 245-7[7] World Health Organization "WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars." ([2020]):[8] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT "Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride." Clin Pharmacol Ther 69 (2001): 194-200[9] Ravic M, Johnston A, Turner P "Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs." Postgrad Med J 66 (1990): s30-4[10] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5[11] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[12] Tran PO, Gleason CE, Robertson RP "Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function." Diabetes 51 (2002): 1772-8[13] Ahmad S "Drug interaction induces hypoglycemia." J Fam Pract 40 (1995): 540-1[14] Baron SH "Salicylates as hypoglycemic agents." Diabetes Care 5 (1982): 64-71[15] Slade IH, and Iosefa RN "Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases." J Am Geriatr Soc 15 (1967): 948-50[16] "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA.[17] Feher MD, Amiel S "ACE inhibitors and hypoglycaemia." Lancet 346 (1995): 125-6[18] Vuksan V, Sievenpiper JL, Koo VY, et al "American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus." Arch Intern Med 160 (2000): 1009-13[19] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K "The effect of gemfibrozil on serum lipids in diabetic patients." Ann Clin Res 11 (1979): 240-5[20] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[21] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA "Effect of pirprofen on glibenclamide kinetics and response." Br J Clin Pharmacol 14 (1982): 123-6[22] Wu B, Sato T, Kiyosue T, Arita M "Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs." Cardiovasc Res 26 (1992): 1095-101[23] Barbato M "Another problem with Kinidin." Med J Aust 141 (1984): 685[24] Phillips RE, Looareesuwan S, White NJ, et al "Hypoglycaemia and antimalarial drugs: quinidine and release of insulin." Br Med J 292 (1986): 1319-21[25] Ahmad S "Gemfibrozil: interaction with glyburide." South Med J 84 (1991): 102[26] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM "Hypoglycemia in patients receiving disopyramide phosphate." Drug Intell Clin Pharm 17 (1983): 635-8[28] Sawka AM, Burgart V, Zimmerman D "Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors." Diabetes Care 24 (2001): 1845-6[29] Wing LM, Miners JO "Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition." Br J Clin Pharmacol 20 (1985): 482-5[30] Tremaine LM, Wilner KD, Preskorn SH "A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide." Clin Pharmacokinet 32(Suppl 1) (1997): 31-36[31] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Tannenbaum H, Anderson LG, Soeldner JS "Phenylbutazone-tolbutamide drug interaction." N Engl J Med 290 (1974): 344[33] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y "Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus." Br J Clin Pharmacol 17 (1984): 89-91[34] Salmela PI, Sotaniemi EA, Viikari J, et al "Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism." Diabetes Care 4 (1981): 535-40[35] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB "Aspirin-induced hypoglycaemia in a patient on haemodialysis." Lancet 2 (1971): 1092-3[36] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD "Fenfluramine increases insulin action in patients with NIDDM." Diabetes Care 12 (1989): 252-8[37] Morris AD, Newton RW, Boyle DI, et al. "ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes." Diabetes Care 20 (1997): 1363-7[38] Kradjan WA, Witt DM, Opheim KE, Wood FC "Lack of interaction between glipizide and co-trimoxazole." J Clin Pharmacol 34 (1994): 997-1002[39] Johnson J, Dobmeier M "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction." DICP 24 (1990): 250-1[40] Pollak PT, Mukherjee SD, Fraser AD "Sertraline-induced hypoglycemia." Ann Pharmacother 35 (2001): 1371-4[41] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[42] Feldman JM, Chapman B "Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion." Diabetologia 11 (1975): 487-94[43] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R "Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas." Metabolism 38 (1989): 179-83[44] Daubresse JC, Luyckx AS, Lefebvre PJ "Potentiation of hypoglycemic effect of sulfonylureas by clofibrate." N Engl J Med 294 (1976): 613[45] Cooper AJ, Ashcroft G "Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs." Lancet 1 (1966): 407-9[46] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[47] Quevedo SF, Krauss DS, Chazan JA, et al "Fasting hypoglycemia secondary to disopyramide therapy." JAMA 245 (1981): 2424[48] Lozada A, Dujovne CA "Drug interactions with fibric acids." Pharmacol Ther 63 (1994): 163-76[49] Shah SJ, Bhandarkar SD, Satoskar RS "Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone." Int J Clin Pharmacol Ther Toxicol 22 (1984): 470-2[50] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[51] Nikkila EA, Ylikahri R, Huttunen JK "Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia." Proc R Soc Med 69 (1976): 58-63[52] Davis TM, Karbwang J, Looareesuwan S, et al "Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers." Br J Clin Pharmacol 30 (1990): 397-403[53] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M "Lisinopril administration improves insulin action in aged patients with hypertension." J Hum Hypertens 9 (1995): 541-6[54] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[55] Hundal RS, Petersen KF, Mayerson AB, et al "Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes." J Clin Invest 109 (2002): 1321-6[56] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[57] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[58] de Salcedo I, Gorringe AL, Silva JL, Santos JA "Gemfibrozil in a group of diabetics." Proc R Soc Med 69 (1976): 64-70[59] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[60] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension." Br J Clin Pharmacol 46 (1998): 467-71[61] Prince RL, Larkins RG, Alford FP "The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects." Metabolism 30 (1981): 293-8[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C "Severe hypoglycemia associated with disopyramide." West J Med 138 (1983): 95-7[63] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[64] Ferrari C, Fressati S, Romussi M, et al. "Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia." Metabolism 26 (1977): 129-39[65] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7[66] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8[67] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K "Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection." Eur J Endocrinol 136 (1997): 3046[68] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ "Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents." Br J Clin Pharmacol 7 (1979): 599-603[69] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL "Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect." Int J Obes 7 (1983): 289-97[70] Whitcroft IA, Thomas JM, Rawsthorne A, et al "Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics." Horm Metab Res Suppl 22 (1990): 42-6[71] Rubin M, Zakheim B, Pitchumoni C "Disopyramide-induced profound hypoglycemia." N Y State J Med July,Aug,S (1983): 1057-8[72] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S "Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release." Am J Physiol 265 (1993): c337-42[73] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW "Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats." Diabetes 38 (1989): 499-503[74] "Product Information. Micronase (glyburide)." Pharmacia and Upjohn, Kalamazoo, MI.[75] Harrison LC, King-Roach A, Martin FI, Melick RA "The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue." Postgrad Med J 51 Suppl 1 (1975): 110-4[76] Petitpierre B, Perrin L, Rudhardt M, et al "Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy." Int J Clin Pharmacol 6 (1972): 120-4[77] Pond SM, Birkett DJ, Wade DN "Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole." Clin Pharmacol Ther 22 (1977): 573-9[78] Sone H, Takahashi A, Yamada N "Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea." Ann Intern Med 134 (2001): 344[79] Giugliano D, Ceriello A, Saccomanno F, et al "Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus." J Clin Endocrinol Metab 61 (1985): 160-6[80] Goldberg IJ, Brown LK, Rayfield EJ "Disopyramide (norpace)-induced hypoglycemia." Am J Med 69 (1980): 463-6[81] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C "Disopyramide-induced hypoglycemia: case report and review of the literature." Fundam Clin Pharmacol 3 (1989): 527-35[82] Aleyassine H, Gardiner RJ "Dual action of antidepressant drugs (MAO inhibitors) on insulin release." Endocrinology 96 (1975): 702-10[83] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL "Disopyramide-induced hypoglycaemia and increased serum insulin." N Z Med J July (1987): 407-8[84] Baciewicz AM, Swafford WB Jr "Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole." Drug Intell Clin Pharm 18 (1984): 309-10[85] Kubacka RT, Antla EJ, Juhl RP, Welshman IR "Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects." Ann Pharmacother 30 (1996): 20-6[86] Johnson JA, Kappel JE, Sharif MN "Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient." Ann Pharmacother 27 (1993): 304-6[87] Aleyassine H, Lee SH "Inhibition of insulin release by substrates and inhibitors of monoamine oxidase." Am J Physiol 222 (1972): 565-9[88] Cattaneo AG, Caviezel F, Pozza G "Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man." Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[89] Almirall J, Montoliu J, Torras A, Revert L "Propoxyphene-induced hypoglycemia in a patient with chronic renal failure." Nephron 53 (1989): 273-5[90] Phillips AF, Matty PJ, Porte PJ, Raye JR "Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb." Am J Obstet Gynecol 148 (1984): 481-7[91] Vuksan V, Stavro MP, Sievenpiper JL, et al "Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes." Diabetes Care 23 (2000): 1221-6[92] Richardson T, Foster J, Mawer GE "Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects." Br J Clin Pharmacol 22 (1986): 43-8[93] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3[94] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM "Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism." Clin Pharmacol Ther 17 (1975): 731-4[95] Diwan PV, Sastry MS, Satyanarayana NV "Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans." Indian J Exp Biol 30 (1992): 317-9[96] Semel JD, Wortham E, Karl DM "Fasting hypoglycemia associated with disopyramide." Am Heart J 106 (1983): 1160-1[97] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7[98] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[99] Wiederholt IC, Genco M, Foley JM "Recurrent episodes of hypoglycemia induced by propoxyphene." Neurology 17 (1967): 703-6[100] Hellman B "Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells." Metabolism 23 (1974): 839-46[101] Harris EL "Adverse reactions to oral antidiabetic agents." Br Med J 3 (1971): 29-30[102] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK "Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide." Br J Clin Pharmacol 30 (1990): 245-52[103] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[104] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[105] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[106] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[107] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[108] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[109] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[110] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[111] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[112] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67139, 'Citalopram', 'Tolcapone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Vilazodone, St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67226/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67140, 'Citalopram', 'Tolmetin', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 'Chondroitin sulfate, Glucosamine, Tolazoline, Dimethyl sulfoxide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67227/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67141, 'Citalopram', 'Tolterodine', 'Minor', 'Coadministration with drugs that are inhibitors of CYP450 2D6 may increase the plasma concentrations of tolterodine, which is primarily metabolized by this isoenzyme in patients that are extensive metabolizers, or EMs (approximately 93% of Caucasians and more than 98% of Asians and individuals of African descent). Moreover, since the active 5-hydroxymethyl metabolite (5-HM) generated by CYP450 2D6 is equipotent compared with tolterodine, and the sum of unbound serum concentrations of tolterodine and 5-HM are only 25% higher during the interaction, little alteration in the overall pharmacologic activity would be expected. Thus, dosage reductions should not be necessary.', NULL, '-', NULL, '-', 'Metabolism', 'St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 'Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Avanafil, Ammonium chloride, Dimethyl sulfoxide', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67228/', '[1] Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63[2] "Product Information. Detrol (tolterodine)." Pharmacia and Upjohn, Kalamazoo, MI.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67142, 'Citalopram', 'Topiramate', 'Moderate', 'The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.', 'Antagonism', 'Oxitriptan, Viloxazine, St. John''s Wort, Tryptophan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67229/', '[1] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al "Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies." Epilepsia 57 (2016): 2067-79[4] "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[6] "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al "Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study." Seizure 59 (2018): 28-33[10] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A "Hyponatremia associated with sodium valproate in a 22-year-old male." Nephrol Dial Transplant 23 (2008): epub[12] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[13] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[16] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[17] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[18] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK "Sodium valproate-induced hyponatremia: a case report." Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[22] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[24] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[26] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[28] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67143, 'Citalopram', 'Toremifene', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, More', 'Darolutamide, Aminoglutethimide', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67230/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67144, 'Citalopram', 'Torasemide', 'Moderate', 'Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.', NULL, 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.', NULL, 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Tinidazole, Mitapivat, Ascorbic acid, Oxytetracycline, Ciclopirox, Sulfamethizole, Simeprevir, Diazoxide, Econazole, Povidone-iodine, Sulfisoxazole, More', 'Desipramine, St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67231/', '[1] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995): 809-10[3] Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996): 885[4] Odeh M, Beny A, Oliven A "Severe symptomatic hyponatremia during citalopram therapy." Am J Med Sci 321 (2001): 159-60[5] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991): 542-3[6] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[7] Jacob S, Spinler SA "Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults." Ann Pharmacother 40 (2006): 1618-22[8] Fitzgerald MA "Hyponatremia associated with SSRI use in a 65-year-old woman." Nurse Pract 33 (2008): 11-2[9] van Campen JP, Voets AJ "SIADH caused by paroxetine." Ann Pharmacother 30 (1996): 1499[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996): 524[12] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[13] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[14] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997): 93-5[15] Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993): 1564[16] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[17] Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996): 680-3[18] Odeh M, Seligmann H, Oliven A "Severe life-threatening hyponatremia during paroxetine therapy." J Clin Pharmacol 39 (1999): 1290-1[19] Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995): 809[20] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[21] "Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996): 562[22] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997): 580[23] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[24] Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992): 1332[25] Barclay TS, Lee AJ "Citalopram-associated SIADH." Ann Pharmacother 36 (2002): 1558-63[26] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[27] Covyeou JA, Jackson CW "Hyponatremia associated with escitalopram." N Engl J Med 356 (2007): 94-5[28] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[29] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[30] Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996): 1413[31] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[32] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[33] Spigset O, hedenmalm K "Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions." Pharmacotherapy 17 (1997): 348-52[34] Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990): 1569-70[35] Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993): 723-4[36] Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994): 543-4[37] Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993): 62-3[38] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[39] Hwang AS, Magraw RM "Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine." Am J Psychiatry 146 (1989): 399[40] Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990): 948-9[41] Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997): 306-7[42] Kazal LA, Jr Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993): 341-3[43] Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995): 390[44] Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993): 143[45] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[46] Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997): 108-10[47] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[48] Rosner MH "Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors." Am J Med Sci 327 (2004): 109-11[49] Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994): 779-80[50] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[51] Madhusoodanan S, Brenner R, Brafman I, Bogunovic O "Hyponatremia associated with paroxetine use." South Med J 92 (1999): 843[52] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[53] Esposito P, Rampino T, Gregorini M, et al. "Severe symptomatic hyponatremia during sibutramine therapy: a case report." Am J Kidney Dis 52 (2008): 137-9[54] Spier SA, Frontera MA "Unexpected deaths in depressed medical inpatients treated with fluoxetine." J Clin Psychiatry 52 (1991): 377-82[55] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[56] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[57] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67145, 'Citalopram', 'Tositumomab', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Iodide I-131', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67232/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67146, 'Citalopram', 'Tranylcypromine', 'Major', 'By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of selective serotonin reuptake inhibitors (SSRIs) and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', NULL, 'In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.', NULL, 'In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with SSRIs, and vice versa.', 'Metabolism', 'Tranylcypromine', 'Citalopram, Esketamine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67233/', '[1] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20[2] Kline SS, Mauro LS, Scala-Bennett DM, Zick D "Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death." Clin Pharm 8 (1989): 510-4[3] Bhatara VS, Bandettini FC "Possible interaction between sertraline and tranylcypromine." Clin Pharm 12 (1993): 222-5[4] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[7] Suchowersky O, deVries JD "Interaction of fluoxetine and selegiline." Can J Psychiatry 35 (1990): 571-2[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[9] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[10] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[11] Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):[12] Suchowersky O, deVries J "Possible interactions between deprenyl and prozac." Can J Neurol Sci 17 (1990): 352-3[13] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[14] Sternbach H "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 850-1[15] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[16] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[17] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[18] Phillips SD, Ringo P "Phenelzine and venlafaxine interaction." Am J Psychiatry 152 (1995): 1400-1[19] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ "Adverse consequences of fluoxetine-MAOI combination therapy." J Clin Psychiatry 51 (1990): 222-5[20] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[21] Jimenez-Genchi A "Immediate switching from moclobemide to duloxetine may induce serotonin syndrome." J Clin Psychiatry 67 (2006): 1821-1822[22] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[23] Graber MA, Hoehns TB, Perry PJ "Sertraline-phenelzine drug interaction: a serotonin syndrome reaction." Ann Pharmacother 28 (1994): 732-5[24] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[25] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[26] Graham PM, Ilett KF "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 1255-6[27] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[28] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[29] Brannan SK, Talley BJ, Bowden CL "Sertraline and isocarboxazid cause a serotonin syndrome." J Clin Psychopharmacol 14 (1994): 144-5[30] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[31] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[32] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[33] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[34] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[35] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[36] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[37] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[38] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[39] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[40] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[41] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[42] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[43] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[44] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[45] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[46] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[47] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[48] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[49] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[50] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[51] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[52] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[53] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[54] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80[55] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[56] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[57] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[58] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67147, 'Citalopram', 'Trazodone', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval including tricyclic antidepressants and other antidepressants (e.g., trazodone) may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death. Concomitant use of agents with serotonergic activity including selective serotonin reuptake inhibitors, tricyclic antidepressants, and other antidepressants may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure. However, if treatment with citalopram is required in these patients, the labeling recommends that the dosage not exceed 40 mg/day, as higher dosages may have an excessive effect on the QT interval and confer no additional benefit in the treatment of depression. In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).', 'Synergism', 'Viloxazine, Trazodone', 'Citalopram, Esketamine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67234/', '[1] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[2] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[3] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[4] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[5] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[6] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[7] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[8] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[9] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[10] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[11] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[12] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[13] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[14] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[15] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[17] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[18] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[19] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[20] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[21] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[22] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67148, 'Citalopram', 'Treprostinil', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Desipramine, Trimipramine, Maprotiline, Oxitriptan, Mirtazapine, Bupropion, Viloxazine, Trazodone, Tryptophan, Amitriptyline, Nortriptyline, More', 'Protein C, Selexipag', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67235/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67149, 'Citalopram', 'Triamterene', 'Moderate', 'Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.', NULL, 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.', NULL, 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Desipramine, St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Finerenone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67236/', '[1] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995): 809-10[3] Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996): 885[4] Odeh M, Beny A, Oliven A "Severe symptomatic hyponatremia during citalopram therapy." Am J Med Sci 321 (2001): 159-60[5] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991): 542-3[6] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[7] Jacob S, Spinler SA "Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults." Ann Pharmacother 40 (2006): 1618-22[8] Fitzgerald MA "Hyponatremia associated with SSRI use in a 65-year-old woman." Nurse Pract 33 (2008): 11-2[9] van Campen JP, Voets AJ "SIADH caused by paroxetine." Ann Pharmacother 30 (1996): 1499[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996): 524[12] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[13] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[14] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997): 93-5[15] Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993): 1564[16] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[17] Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996): 680-3[18] Odeh M, Seligmann H, Oliven A "Severe life-threatening hyponatremia during paroxetine therapy." J Clin Pharmacol 39 (1999): 1290-1[19] Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995): 809[20] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[21] "Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996): 562[22] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997): 580[23] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[24] Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992): 1332[25] Barclay TS, Lee AJ "Citalopram-associated SIADH." Ann Pharmacother 36 (2002): 1558-63[26] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[27] Covyeou JA, Jackson CW "Hyponatremia associated with escitalopram." N Engl J Med 356 (2007): 94-5[28] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[29] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[30] Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996): 1413[31] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[32] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[33] Spigset O, hedenmalm K "Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions." Pharmacotherapy 17 (1997): 348-52[34] Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990): 1569-70[35] Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993): 723-4[36] Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994): 543-4[37] Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993): 62-3[38] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[39] Hwang AS, Magraw RM "Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine." Am J Psychiatry 146 (1989): 399[40] Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990): 948-9[41] Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997): 306-7[42] Kazal LA, Jr Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993): 341-3[43] Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995): 390[44] Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993): 143[45] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[46] Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997): 108-10[47] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[48] Rosner MH "Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors." Am J Med Sci 327 (2004): 109-11[49] Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994): 779-80[50] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[51] Madhusoodanan S, Brenner R, Brafman I, Bogunovic O "Hyponatremia associated with paroxetine use." South Med J 92 (1999): 843[52] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[53] Esposito P, Rampino T, Gregorini M, et al. "Severe symptomatic hyponatremia during sibutramine therapy: a case report." Am J Kidney Dis 52 (2008): 137-9[54] Spier SA, Frontera MA "Unexpected deaths in depressed medical inpatients treated with fluoxetine." J Clin Psychiatry 52 (1991): 377-82[55] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[56] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[57] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67150, 'Citalopram', 'Triazolam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67237/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67151, 'Citalopram', 'Trichlormethiazide', 'Moderate', 'Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.', NULL, 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.', NULL, 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Tinidazole, Mitapivat, Ascorbic acid, Oxytetracycline, Ciclopirox, Sulfamethizole, Simeprevir, Diazoxide, Econazole, Povidone-iodine, Sulfisoxazole, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67238/', '[1] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995): 809-10[3] Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996): 885[4] Odeh M, Beny A, Oliven A "Severe symptomatic hyponatremia during citalopram therapy." Am J Med Sci 321 (2001): 159-60[5] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991): 542-3[6] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[7] Jacob S, Spinler SA "Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults." Ann Pharmacother 40 (2006): 1618-22[8] Fitzgerald MA "Hyponatremia associated with SSRI use in a 65-year-old woman." Nurse Pract 33 (2008): 11-2[9] van Campen JP, Voets AJ "SIADH caused by paroxetine." Ann Pharmacother 30 (1996): 1499[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996): 524[12] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[13] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[14] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997): 93-5[15] Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993): 1564[16] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[17] Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996): 680-3[18] Odeh M, Seligmann H, Oliven A "Severe life-threatening hyponatremia during paroxetine therapy." J Clin Pharmacol 39 (1999): 1290-1[19] Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995): 809[20] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[21] "Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996): 562[22] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997): 580[23] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[24] Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992): 1332[25] Barclay TS, Lee AJ "Citalopram-associated SIADH." Ann Pharmacother 36 (2002): 1558-63[26] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[27] Covyeou JA, Jackson CW "Hyponatremia associated with escitalopram." N Engl J Med 356 (2007): 94-5[28] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[29] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[30] Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996): 1413[31] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[32] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[33] Spigset O, hedenmalm K "Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions." Pharmacotherapy 17 (1997): 348-52[34] Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990): 1569-70[35] Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993): 723-4[36] Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994): 543-4[37] Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993): 62-3[38] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[39] Hwang AS, Magraw RM "Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine." Am J Psychiatry 146 (1989): 399[40] Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990): 948-9[41] Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997): 306-7[42] Kazal LA, Jr Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993): 341-3[43] Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995): 390[44] Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993): 143[45] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[46] Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997): 108-10[47] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[48] Rosner MH "Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors." Am J Med Sci 327 (2004): 109-11[49] Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994): 779-80[50] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[51] Madhusoodanan S, Brenner R, Brafman I, Bogunovic O "Hyponatremia associated with paroxetine use." South Med J 92 (1999): 843[52] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[53] Esposito P, Rampino T, Gregorini M, et al. "Severe symptomatic hyponatremia during sibutramine therapy: a case report." Am J Kidney Dis 52 (2008): 137-9[54] Spier SA, Frontera MA "Unexpected deaths in depressed medical inpatients treated with fluoxetine." J Clin Psychiatry 52 (1991): 377-82[55] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[56] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[57] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67152, 'Citalopram', 'Triclabendazole', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More', 'Praziquantel, Oxamniquine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67239/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67153, 'Citalopram', 'Trifluoperazine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67240/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67154, 'Citalopram', 'Triflupromazine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67241/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67155, 'Citalopram', 'Trihexyphenidyl', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67242/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67156, 'Alimemazine', 'Citalopram', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', 'Azelastine, Ketotifen', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67243/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67157, 'Citalopram', 'Trimethadione', 'Moderate', 'The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.', 'Antagonism', 'Oxitriptan, Bupropion, Viloxazine, Tryptophan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67244/', '[1] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al "Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies." Epilepsia 57 (2016): 2067-79[4] "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[6] "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al "Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study." Seizure 59 (2018): 28-33[10] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A "Hyponatremia associated with sodium valproate in a 22-year-old male." Nephrol Dial Transplant 23 (2008): epub[12] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[13] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[16] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[17] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[18] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK "Sodium valproate-induced hyponatremia: a case report." Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[22] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[24] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[26] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[28] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67158, 'Citalopram', 'Trimethobenzamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion', 'Azelastine, Ketotifen', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67245/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67159, 'Citalopram', 'Trimipramine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval including tricyclic antidepressants and other antidepressants (e.g., trazodone) may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death. Concomitant use of agents with serotonergic activity including selective serotonin reuptake inhibitors, tricyclic antidepressants, and other antidepressants may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure. However, if treatment with citalopram is required in these patients, the labeling recommends that the dosage not exceed 40 mg/day, as higher dosages may have an excessive effect on the QT interval and confer no additional benefit in the treatment of depression. In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).', 'Synergism', 'Trimipramine', 'Citalopram, Esketamine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67246/', '[1] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[2] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[3] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[4] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[5] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[6] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[7] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[8] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[9] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[10] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[11] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[12] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[13] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[14] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[15] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[17] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[18] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[19] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[20] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[21] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[22] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67160, 'Citalopram', 'Tripelennamine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Duloxetine, Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion', 'Azelastine, Ketotifen, Tetracaine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67247/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67161, 'Citalopram', 'Triprolidine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Vilazodone, Trimipramine, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion', 'Azelastine, Ketotifen', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67248/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67162, 'Citalopram', 'Triptorelin', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More', 'Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67249/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67163, 'Citalopram', 'Troleandomycin', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.', NULL, '-', NULL, '-', 'Metabolism', 'Maprotiline, St. John''s Wort, Milnacipran, Vortioxetine, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, More', 'Lincomycin, Dirithromycin', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67250/', '[1] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[2] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67164, 'Citalopram', 'Tryptophan', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', NULL, 'The concomitant use of serotonin reuptake inhibitors and tryptophan should be avoided.', NULL, 'The concomitant use of serotonin reuptake inhibitors and tryptophan should be avoided.', 'Synergism', 'Citalopram, Esketamine', 'Bupropion, Viloxazine, Esketamine, Tryptophan', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67251/', '[1] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[2] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[4] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[5] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[6] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[7] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[8] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[9] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[10] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[11] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[12] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[13] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[15] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[16] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[17] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[18] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67165, 'Citalopram', 'Tucatinib', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.', NULL, '-', NULL, '-', 'Metabolism', 'Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, More', 'Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67252/', '[1] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[2] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67166, 'Citalopram', 'Urea', 'Moderate', 'Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.', NULL, 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.', NULL, 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 'Tromethamine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67253/', '[1] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995): 809-10[3] Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996): 885[4] Odeh M, Beny A, Oliven A "Severe symptomatic hyponatremia during citalopram therapy." Am J Med Sci 321 (2001): 159-60[5] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991): 542-3[6] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[7] Jacob S, Spinler SA "Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults." Ann Pharmacother 40 (2006): 1618-22[8] Fitzgerald MA "Hyponatremia associated with SSRI use in a 65-year-old woman." Nurse Pract 33 (2008): 11-2[9] van Campen JP, Voets AJ "SIADH caused by paroxetine." Ann Pharmacother 30 (1996): 1499[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996): 524[12] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[13] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[14] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997): 93-5[15] Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993): 1564[16] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[17] Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996): 680-3[18] Odeh M, Seligmann H, Oliven A "Severe life-threatening hyponatremia during paroxetine therapy." J Clin Pharmacol 39 (1999): 1290-1[19] Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995): 809[20] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[21] "Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996): 562[22] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997): 580[23] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[24] Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992): 1332[25] Barclay TS, Lee AJ "Citalopram-associated SIADH." Ann Pharmacother 36 (2002): 1558-63[26] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[27] Covyeou JA, Jackson CW "Hyponatremia associated with escitalopram." N Engl J Med 356 (2007): 94-5[28] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[29] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[30] Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996): 1413[31] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[32] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[33] Spigset O, hedenmalm K "Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions." Pharmacotherapy 17 (1997): 348-52[34] Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990): 1569-70[35] Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993): 723-4[36] Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994): 543-4[37] Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993): 62-3[38] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[39] Hwang AS, Magraw RM "Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine." Am J Psychiatry 146 (1989): 399[40] Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990): 948-9[41] Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997): 306-7[42] Kazal LA, Jr Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993): 341-3[43] Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995): 390[44] Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993): 143[45] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[46] Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997): 108-10[47] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[48] Rosner MH "Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors." Am J Med Sci 327 (2004): 109-11[49] Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994): 779-80[50] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[51] Madhusoodanan S, Brenner R, Brafman I, Bogunovic O "Hyponatremia associated with paroxetine use." South Med J 92 (1999): 843[52] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[53] Esposito P, Rampino T, Gregorini M, et al. "Severe symptomatic hyponatremia during sibutramine therapy: a case report." Am J Kidney Dis 52 (2008): 137-9[54] Spier SA, Frontera MA "Unexpected deaths in depressed medical inpatients treated with fluoxetine." J Clin Psychiatry 52 (1991): 377-82[55] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[56] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[57] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67167, 'Citalopram', 'Urokinase', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Protein C, Selexipag', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67254/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67168, 'Citalopram', 'Valbenazine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone', 'Dalfampridine, Tafamidis', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67255/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67169, 'Citalopram', 'Valerian', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67256/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67170, 'Citalopram', 'Vandetanib', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, More', 'Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67257/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67171, 'Citalopram', 'Vardenafil', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine', 'Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Avanafil, Ammonium chloride, Dimethyl sulfoxide', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67258/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67172, 'Citalopram', 'Vasopressin', 'Moderate', 'The antidiuretic response to vasopressin or desmopressin may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, selective serotonin reuptake inhibitors, tricyclic/tetracyclic antidepressants, carbamazepine, chlorpropamide, chlorpromazine, clofibrate, eslicarbazepine, fludrocortisone, haloperidol, lamotrigine, oxcarbazepine, urea, and some antineoplastic agents (e.g., vinca alkaloids, cisplatin, cyclophosphamide). These drugs can occasionally cause fluid retention, in some cases secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Coadministration with vasopressin or desmopressin may, therefore, increase the risk of water intoxication and/or hyponatremia. Seizure and coma in association with severe hyponatremia have been reported during concomitant use of desmopressin and imipramine or ibuprofen.', NULL, 'Caution is advised when vasopressin or desmopressin is used in combination with drugs that can cause fluid retention or SIADH.', NULL, 'Caution is advised when vasopressin or desmopressin is used in combination with drugs that can cause fluid retention or SIADH. Some authorities recommend adjusting vasopressin dosage as needed. Serum electrolytes, especially sodium, as well as BUN and creatinine should be monitored regularly. Patients should be advised to seek medical attention if they develop signs and symptoms of water intoxication or hyponatremia such as anorexia, nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, unsteadiness (which may lead to falls), anuria, and weight gain. Severe hyponatremia can be life-threatening if it is not promptly diagnosed and treated; therefore, early treatment is important to help prevent progression to seizures, coma, respiratory arrest, and death.', 'Synergism', 'Phenelzine, Tranylcypromine, St. John''s Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Tryptophan, Bupropion, Esketamine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67259/', '[1] Vanhees SL, Paridaens R, Vansteenkiste JF "Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review." Ann Oncol 11 (2000): 1061-5[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Kosmidis HV, Bouhoutsou DO, Varvoutsi MC, et al. "Vincristine overdose: experience with 3 patients." Pediatr Hematol Oncol 8 (1991): 171-8[4] Maramattom BV "Duloxetine-induced syndrome of inappropriate antidiuretic hormone secretion and seizures." Neurology 66 (2006): 773-4[5] ten Holt WL, van Iperen CE, Schrijver G, Bartelink AK "Severe hyponatremia during therapy with fluoxetine." Arch Intern Med 156 (1996): 681-2[6] Miller MG "Tricyclics as a possible cause of hyponatremia in psychiatric patients." Am J Psychiatry 146 (1989): 807[7] Petersson I, Nilsson G, Hansson B-G, Hedner T "Water intoxication associated with non-steroidal anti-inflammatory drug therapy." Acta Med Scand 221 (1987): 221-3[8] Nielsen OA, Johannessen AC, Bardrum B "Oxcarbazepine-induced hyponatremia, a cross-sectional study." Epilepsy Res 2 (1988): 269-71[9] Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996): 1413[10] Tanay A, Firemann Z, Yust I, Abramov AL "Chlorpropamide-induced syndrome of inappropriate antidiuretic hormone secretion." J Am Geriatr Soc 29 (1981): 334-6[11] Catalano G, Kanfer SN, Catalano MC, Alberts VA "The role of sertraline in a patient with recurrent hyponatremia." Gen Hosp Psychiatry 18 (1996): 278-83[12] Kokko H, Hall PD, Afrin LB "Fentanyl-associated syndrome of inappropriate antidiuretic hormone secretion." Pharmacotherapy 22 (2002): 1188-92[13] Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993): 143[14] Giles PD, Seem CC "Dothiepin and water handling." Lancet 2 (1985): 1013[15] Stephens WP, Coe JY, Baylis PH "Plasma arginine vasopressin concentrations and antidiuretic action of carbamazepine." Br Med J 1 (1978): 1445-7[16] el Weshi A, Thieblemont C, Cottin V, Barbet N, Catimel G "Cisplatin-induced hyponatremia and renal sodium wasting." Acta Oncol 34 (1995): 264-5[17] Goldstein L, Barker M, Segall F, Asihene R, Balser S, Lautenbach D, Mccoy M "Seizure and transient SIADH associated with sertraline." Am J Psychiatry 153 (1996): 732[18] Lahr MB "Hyponatremia during carbamazepine therapy." Clin Pharmacol Ther 37 (1985): 693-6[19] Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996): 885[20] Wilkinson TJ, Begg EJ, Winter AC, Sainsbury R "Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people." Br J Clin Pharmacol 47 (1999): 211-7[21] Kadowaki T, Hagura R, Kajinuma H, et al "Chlorpropamide-induced hyponatremia: incidence and risk factors." Diabetes Care 6 (1983): 468-71[22] Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990): 948-9[23] Laycock JF, Lewis AF "Potentiation of the response to vasopressin (pitressin) by treatment with a combination of chlorpropamide and chlorothiazide in Brattleboro rats with hereditary hypothalamic diabetes insipidus." Br J Pharmacol 59 (1977): 11-6[24] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[25] Gandelman MS "Review of carbamazepine-induced hyponatremia." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994): 211-33[26] Ryan M, Adams AG, Larive LL "Hyponatremia and leukopenia associated with oxcarbazepine following carbamazepine therapy." Am J Health Syst Pharm 58 (2001): 1637-9[27] Ananth J, Lin KM "Siadh: a serious side effect of psychotropic drugs." Int J Psychiatry Med 16 (1986): 401-7[28] Rider JM, Mauger TF, Jameson JP, Notman DD "Water handling in patients receiving haloperidol decanoate." Ann Pharmacother 29 (1995): 663-6[29] Wylie KR, Harris SJ, Harrop FM "Lofepramine-induced hyponatraemia." Br J Psychiatry 154 (1989): 419-20[30] Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997): 108-10[31] Draper B, Berman K "Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly." Drugs Aging 25 (2008): 501-19[32] Whittaker JA, Parry DH, Bunch C, Weatherall DJ "Coma associated with vincristine therapy." Br Med J 4 (1973): 335-7[33] Pledger DR, Mathew H "Hyponatraemia and clomipramine therapy." Br J Psychiatry 154 (1989): 263-4[34] Boyd IW "Hyponatremia with venlafaxine." Ann Pharmacother 32 (1998): 981[35] Garrett CA, Simpson TA "Syndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy." Ann Pharmacother 32 (1998): 1306-9[36] Lichtigfeld FJ, Gillman MA "Dangerous synergism between sedatives and a hyponatraemic state." J R Soc Med 83 (1990): 185[37] Woster P, Carrazana EJ "Oxcarbazepine and hyponatremia." Am J Health Syst Pharm 59 (2002): 467[38] McCarron M, Wright GD, Roberts SD "Water intoxication after low dose cyclophosphamide." BMJ 311 (1995): 292[39] Roxanas MG "Mirtazapine-induced hyponatraemia." Med J Aust 179 (2003): 453-4[40] Jacob S, Spinler SA "Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults." Ann Pharmacother 40 (2006): 1618-22[41] "Product Information. Vasopressin (vasopressin)." APP (Abraxis Pharmaceutical Products), Schaumberg, IL.[42] Littlewood TJ, Smith AP "Syndrome of inappropriate antidiuretic hormone secretion due to treatment of lung cancer with cisplatin." Thorax 39 (1984): 636-7[43] Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995): 390[44] Luzecky MH, Burman KD, Schultz ER "The syndrome of inappropriate secretion of antidiuretic hormone associated with amitriptyline administration." South Med J 67 (1974): 495-7[45] Kosten TR, Camp W "Inappropriate secretion of antidiuretic hormone in a patient receiving piperazine phenothiazines." Psychosomatics 21 (1980): 351,354-5[46] Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990): 1569-70[47] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997): 93-5[48] Hamburger S, Langley H, Bowers G "The syndrome of inappropriate secretion of antidiuretic hormone associated with amitriptyline or trifluoperazine administration." J Kans Med Soc 81 (1980): 469-70[49] Kimura T, Ota K, Shoju M et al "Chlorpropamide-induced ADH release, hyponatremia and central pontine myelinolysis in diabetes mellitus." Tohoku J Exp Med 177 (1995): 303-13[50] Cutting HO "Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy." Am J Med 51 (1971): 269-71[51] Kagawa K, Fujitaka K, Isobe T, et al "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion." Intern Med 40 (2001): 1020-3[52] Bavbek N, Kargili A, Akcay A, Kaya A "Recurrent hyponatremia associated with citalopram and mirtazapine." Am J Kidney Dis 48 (2006): e61-2[53] Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996): 680-3[54] Matsumura M, Yamaguchi M, Sato T "Severe hyponatremia in a patient treated with levomepromazine and carbamazepine." Intern Med 40 (2001): 459[55] Rault RM "Case report: hyponatremia associated with nonsteroidal antiinflammatory drugs." Am J Med Sci 305 (1993): 318-20[56] Iyer AV, Krasnow SH, Dufour DR, Arcenas AS "Sodium-wasting nephropathy caused by cisplatin in a patient with small-cell lung cancer." Clin Lung Cancer 5 (2003): 187-9[57] Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997): 306-7[58] "Product Information. Pitressin (vasopressin)." Parke-Davis, Morris Plains, NJ.[59] Gupta AK, Saravay SM "Venlafaxine-induced hyponatremia." J Clin Psychopharmacol 17 (1997): 223-5[60] Munro AH, Crompton GK "Inappropriate antidiuretic hormone secretion in oat-cell carcinoma of bronchus. Aggravation of hyponatraemia by intravenous cyclophosphamide." Thorax 27 (1972): 640-2[61] Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994): 543-4[62] Hwang AS, Magraw RM "Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine." Am J Psychiatry 146 (1989): 399[63] Schwab M, Roder F, Morike K, Thon KP, Klotz U "Drug-induced hyponatraemia in elderly patients." Br J Clin Pharmacol 48 (1999): 105-6[64] Ritch PS "Cis-dichlorodiammineplatinum II-induced syndrome of inappropriate secretion of antidiuretic hormone." Cancer 61 (1988): 448-50[65] Kinzie BJ "Management of the syndrome of inappropriate secretion of antidiuretic hormone." Clin Pharm 6 (1987): 625-33[66] Agrawal NK, Rastogi A, Goyal R, Singh SK "Sertraline-induced hyponatremia in the elderly." CJEM 9 (2007): 415[67] Davison P, Wardrope J "Acute amitriptyline withdrawal and hyponatraemia. A case report." Drug Saf 8 (1993): 78-80[68] Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994): 779-80[69] Epstein S, Van Mieghem W, Simson E, Jackson WP "Chlorpropamide hyponatremia." N Engl J Med 286 (1972): 785[70] Sloan RW, Kreider RM, Luderer JR "The effect of chlorpropamide hyponatremia on mental status in a nursing home population." J Fam Pract 16 (1983): 937-42[71] Jayachandran NV, Chandrasekhara PK, Thomas J, Agrawal S, Narsimulu G "Cyclophosphamide-associated complications: we need to be aware of SIADH and central pontine myelinolysis." Rheumatology 48 (2009): 89-90[72] Moses AM, Miller M "Drug-induced dilutional hyponatremia." N Engl J Med 291 (1974): 1234-9[73] Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994): 85-6[74] Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995): 809[75] Stuart MJ, Cuaso C, Miller M, Oski FA "Syndrome of recurrent increased secretion of antidiuretic hormone following multiple doses of vincristine." Blood 45 (1975): 315-20[76] Aasen G, Frey HM "Excessive sensitivity to the hyponatremic effect of chlorpropamide in a patient with diabetes mellitus and anterior pituitary insufficiency." Acta Med Scand 208 (1980): 233-6[77] Ashton MG, Ball SG, Thomas TH, Lee MR "Water intoxication associated with carbamazepine tretment." Br Med J 1 (1977): 1134-5[78] Smith NJ, Espir ML, Baylis PH "Raised plasma arginine vasopressin concentration in carbamazepine-induced water intoxication." Br Med J 2 (1977): 804[79] Sarret D, Le Berre JP, Zemraoui N "Tramadol-induced hyponatremia." Am J Kidney Dis 52 (2008): 1026; author reply 1027[80] Instituto de Salud Pblica de Chile "Sistema de Consulta de Productos Registrados. Available from: URL: http://registrosanitario.ispch.gob.cl/" ([cited 2013]):[81] Madhusoodanan S, Osnos R "Amitriptyline induced hyponatremia: a case report." Mt Sinai J Med 48 (1981): 431-3[82] Mitsch RA, Lee AK "Syndrome of inappropriate antidiuretic hormone with imipramine." Drug Intell Clin Pharm 20 (1986): 787-9[83] Degner D, Grohmann R, Kropp S, et al. "Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP." Pharmacopsychiatry 37 Suppl 1 (2004): S39-45[84] Masood GR, Karki SD, Patterson WR "Hyponatremia with venlafaxine." Ann Pharmacother 32 (1998): 49-51[85] "Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996): 562[86] Orbo A, Simonsen E "Cisplatin-induced sodium and magnesium wastage." Eur J Cancer 28A (1992): 1294[87] Kazal LA, Jr Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993): 341-3[88] Moses AM, Howanitz J, van Gemert M, Miller M "Clofibrate-induced antidiuresis." J Clin Invest 52 (1973): 535-42[89] Johannessen AC, Nielsen OA "Hyponatremia induced by oxcarbazepine." Epilepsy Res 1 (1987): 155-6[90] Harlow PJ, DeClerck YA, Shore NA, Ortega JA, Carranza A, Heuser E "A fatal case of inappropriate ADH secretion induced by cyclophosphamide therapy." Cancer 44 (1979): 896-8[91] Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992): 1332[92] Fort S, Bannister P, Manning A, Bolton R, Losowsky MS "Inappropriate antidiuretic hormone secretion associated with dothiepin." Lancet 2 (1985): 551[93] Zawada ET "Renal consequences of nonsteroidal antiinflammatory drugs." Postgrad Med J 71 (1982): 223-30[94] "Product Information. DDAVP (desmopressin)." Rhone-Poulenc Rorer, Collegeville, PA.[95] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991): 542-3[96] Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S "Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review." Epilepsia 35 (1994): 181-8[97] Famularo G, Gasbarrone L, De Virgilio A, Minisola G "Mirtazapine-associated hyponatremia in an elderly patient." Ann Pharmacother 43 (2009): 1144-5[98] O''Sullivan D, Oyebode F "Hyponatraemia and lofepramine." Br J Psychiatry 150 (1987): 720-1[99] Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983): 708-10[100] Harris RC "Cyclooxygenase-2 inhibition and renal physiology." Am J Cardiol 89(6 Suppl 1) (2002): 10-7[101] Shang CY, Soong WT, Lin HN "Hypokalemia with venlafaxine." J Clin Psychiatry 63 (2002): 1049-50[102] Guay DR "Hyponatremia associated with selective serotonin reuptake inhibitors. Available from: URL: http://www.ascp.com/publications/tcp/2000/feb/cr_hypo.shtml." ([2000 Feb]):[103] Culine S, Ghosn M, Droz JP "Inappropriate antidiuretic hormone secretion induced by ifosfamide." Eur J Cancer 26 (1990): 922[104] "Product Information. Vasostrict (vasopressin)." Par Pharmaceutical Inc, Chestnut Ridge, NY.[105] DeFronzo RA, Braine H, Colvin M, Davis PJ "Water intoxication in man after cyclophosphamide therapy: time course and relation to drug activation." Ann Intern Med 78 (1973): 861-9[106] Cilli AS, Algun E "Oxcarbazepine-induced syndrome of inappropriate secretion of antidiuretic hormone." J Clin Psychiatry 63 (2002): 742[107] Levsky ME, Schwartz JB "Sertraline-induced hyponatremia in an older patient." J Am Geriat Soc 46 (1998): 1582-3[108] Perucca E, Garratt A, Hebdige S, Richens A "Water intoxication in epileptic patients receiving carbamazepine." J Neural Neurosurg Psychiatry 41 (1978): 713-8[109] van Campen JP, Voets AJ "SIADH caused by paroxetine." Ann Pharmacother 30 (1996): 1499[110] Henkin Y, Kaplan Z, Alkan M "Psychiatric presentation of hyponatremia associated with the use of amitriptyline: a report of two cases." Isr J Med Sci 25 (1989): 587-9[111] Bjorck E, Samuelsson J "Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) after treatment with cyclophosphamide, alpha-interferon and betamethasone in a patient with multiple myeloma." Eur J Haematol 56 (1996): 323-5[112] Davis FB, Davis PJ "Water metabolism in diabetes mellitus." Am J Med 70 (1981): 210-4[113] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[114] "Product Information. Stimate (desmopressin)." Forest Pharmaceuticals, St. Louis, MO.[115] Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993): 1564[116] Oldham RK, Pomeroy TC "Vincristine-induced syndrome of inappropriate secretion of antidiuretic hormone." South Med J 65 (1972): 1010-2[117] Levin L, Sealy R, Barron J "Syndrome of inappropriate antidiuretic hormone secretion following cis-dichlorodiammineplatinum II in a patient with malignant thymoma." Cancer 50 (1982): 2279-82[118] Garson M "Syndrome of dilutional hyponatraemia secondary to tricyclic antidepressant." Practitioner 222 (1979): 411-2[119] Cinotti GA, Stirati G, Ruggiero F "Abnormal water retention and symptomatic hyponatraemia in idiopathic diabetes insipidus during chlorpropamide therapy." Postgrad Med J 48 (1972): 107-11[120] Ortenzi A, Paggi A, Foschi N, Sabbatini D, Pistoli E "Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy." Funct Neurol 23 (2008): 97-100[121] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[122] Colgate R "Hyponatraemia and inappropriate secretion of antidiuretic hormone associated with the use of imipramine." Br J Psychiatry 163 (1993): 819-22[123] Paliwal V, Garg RK, Kar AM, Singh MK "Oxcarbazepine induced hyponatremic coma." Neurol India 54 (2006): 214-5[124] Nisbet P "Chlorpropamide-induced hyponatraemia." Br Med J 1 (1977): 904[125] Adlakha A, Manocha AP, Bechard DL "Imipramine-induced syndrome of inappropriate antidiuretic hormone secretion." South Med J 84 (1991): 1507-9[126] Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996): 524[127] Hamed M, Mitchell H, Clow DJ "Hyponatraemic convulsion associated with desmopressin and imipramine treatment." BMJ 306 (1993): 1169[128] Henry DA, Lawson DH, Reavey P, Renfrew S "Hyponatraemia during carbamazepine treatment." Br Med J 1 (1977): 83-4[129] Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006): 142-5[130] Zalin AM, Hutchinson CE, Jong M, Matthews K "Hyponatraemia during treatment with chlorpropamide and Moduretic (amiloride plus hydrochlorothiazide)." Br Med J (Clin Res Ed) 289 (1984): 659[131] Cantwell BM, Idle M, Millward MJ, Hall G, Lind MJ "Encephalopathy with hyponatremia and inappropriate arginine vasopressin secretion following an intravenous ifosfamide infusion." Ann Oncol 1 (1990): 232[132] Parker WA "Imipramine-induced syndrome of inappropriate antidiuretic hormone secretion." Drug Intell Clin Pharm 18 (1984): 890-4[133] Kruger S, Lindstaedt M "Duloxetine and hyponatremia: a report of 5 cases." J Clin Psychopharmacol 27 (2007): 101-104[134] Cheung NT, Coley S, Sheeran T, Situnayake RD "Syndrome of inappropriate secretion of antidiuretic hormone induced by diclofenac." BMJ 306 (1993): 186[135] Belton K, Thomas SH "Drug-induced syndrome of inappropriate antidiuretic hormone secretion." Postgrad Med J 75 (1999): 509-10[136] Okamoto M, Nako Y, Tachibana A, et al "Efficacy of phenytoin against hyponatremic seizures due to SIADH after administration of anticancer drugs in a neonate." J Perinatol 22 (2002): 247-8[137] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[138] Garcia M, Miller M, Moses AM "Chlorpropamide-induced water retention in patients with diabetes mellitus." Ann Intern Med 75 (1971): 549-54[139] Kuroda H, Kawamura M, Hato T, et al. "Syndrome of inappropriate secretion of antidiuretic hormone after chemotherapy with vinorelbine." Cancer Chemother Pharmacol (2007):[140] Kuz GM, Manssourian A "Carbamazepine-induced hyponatremia: assessment of risk factors." Ann Pharmacother 39 (2005): 1943-6[141] O''Regan S, Carson S, Chesney RW, Drummond KN "Electrolyte and acid-base disturbances in the management of leukemia." Blood 49 (1977): 345-53[142] Robson WL, Leung AK "Hyponatraemia following desmopressin." BMJ 307 (1993): 64-5[143] Bluff DD, Oji N "SIADH in a patient receiving sertraline." Ann Intern Med 123 (1995): 811[144] Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993): 62-3[145] Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993): 723-4[146] Kato A, Sugiura T, Yamamoto T, et al "Water intoxication induced by low-dose oral cyclophosphamide in a patient with anti-neutrophil cytoplasmic antibody-related glomerulonephritis." NDT Plus 1 (2008): 286-8[147] Flint AJ, Crosby J, Genik JL "Recurrent hyponatremia associated with fluoxetine and paroxetine." Am J Psychiatry 153 (1996): 134[148] Egger C, Muehlbacher M, Nickel M, Geretsegger C, Stuppaeck C "A case of recurrent hyponatremia induced by venlafaxine." J Clin Psychopharmacol 26 (2006): 439[149] Otsuka F, Hayashi Y, Ogura T, et al "Syndrome of inappropriate secretion of antidiuretic hormone following intra-thoracic cisplatin." Intern Med 35 (1996): 290-4[150] Nagappa M, Bhat RR, Sudeep K, Mishra SK, Badhe AS, Hemavathi B "Vincrisitine-induced acute life-threatening hyponatremia resulting in seizure and coma." Indian J Crit Care Med 13 (2009): 167-8[151] "Non-steroidal anti-inflammatory drugs and the kidney." Br Med J (Clin Res Ed) 293 (1986): 202-3[152] Leung M, Remick R "Sertraline-associated hyponatremia." Can J Psychiatry 40 (1995): 497-8[153] Webberley MJ, Murray JA "Life-threatening acute hyponatraemia induced by low dose cyclophosphamide and indomethacin." Postgrad Med J 65 (1989): 950-2[154] DeFronzo RA, Colvin OM, Braine H, Robertson GL, Davis PJ "Proceedings: cyclophosphamide and the kidney." Cancer 33 (1974): 483-91[155] Lane RM "SSRIs and hyponatraemia." Br J Clin Pract 51 (1997): 144-6[156] Appel WC "Possible roles of normeperidine and hyponatremia in a postoperative death." Can Med Assoc J 137 (1987): 912-3[157] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997): 580[158] Tomiwa K, Mikawa H, Hazama F, Yazawa K, Hosoya R, Ohya T, Nishimura K "Syndrome of inappropriate secretion of antidiuretic hormone caused by vincristine therapy: a case report of the neuropathology." J Neurol 229 (1983): 267-72[159] Dirks AC, van Hyfte DM "Recurrent hyponatremia after substitution of citalopram with duloxetine." J Clin Psychopharmacol 27 (2007): 313[160] Izzedine H, Launay-Vacher V, Ciroldi M, Fardet L, Deray G "Fanconi and inappropriate secretion of antidiuretic hormone syndromes secondary to venlafaxine therapy." Nephron 92 (2002): 944-6[161] Meynaar IA, Peeters AJ, Mulder AH, Ottervanger JP "Syndrome of inappropriate ADH secretion attributed to the serotonin re-uptake inhibitors, venlafaxine and paroxetine." Neth J Med 50 (1997): 243-5[162] "Inappropriate antidiuretic hormone secretion." West J Med 122 (1975): 145-9[163] Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003): 1694-702[164] Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996): 519-27[165] Lazarevic V, Hagg E, Wahlin A "Hiccups and severe hyponatremia associated with high-dose cyclophosphamide in conditioning regimen for allogeneic stem cell transplantation." Am J Hematol 82 (2007): 88[166] Moses AM, Howanitz J, Miller M "Diuretic action of three sulfonylurea drugs." Ann Intern Med 78 (1973): 541-4[167] Safdieh JE, Rudominer R "A case of hyponatremia induced by duloxetine." J Clin Psychopharmacol 26 (2006): 675-676[168] Fonseca VA, Deb M, Gokani SS, Bhandarkar SD "Chlorpropamide induced syndrome of inappropriate antidiuretic hormone secretion." J Postgrad Med 26 (1980): 127-30[169] Weir MR "Renal effects of nonselective NSAIDs and coxibs." Cleve Clin J Med 69(Suppl 1) (2002): SI53-8[170] Nicholson RG, Feldman W "Hyponatremia in association with vincristine therapy." Can Med Assoc J 106 (1972): 356-7[171] Kalff R, Houtkooper MA, Meyer JW, et al "Carbamazepine and serum sodium levels." Epilepsia 24 (1984): 390-7[172] Dong X, Leppik IE, White J, Rarick J "Hyponatremia from oxcarbazepine and carbamazepine." Neurology 65 (2005): 1976-8[173] Bourgeois JA "Reversible hyponatremia and venlafaxine." Psychosomatics 46 (2005): 495-6[174] Purcell P, Valmana A "Toxic epidermal necrolysis following chlorpromazine ingestion complicated by SIADH." Postgrad Med J 72 (1996): 186-9[175] Steinhoff BJ, Stoll KD, Stodieck SR, Paulus W "Hyponatremic coma under oxcarbazepine therapy." Epilepsy Res 11 (1992): 67-70[176] Isojarvi JI, Huuskonen UE, Pakarinen AJ, Vuolteenaho O, Myllyla VV "The regulation of serum sodium after replacing carbamazepine with oxcarbazepine." Epilepsia 42 (2001): 741-5[177] Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995): 809-10[178] Bissett D Cornford EJ Sokal M "Hyponatraemia following cisplatin chemotherapy." Acta Oncol 28 (1989): 823[179] Matuk F, Kalyanaraman K "Inappropriate ADH secretion." Arch Neurol 34 (1977): 725[180] Zavagli G Ricci G Tataranni G Mapelli G Abbasciano V "Life-threatening hyponatremia caused by vinblastine." Med Oncol Tumor Pharmacother 5 (1988): 67-9[181] Ljung R "Use of desmopressin and concomitant use of potentially interacting drugs in elderly patients in Sweden." Eur J Clin Pharmacol (2008):[182] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79[183] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[184] Collins GB, Brosnihan KB, Zuti RA, Messina M, Gupta MK "Neuroendocrine, fluid balance, and thirst responses to alcohol in alcoholics." Alcohol Clin Exp Res 16 (1992): 228-32[185] Hirschl MM, Derfler K, Bieglmayer C, et.al "Hormonal derangements in patients with severe alcohol intoxication." Alcohol Clin Exp Res 18 (1994): 761-6[186] "Product Information. Vasostrict (vasopressin)." Par Pharmaceutical Inc, Chestnut Ridge, NY.[187] Taivainen H, Laitinen K, Tahtela R, Kilanmaa K, Valimaki MJ "Role of plasma vasopressin in changes of water balance accompanying acute alcohol intoxication." Alcohol Clin Exp Res 19 (1995): 759-62[188] Cerner Multum, Inc. "Australian Product Information." O 0[189] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[190] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[191] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[192] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67173, 'Citalopram', 'Vemurafenib', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion, Esketamine', 'Tinidazole, Mitapivat, Ascorbic acid, Oxytetracycline, Ciclopirox, Sulfamethizole, Simeprevir, Diazoxide, Econazole, Povidone-iodine, Sulfisoxazole, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67260/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67174, 'Citalopram', 'Venlafaxine', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval including tricyclic antidepressants and other antidepressants (e.g., trazodone) may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death. Concomitant use of agents with serotonergic activity including selective serotonin reuptake inhibitors, tricyclic antidepressants, and other antidepressants may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure. However, if treatment with citalopram is required in these patients, the labeling recommends that the dosage not exceed 40 mg/day, as higher dosages may have an excessive effect on the QT interval and confer no additional benefit in the treatment of depression. In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).', 'Synergism', 'Esketamine, Venlafaxine', 'Citalopram, Esketamine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67261/', '[1] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[2] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[3] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[4] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[5] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[6] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[7] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[8] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[9] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[10] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[11] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[12] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[13] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[14] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[15] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[17] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[18] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[19] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[20] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[21] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[22] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67175, 'Citalopram', 'Verapamil', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.', NULL, '-', NULL, '-', 'Metabolism', 'Desvenlafaxine, St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Esketamine', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67262/', '[1] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[2] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67176, 'Citalopram', 'Vigabatrin', 'Moderate', 'The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.', 'Antagonism', 'Oxitriptan, Bupropion, Viloxazine, Tryptophan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67263/', '[1] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al "Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies." Epilepsia 57 (2016): 2067-79[4] "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[6] "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al "Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study." Seizure 59 (2018): 28-33[10] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A "Hyponatremia associated with sodium valproate in a 22-year-old male." Nephrol Dial Transplant 23 (2008): epub[12] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[13] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[16] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[17] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[18] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK "Sodium valproate-induced hyponatremia: a case report." Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[22] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[24] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[26] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[28] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67177, 'Citalopram', 'Vilazodone', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'Vilazodone, Esketamine', 'Citalopram, Esketamine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67264/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67178, 'Citalopram', 'Vorapaxar', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Maprotiline, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More', 'Protein C, Selexipag', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67265/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67179, 'Citalopram', 'Voriconazole', 'Major', 'Coadministration with CYP450 2C19 inhibitors may increase the plasma concentrations of citalopram, which is partially metabolized by the isoenzyme. Cases of QT interval prolongation and torsade de pointes have been reported during postmarketing use. In general, the risk of ventricular arrhythmia in association with QT prolongation is largely unpredictable, but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia).', NULL, 'Given the risk of dose-dependent QT prolongation, citalopram dosage should not exceed 20 mg/day when prescribed in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole.', NULL, 'Given the risk of dose-dependent QT prolongation, citalopram dosage should not exceed 20 mg/day when prescribed in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole. Alternatives should be considered when possible, and hypokalemia or hypomagnesemia should be corrected prior to initiation of citalopram treatment and periodically monitored. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Metabolism', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Bupropion, Esketamine, Fluvoxamine', 'Flucytosine, Anidulafungin, Micafungin, Oteseconazole', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67266/', '[1] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[2] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[3] Priskorn M, Larsen F, Segonzac A, Moulin M "Pharmacokinetic interaction study of citalopram and cimetidine in healhy subjects." Eur J Clin Pharmacol 52 (1997): 241-2[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[9] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67180, 'Citalopram', 'Vortioxetine', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'Viloxazine, Vortioxetine, Esketamine', 'Citalopram, Esketamine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67267/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67181, 'Citalopram', 'Voxelotor', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.', NULL, '-', NULL, '-', 'Metabolism', 'Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, More', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67268/', '[1] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[2] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67182, 'Citalopram', 'Warfarin', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Phenelzine, Tranylcypromine, Maprotiline, Isocarboxazid, Oxitriptan, Tryptophan, Esketamine', 'Protein C, Selexipag', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67269/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67183, 'Citalopram', 'Zafirlukast', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.', NULL, '-', NULL, '-', 'Metabolism', 'Maprotiline, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Fluvoxamine, Phenelzine, More', 'Omalizumab, Tezepelumab, Benralizumab, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, Bromotheophylline', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67270/', '[1] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[2] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67184, 'Citalopram', 'Zaleplon', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67271/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67185, 'Citalopram', 'Zanubrutinib', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Phenelzine, Desipramine, Tranylcypromine, Trimipramine, Maprotiline, Isocarboxazid, Oxitriptan, Mirtazapine, Bupropion, Trazodone, Tryptophan, More', 'Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67272/', '[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6[3] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001): 167-76[5] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5[7] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005): 175-81[9] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999): 1106-9[12] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9[14] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132[16] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[17] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993): 241[24] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2[27] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64[29] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[30] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. "Australian Product Information." O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997): 170-2[37] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[39] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[41] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[42] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67186, 'Citalopram', 'Ziconotide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion', 'Methoxyflurane, Salsalate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67273/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67187, 'Citalopram', 'Ziprasidone', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'Oxitriptan, Vilazodone, Vortioxetine, Tryptophan', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67274/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm." ([2011 Aug 24]):[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm." ([2012 Mar 28]):[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[9] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[12] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[14] "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL.[15] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67188, 'Citalopram', 'Zolmitriptan', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.', 'Synergism', 'Esketamine', 'Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Erenumab, Fremanezumab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67275/', '[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50[3] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[6] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994): 983-5[9] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002): 1651-2[14] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990): 722-3[15] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004): 111-3[16] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[17] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21[18] "Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994): 642-4[22] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000): 871-4[23] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998): 950,953[24] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8[27] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9[32] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999): 871-4[35] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000): 254-6[36] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20[40] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2[41] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[42] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007): 346-7[50] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997): 287-9[52] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.[53] "Product Information. Oleptro (traZODone)." Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995): 159-60[55] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med (2012):[63] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4[73] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994): 593-7[75] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[80] "Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[82] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005): 351-3[88] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004): 289-90[90] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001): 432-4[93] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003): E8-E11[95] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5[98] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67189, 'Citalopram', 'Zolpidem', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67276/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67190, 'Citalopram', 'Zonisamide', 'Moderate', 'The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.', NULL, 'SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.', 'Antagonism', 'Oxitriptan, Tryptophan', 'Tinidazole, Mitapivat, Ascorbic acid, Oxytetracycline, Ciclopirox, Sulfamethizole, Simeprevir, Diazoxide, Econazole, Povidone-iodine, Sulfisoxazole, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67277/', '[1] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al "Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies." Epilepsia 57 (2016): 2067-79[4] "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[6] "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al "Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study." Seizure 59 (2018): 28-33[10] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A "Hyponatremia associated with sodium valproate in a 22-year-old male." Nephrol Dial Transplant 23 (2008): epub[12] "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.[13] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[15] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[16] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[17] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[18] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK "Sodium valproate-induced hyponatremia: a case report." Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[22] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[24] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[26] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[28] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67191, 'Acetohexamide', 'Potassium citrate', 'Minor', 'Alkalinization of the urine may increase the renal clearance of some sulfonylureas for which renal elimination is pH dependent. The clinical significance of this interaction is unknown. Management consists of monitoring blood glucose frequently during the initial period of coadministration. The sulfonylurea dosage should be adjusted as needed and appropriate.', NULL, '-', NULL, '-', 'Excretion', 'Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Glimepiride, Albiglutide, Rosiglitazone, More', 'Potassium chloride, Potassium bicarbonate, Potassium gluconate', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67278/', '[1] Neuvonen PJ, Karkkainen S "Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics." Clin Pharmacol Ther 33 (1983): 386-93[2] Kivisto KT, Neuvonen PJ "Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide." Eur J Clin Pharmacol 40 (1991): 383-6[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[5] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[6] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[7] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[8] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[9] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[10] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[11] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67192, 'Aluminum hydroxide', 'Potassium citrate', 'Major', 'The concomitant administration of aluminum-containing products (e.g., antacids and phosphate binders) and citrates may significantly increase serum aluminum concentrations, resulting in toxicity. Citrates enhance the gastrointestinal absorption of aluminum by an unknown mechanism, which may involve the formation of a soluble aluminum-citrate complex. Patients with end-stage renal disease are particularly at risk of developing hyperaluminemia and encephalopathy. Fatalities have been reported.', NULL, 'The concomitant use of aluminum- and citrate-containing products should be avoided in renally impaired patients.', NULL, 'The concomitant use of aluminum- and citrate-containing products should be avoided in renally impaired patients. Some experts also recommend that healthy patients should separate doses of aluminum-containing antacids and citrates by 2 to 3 hours.', 'Absorption', 'Magnesium oxide, Magaldrate, Calcium carbonate, Magnesium hydroxide, Magnesium carbonate', 'Potassium chloride, Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67279/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Davies NT "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc 38 (1979): 121-8[5] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Mangels AR "Bone nutrients for vegetarians." Am J Clin Nutr 100 (2014): epub[9] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67193, 'Amoxapine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Citalopram, Sertraline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67280/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67194, 'Potassium citrate', 'Azatadine', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67281/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67195, 'Belladonna', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Potassium bicarbonate, Potassium gluconate', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67282/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67196, 'Bromfenac', 'Potassium citrate', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Fluocinolone acetonide, Cortisone, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Triamcinolone, Dexamethasone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67283/', '[1] "Product Information. Potassium Chloride ER (potassium chloride)." Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. K-Phos Original (potassium acid phosphate)." Beach Pharmaceuticals, Tampa, FL.[4] "Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate)." Patrin Pharma, Skokie, IL.[5] "Product Information. SSKI (potassium iodide)." Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] "Product Information. Potassium Chloride (potassium chloride)." Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67197, 'Chlorcyclizine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67284/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67198, 'Chlorpromazine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67285/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67199, 'Citric acid', 'Cinoxacin', 'Moderate', 'Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.', NULL, 'Concomitant use should generally be avoided.', NULL, 'Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.', 'Excretion', 'Delafloxacin', 'Glutamic acid, Pancrelipase', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67286/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67200, 'Clemastine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67287/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67201, 'Clomipramine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Citalopram, Sertraline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67288/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67202, 'Clozapine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67289/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67203, 'Cyclizine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67290/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67204, 'Cyclobenzaprine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Carisoprodol, Chlorzoxazone, Tizanidine, Baclofen, Methocarbamol, Chlormezanone', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67291/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67205, 'Cyproheptadine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67292/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67206, 'Darifenacin', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67293/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67207, 'Desipramine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Citalopram, Sertraline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67294/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67208, 'Dexbrompheniramine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67295/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67209, 'Dicyclomine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Papaverine, Alosetron, Isometheptene', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67296/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67210, 'Diflunisal', 'Potassium citrate', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Acetaminophen, Ziconotide, Methoxyflurane', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67297/', '[1] "Product Information. Potassium Chloride ER (potassium chloride)." Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. K-Phos Original (potassium acid phosphate)." Beach Pharmaceuticals, Tampa, FL.[4] "Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate)." Patrin Pharma, Skokie, IL.[5] "Product Information. SSKI (potassium iodide)." Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] "Product Information. Potassium Chloride (potassium chloride)." Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67211, 'Dimenhydrinate', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67298/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67212, 'Diphenhydramine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67299/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67213, 'Disopyramide', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67300/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67214, 'Doxepin', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Citalopram, Sertraline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67301/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67215, 'Doxepin (topical)', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Citalopram, Sertraline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67302/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67216, 'Doxylamine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67303/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67217, 'Drospirenone', 'Potassium citrate', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', NULL, 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', NULL, 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67304/', '[1] Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70[2] "Product Information. Yasmin (drospirenone-ethinyl estradiol)" Berlex Laboratories, Richmond, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67218, 'Enalapril', 'Potassium citrate', 'Major', 'Concomitant use of angiotensin converting enzyme (ACE) inhibitors and potassium salts may increase the risk of hyperkalemia. Inhibition of ACE results in decreased aldosterone secretion, which in turn causes potassium retention.', NULL, 'Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice.', NULL, 'Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67305/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Chan TY, Critchley JA "Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements." Drug Saf 7 (1992): 159-61[3] Warren SE, O''Connor DT "Hyperkalemia resulting from captopril administration." JAMA 244 (1980): 2551-2[4] Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association "Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association." Circulation 104 (2001): 1985-91[5] Large DM, Carr PH, Laing I, Davies M "Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism." Postgrad Med J 60 (1984): 370-3[6] Schuna AA, Schmidt GR, Pitterle ME "Serum potassium concentrations after initiation of captopril therapy." Clin Pharm 5 (1986): 920-3[7] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[8] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[9] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[10] Packer M, Lee WH "Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure." Am J Cardiol 57 (1986): 347-8[11] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[12] Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70[13] Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2[14] Speirs CJ, Dollery CT, Inman WH, et al "Postmarketing surveillance of enalapril II: investigation of the potential role of enalapril in deaths with renal failure." Br Med J 297 (1988): 830-2[15] Jarman PR, Kehely AM, Mather HM "Hyperkalaemia in diabetes: prevalence and associations." Postgrad Med J 71 (1995): 551-2[16] Obialo CI, Ofili EO, Mirza T "Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease." Am J Cardiol 90 (2002): 663-5[17] Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN "Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis." Hypertension 1 (1979): 279-80[18] Graves JW "Hyperkalemia due to a potassium-based water softener." N Engl J Med 339 (1998): 1790-1[19] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[20] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538[21] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12[22] Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812[23] Stoltz ML, Andrews CE Jr "Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use ." JAMA 264 (1990): 2737-8[24] Reardon LC, Macpherson DS "Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?" Arch Intern Med 158 (1998): 26-32[25] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[26] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[27] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67219, 'Enoxacin', 'Potassium citrate', 'Moderate', 'Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.', NULL, 'Concomitant use should generally be avoided.', NULL, 'Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.', 'Excretion', 'Delafloxacin', 'Potassium chloride, Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67306/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67220, 'Ephedrine (nasal)', 'Potassium citrate', 'Moderate', 'Alkalization of the urine decreases the urinary excretion increases the elimination half-life of ephedrine, pseudoephedrine, and related drugs. Toxicity from long-term use of pseudoephedrine has been demonstrated in patients with persistently alkaline urine.', NULL, 'Patients should be monitored for toxic effects such as tremor, anxiety, insomnia, irritability, or nervousness.', NULL, 'Patients should be monitored for toxic effects such as tremor, anxiety, insomnia, irritability, or nervousness. Dosage reductions may be required.', 'Excretion', 'Tropicamide, Phenylephrine, Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, More', 'Potassium chloride, Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67307/', '[1] Wilkinson GR, Beckett AH "Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output." J Pharmacol Exp Ther 162 (1968): 139-47[2] Brater DC, Kaojarern S, Benet LZ, et al "Renal excretion of pseudoephedrine." Clin Pharmacol Ther 28 (1980): 690-4[3] Kuntzman RG, Tsai I, Brand L, Mark LC "The influence of urinary pH on the plasma half-life of pseudoephedrine in man and dog and a sensitive assay for its determination in human plasma." Clin Pharmacol Ther 12 (1971): 62-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67221, 'Eplerenone', 'Potassium citrate', 'Major', 'The principal risk of eplerenone is hyperkalemia. Coadministration with potassium salts or potassium-sparing diuretics may increase this risk due to additive pharmacodynamic effects.', NULL, 'Given the potential for serious, sometimes fatal cardiac arrhythmias associated with hyperkalemia, the use of eplerenone with potassium salts or potassium-sparing diuretics is considered contraindicated.', NULL, 'Given the potential for serious, sometimes fatal cardiac arrhythmias associated with hyperkalemia, the use of eplerenone with potassium salts or potassium-sparing diuretics is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67308/', '[1] Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006): 49-58[2] "Product Information. Inspra (eplerenone)." Searle, Chicago, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67222, 'Eprosartan', 'Potassium citrate', 'Major', 'Concomitant use of angiotensin II receptor blockers (ARBs) and potassium salts may increase the risk of hyperkalemia. Inhibition of angiotensin II results in decreased aldosterone secretion, which in turn causes potassium retention. Risk factors for developing severe or life-threatening hyperkalemia may include renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, and concomitant use of other agents that block the renin-angiotensin-aldosterone system or otherwise increase serum potassium levels.', NULL, 'Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.', NULL, 'Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67309/', '[1] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12[2] Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812[3] Obialo CI, Ofili EO, Mirza T "Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease." Am J Cardiol 90 (2002): 663-5[4] Jarman PR, Kehely AM, Mather HM "Hyperkalaemia in diabetes: prevalence and associations." Postgrad Med J 71 (1995): 551-2[5] "Product Information. Cozaar (losartan)." Merck & Co, Inc, West Point, PA.[6] Large DM, Carr PH, Laing I, Davies M "Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism." Postgrad Med J 60 (1984): 370-3[7] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[8] "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals, East Hanover, NJ.[9] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[10] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[11] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[12] "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals, East Hanover, NJ.[13] "Product Information. Cozaar (losartan)." Merck & Co, Inc, West Point, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67223, 'Etodolac', 'Potassium citrate', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67310/', '[1] "Product Information. Potassium Chloride ER (potassium chloride)." Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. K-Phos Original (potassium acid phosphate)." Beach Pharmaceuticals, Tampa, FL.[4] "Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate)." Patrin Pharma, Skokie, IL.[5] "Product Information. SSKI (potassium iodide)." Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] "Product Information. Potassium Chloride (potassium chloride)." Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67224, 'Fenoprofen', 'Potassium citrate', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67311/', '[1] "Product Information. Potassium Chloride ER (potassium chloride)." Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. K-Phos Original (potassium acid phosphate)." Beach Pharmaceuticals, Tampa, FL.[4] "Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate)." Patrin Pharma, Skokie, IL.[5] "Product Information. SSKI (potassium iodide)." Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] "Product Information. Potassium Chloride (potassium chloride)." Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67225, 'Flavoxate', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67312/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67226, 'Flecainide', 'Potassium citrate', 'Minor', 'Agents that alkalinize the urine decrease the renal elimination of flecainide. The result may be increased plasma flecainide levels and increased effectiveness. The patient should be monitored for flecainide toxicity, and plasma flecainide levels should be checked when appropriate. Also, flecainide effectiveness may be decreased when an agent that alkalinizes the urine is discontinued.', NULL, '-', NULL, '-', 'Excretion', 'Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Potassium bicarbonate, Potassium gluconate', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67313/', '[1] Hertrampf R, Gundert-Remy U, Beckmann J, et al "Elimination of flecainide as a function of urinary flow rate and pH." Eur J Clin Pharmacol 41 (1991): 61-3', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67227, 'Fluphenazine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67314/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67228, 'Flurbiprofen', 'Potassium citrate', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67315/', '[1] "Product Information. Potassium Chloride ER (potassium chloride)." Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. K-Phos Original (potassium acid phosphate)." Beach Pharmaceuticals, Tampa, FL.[4] "Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate)." Patrin Pharma, Skokie, IL.[5] "Product Information. SSKI (potassium iodide)." Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] "Product Information. Potassium Chloride (potassium chloride)." Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67229, 'Fosinopril', 'Potassium citrate', 'Major', 'Concomitant use of angiotensin converting enzyme (ACE) inhibitors and potassium salts may increase the risk of hyperkalemia. Inhibition of ACE results in decreased aldosterone secretion, which in turn causes potassium retention.', NULL, 'Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice.', NULL, 'Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67316/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Chan TY, Critchley JA "Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements." Drug Saf 7 (1992): 159-61[3] Warren SE, O''Connor DT "Hyperkalemia resulting from captopril administration." JAMA 244 (1980): 2551-2[4] Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association "Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association." Circulation 104 (2001): 1985-91[5] Large DM, Carr PH, Laing I, Davies M "Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism." Postgrad Med J 60 (1984): 370-3[6] Schuna AA, Schmidt GR, Pitterle ME "Serum potassium concentrations after initiation of captopril therapy." Clin Pharm 5 (1986): 920-3[7] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[8] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[9] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[10] Packer M, Lee WH "Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure." Am J Cardiol 57 (1986): 347-8[11] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[12] Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70[13] Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2[14] Speirs CJ, Dollery CT, Inman WH, et al "Postmarketing surveillance of enalapril II: investigation of the potential role of enalapril in deaths with renal failure." Br Med J 297 (1988): 830-2[15] Jarman PR, Kehely AM, Mather HM "Hyperkalaemia in diabetes: prevalence and associations." Postgrad Med J 71 (1995): 551-2[16] Obialo CI, Ofili EO, Mirza T "Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease." Am J Cardiol 90 (2002): 663-5[17] Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN "Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis." Hypertension 1 (1979): 279-80[18] Graves JW "Hyperkalemia due to a potassium-based water softener." N Engl J Med 339 (1998): 1790-1[19] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[20] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538[21] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12[22] Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812[23] Stoltz ML, Andrews CE Jr "Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use ." JAMA 264 (1990): 2737-8[24] Reardon LC, Macpherson DS "Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?" Arch Intern Med 158 (1998): 26-32[25] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[26] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[27] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67230, 'Gatifloxacin', 'Potassium citrate', 'Moderate', 'Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.', NULL, 'Concomitant use should generally be avoided.', NULL, 'Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.', 'Excretion', 'Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More', 'Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67317/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67231, 'Gemifloxacin', 'Potassium citrate', 'Moderate', 'Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.', NULL, 'Concomitant use should generally be avoided.', NULL, 'Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.', 'Excretion', 'Delafloxacin', 'Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67318/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67232, 'Glipizide', 'Potassium citrate', 'Minor', 'Alkalinization of the urine may increase the renal clearance of some sulfonylureas for which renal elimination is pH dependent. The clinical significance of this interaction is unknown. Management consists of monitoring blood glucose frequently during the initial period of coadministration. The sulfonylurea dosage should be adjusted as needed and appropriate.', NULL, '-', NULL, '-', 'Excretion', 'Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Glimepiride, Albiglutide, Rosiglitazone, More', 'Potassium bicarbonate, Potassium gluconate', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67319/', '[1] Neuvonen PJ, Karkkainen S "Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics." Clin Pharmacol Ther 33 (1983): 386-93[2] Kivisto KT, Neuvonen PJ "Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide." Eur J Clin Pharmacol 40 (1991): 383-6[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[5] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[6] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[7] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[8] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[9] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[10] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[11] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67233, 'Glyburide', 'Potassium citrate', 'Minor', 'Alkalinization of the urine may increase the renal clearance of some sulfonylureas for which renal elimination is pH dependent. The clinical significance of this interaction is unknown. Management consists of monitoring blood glucose frequently during the initial period of coadministration. The sulfonylurea dosage should be adjusted as needed and appropriate.', NULL, '-', NULL, '-', 'Excretion', 'Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Glimepiride, Albiglutide, Rosiglitazone, More', 'Potassium bicarbonate, Potassium gluconate', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67320/', '[1] Neuvonen PJ, Karkkainen S "Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics." Clin Pharmacol Ther 33 (1983): 386-93[2] Kivisto KT, Neuvonen PJ "Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide." Eur J Clin Pharmacol 40 (1991): 383-6[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[5] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[6] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[7] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[8] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[9] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[10] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[11] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67234, 'Grepafloxacin', 'Potassium citrate', 'Moderate', 'Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.', NULL, 'Concomitant use should generally be avoided.', NULL, 'Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.', 'Excretion', 'Delafloxacin', 'Potassium chloride, Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67321/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67235, 'Hydroxyzine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Clobazam, Meprobamate, Alprazolam, Lorazepam, Chlordiazepoxide, Halazepam, Clorazepic acid, Buspirone, Diazepam, Oxazepam', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67322/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67236, 'Imipramine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Citalopram, Sertraline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67323/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67237, 'Indomethacin', 'Potassium citrate', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Rabeprazole, Misoprostol, Glucosamine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67324/', '[1] "Product Information. Potassium Chloride ER (potassium chloride)." Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. K-Phos Original (potassium acid phosphate)." Beach Pharmaceuticals, Tampa, FL.[4] "Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate)." Patrin Pharma, Skokie, IL.[5] "Product Information. SSKI (potassium iodide)." Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] "Product Information. Potassium Chloride (potassium chloride)." Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67238, 'Insulin human', 'Potassium citrate', 'Minor', 'Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.', NULL, '-', NULL, '-', 'Synergism', 'Liraglutide, Lixisenatide', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67325/', '[1] Hiatt N, Davidson MB, Bonorris G "The effect of potassium chloride infusion on insulin secretion in vivo." Horm Metab Res 4 (1972): 64-8[2] Conn HO "Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism." Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ "The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man." J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[11] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[12] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67239, 'Insulin aspart (aspart)', 'Potassium citrate', 'Minor', 'Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67326/', '[1] Hiatt N, Davidson MB, Bonorris G "The effect of potassium chloride infusion on insulin secretion in vivo." Horm Metab Res 4 (1972): 64-8[2] Conn HO "Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism." Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ "The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man." J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[11] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[12] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67240, 'Insulin aspart (aspart protamine)', 'Potassium citrate', 'Minor', 'Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67327/', '[1] Hiatt N, Davidson MB, Bonorris G "The effect of potassium chloride infusion on insulin secretion in vivo." Horm Metab Res 4 (1972): 64-8[2] Conn HO "Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism." Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ "The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man." J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[11] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[12] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67241, 'Insulin degludec', 'Potassium citrate', 'Minor', 'Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.', NULL, '-', NULL, '-', 'Synergism', 'Liraglutide, Lixisenatide', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67328/', '[1] Hiatt N, Davidson MB, Bonorris G "The effect of potassium chloride infusion on insulin secretion in vivo." Horm Metab Res 4 (1972): 64-8[2] Conn HO "Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism." Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ "The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man." J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[11] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[12] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67242, 'Insulin detemir', 'Potassium citrate', 'Minor', 'Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.', NULL, '-', NULL, '-', 'Synergism', 'Liraglutide, Lixisenatide', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67329/', '[1] Hiatt N, Davidson MB, Bonorris G "The effect of potassium chloride infusion on insulin secretion in vivo." Horm Metab Res 4 (1972): 64-8[2] Conn HO "Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism." Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ "The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man." J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[11] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[12] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67243, 'Insulin glargine', 'Potassium citrate', 'Minor', 'Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.', NULL, '-', NULL, '-', 'Synergism', 'Liraglutide, Lixisenatide', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67330/', '[1] Hiatt N, Davidson MB, Bonorris G "The effect of potassium chloride infusion on insulin secretion in vivo." Horm Metab Res 4 (1972): 64-8[2] Conn HO "Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism." Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ "The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man." J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[11] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[12] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67244, 'Insulin glulisine', 'Potassium citrate', 'Minor', 'Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.', NULL, '-', NULL, '-', 'Synergism', 'Liraglutide, Lixisenatide', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67331/', '[1] Hiatt N, Davidson MB, Bonorris G "The effect of potassium chloride infusion on insulin secretion in vivo." Horm Metab Res 4 (1972): 64-8[2] Conn HO "Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism." Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ "The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man." J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[11] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[12] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67245, 'Insulin human (inhalation, rapid acting)', 'Potassium citrate', 'Minor', 'Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.', NULL, '-', NULL, '-', 'Synergism', 'Liraglutide, Lixisenatide', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67332/', '[1] Hiatt N, Davidson MB, Bonorris G "The effect of potassium chloride infusion on insulin secretion in vivo." Horm Metab Res 4 (1972): 64-8[2] Conn HO "Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism." Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ "The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man." J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[11] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[12] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67246, 'Insulin human (isophane)', 'Potassium citrate', 'Minor', 'Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.', NULL, '-', NULL, '-', 'Synergism', 'Liraglutide, Lixisenatide', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67333/', '[1] Hiatt N, Davidson MB, Bonorris G "The effect of potassium chloride infusion on insulin secretion in vivo." Horm Metab Res 4 (1972): 64-8[2] Conn HO "Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism." Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ "The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man." J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[11] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[12] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67247, 'Insulin lispro', 'Potassium citrate', 'Minor', 'Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.', NULL, '-', NULL, '-', 'Synergism', 'Liraglutide, Lixisenatide', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67334/', '[1] Hiatt N, Davidson MB, Bonorris G "The effect of potassium chloride infusion on insulin secretion in vivo." Horm Metab Res 4 (1972): 64-8[2] Conn HO "Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism." Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ "The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man." J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[11] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[12] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67248, 'Insulin lispro (protamine)', 'Potassium citrate', 'Minor', 'Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67335/', '[1] Hiatt N, Davidson MB, Bonorris G "The effect of potassium chloride infusion on insulin secretion in vivo." Horm Metab Res 4 (1972): 64-8[2] Conn HO "Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism." Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ "The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man." J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[11] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[12] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67249, 'Insulin human (regular)', 'Potassium citrate', 'Minor', 'Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.', NULL, '-', NULL, '-', 'Synergism', 'Liraglutide, Lixisenatide', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67336/', '[1] Hiatt N, Davidson MB, Bonorris G "The effect of potassium chloride infusion on insulin secretion in vivo." Horm Metab Res 4 (1972): 64-8[2] Conn HO "Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism." Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ "The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man." J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[11] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[12] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67250, 'Insulin human (zinc)', 'Potassium citrate', 'Minor', 'Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.', NULL, '-', NULL, '-', 'Synergism', 'Liraglutide, Lixisenatide', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67337/', '[1] Hiatt N, Davidson MB, Bonorris G "The effect of potassium chloride infusion on insulin secretion in vivo." Horm Metab Res 4 (1972): 64-8[2] Conn HO "Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism." Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ "The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man." J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[11] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[12] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67251, 'Insulin human (zinc extended)', 'Potassium citrate', 'Minor', 'Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.', NULL, '-', NULL, '-', 'Synergism', 'Liraglutide, Lixisenatide', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67338/', '[1] Hiatt N, Davidson MB, Bonorris G "The effect of potassium chloride infusion on insulin secretion in vivo." Horm Metab Res 4 (1972): 64-8[2] Conn HO "Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism." Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ "The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man." J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[11] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[12] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67252, 'Irbesartan', 'Potassium citrate', 'Major', 'Concomitant use of angiotensin II receptor blockers (ARBs) and potassium salts may increase the risk of hyperkalemia. Inhibition of angiotensin II results in decreased aldosterone secretion, which in turn causes potassium retention. Risk factors for developing severe or life-threatening hyperkalemia may include renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, and concomitant use of other agents that block the renin-angiotensin-aldosterone system or otherwise increase serum potassium levels.', NULL, 'Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.', NULL, 'Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67339/', '[1] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12[2] Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812[3] Obialo CI, Ofili EO, Mirza T "Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease." Am J Cardiol 90 (2002): 663-5[4] Jarman PR, Kehely AM, Mather HM "Hyperkalaemia in diabetes: prevalence and associations." Postgrad Med J 71 (1995): 551-2[5] "Product Information. Cozaar (losartan)." Merck & Co, Inc, West Point, PA.[6] Large DM, Carr PH, Laing I, Davies M "Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism." Postgrad Med J 60 (1984): 370-3[7] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[8] "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals, East Hanover, NJ.[9] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[10] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[11] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[12] "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals, East Hanover, NJ.[13] "Product Information. Cozaar (losartan)." Merck & Co, Inc, West Point, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67253, 'Potassium citrate', 'Ketoprofen', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib, Tolazoline, Rabeprazole, Dimethyl sulfoxide', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67340/', '[1] "Product Information. Potassium Chloride ER (potassium chloride)." Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. K-Phos Original (potassium acid phosphate)." Beach Pharmaceuticals, Tampa, FL.[4] "Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate)." Patrin Pharma, Skokie, IL.[5] "Product Information. SSKI (potassium iodide)." Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] "Product Information. Potassium Chloride (potassium chloride)." Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67254, 'Potassium citrate', 'Levofloxacin', 'Moderate', 'Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.', NULL, 'Concomitant use should generally be avoided.', NULL, 'Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.', 'Excretion', 'Delafloxacin, Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, More', 'Potassium chloride, Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67341/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67255, 'Potassium citrate', 'Lisdexamfetamine', 'Moderate', 'Alkalinization of the urine can decrease the renal elimination of amphetamines. Amphetamine effects may be prolonged, and the risk of toxicity may be increased.', NULL, 'Urinary alkalinizers should generally not be used with amphetamines, particularly in an amphetamine overdose situation.', NULL, 'Urinary alkalinizers should generally not be used with amphetamines, particularly in an amphetamine overdose situation.', 'Excretion', 'Pemoline, Atomoxetine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Armodafinil, Citicoline, Modafinil', 'Potassium chloride, Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67342/', '[1] Anggard E, Jonsson LE, Hogmark AL, Gunne LM "Amphetamine metabolism in amphetamine psychosis." Clin Pharmacol Ther 14 (1973): 870-80[2] Wilkinson GR, Beckett AH "Absorption, metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output." J Pharmacol Exp Ther 162 (1968): 139-47[3] Davis JM, Kopin IJ, Lemberger L, Axelrod J "Effects of urinary pH on amphetamine metabolism." Ann N Y Acad Sci 179 (1971): 493-501[4] Beckett AH, Rowland M "Urinary excretion kinetics of amphetamine in man." J Pharm Pharmacol 17 (1965): 628-39[5] Beckett AH, Salmon JA, Mitchard M "The relation between blood levels and urinary excretion of amphetamine under controlled acidic and under fluctuating urinary pH values using [C]amphetamine." J Pharm Pharmacol 21 (1969): 251-8[6] Beckett AH, Rowland M, Turner P "Influence of urinary pH on excretion of amphetamine." Lancet 1 (1965): 303[7] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[8] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[9] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67256, 'Potassium citrate', 'Lisinopril', 'Major', 'Concomitant use of angiotensin converting enzyme (ACE) inhibitors and potassium salts may increase the risk of hyperkalemia. Inhibition of ACE results in decreased aldosterone secretion, which in turn causes potassium retention.', NULL, 'Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice.', NULL, 'Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67343/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Chan TY, Critchley JA "Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements." Drug Saf 7 (1992): 159-61[3] Warren SE, O''Connor DT "Hyperkalemia resulting from captopril administration." JAMA 244 (1980): 2551-2[4] Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association "Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association." Circulation 104 (2001): 1985-91[5] Large DM, Carr PH, Laing I, Davies M "Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism." Postgrad Med J 60 (1984): 370-3[6] Schuna AA, Schmidt GR, Pitterle ME "Serum potassium concentrations after initiation of captopril therapy." Clin Pharm 5 (1986): 920-3[7] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[8] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[9] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[10] Packer M, Lee WH "Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure." Am J Cardiol 57 (1986): 347-8[11] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[12] Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70[13] Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2[14] Speirs CJ, Dollery CT, Inman WH, et al "Postmarketing surveillance of enalapril II: investigation of the potential role of enalapril in deaths with renal failure." Br Med J 297 (1988): 830-2[15] Jarman PR, Kehely AM, Mather HM "Hyperkalaemia in diabetes: prevalence and associations." Postgrad Med J 71 (1995): 551-2[16] Obialo CI, Ofili EO, Mirza T "Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease." Am J Cardiol 90 (2002): 663-5[17] Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN "Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis." Hypertension 1 (1979): 279-80[18] Graves JW "Hyperkalemia due to a potassium-based water softener." N Engl J Med 339 (1998): 1790-1[19] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[20] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538[21] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12[22] Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812[23] Stoltz ML, Andrews CE Jr "Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use ." JAMA 264 (1990): 2737-8[24] Reardon LC, Macpherson DS "Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?" Arch Intern Med 158 (1998): 26-32[25] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[26] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[27] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67257, 'Potassium citrate', 'Lithium carbonate', 'Moderate', 'Urinary alkalinizers may increase excretion of lithium. Plasma lithium levels and therapeutic effects may be decreased.', NULL, 'Monitoring of lithium concentrations and therapeutic effect is recommended during concurrent use.', NULL, 'Monitoring of lithium concentrations and therapeutic effect is recommended during concurrent use.', 'Others', 'Potassium chloride, Potassium bicarbonate, Potassium gluconate', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67344/', '[1] Forrest JA "Forced alkaline diuresis for lithium intoxication." Postgrad Med J 51 (1975): 189-91[2] Arthur RK "Lithium levels and "Soda Bic"." Med J Aust 2 (1975): 918[3] Thomsen K, Schou M "Renal lithium excretion in man." Am J Psychol 215 (1968): 823-7[4] McSwiggan C "Interaction of lithium and bicarbonate." Med J Aust 1 (1978): 38-9[5] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67258, 'Potassium citrate', 'Lomefloxacin', 'Moderate', 'Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.', NULL, 'Concomitant use should generally be avoided.', NULL, 'Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.', 'Excretion', 'Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More', 'Potassium chloride, Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67345/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67259, 'Potassium citrate', 'Losartan', 'Major', 'Concomitant use of angiotensin II receptor blockers (ARBs) and potassium salts may increase the risk of hyperkalemia. Inhibition of angiotensin II results in decreased aldosterone secretion, which in turn causes potassium retention. Risk factors for developing severe or life-threatening hyperkalemia may include renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, and concomitant use of other agents that block the renin-angiotensin-aldosterone system or otherwise increase serum potassium levels.', NULL, 'Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.', NULL, 'Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67346/', '[1] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12[2] Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812[3] Obialo CI, Ofili EO, Mirza T "Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease." Am J Cardiol 90 (2002): 663-5[4] Jarman PR, Kehely AM, Mather HM "Hyperkalaemia in diabetes: prevalence and associations." Postgrad Med J 71 (1995): 551-2[5] "Product Information. Cozaar (losartan)." Merck & Co, Inc, West Point, PA.[6] Large DM, Carr PH, Laing I, Davies M "Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism." Postgrad Med J 60 (1984): 370-3[7] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[8] "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals, East Hanover, NJ.[9] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[10] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[11] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[12] "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals, East Hanover, NJ.[13] "Product Information. Cozaar (losartan)." Merck & Co, Inc, West Point, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67260, 'Potassium citrate', 'Loxapine', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67347/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67261, 'Potassium citrate', 'Maprotiline', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Citalopram, Sertraline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67348/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67262, 'Potassium citrate', 'Meclizine', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67349/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67263, 'Potassium citrate', 'Meclofenamic acid', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib, Tolazoline, Rabeprazole, Dimethyl sulfoxide', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67350/', '[1] "Product Information. Potassium Chloride ER (potassium chloride)." Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. K-Phos Original (potassium acid phosphate)." Beach Pharmaceuticals, Tampa, FL.[4] "Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate)." Patrin Pharma, Skokie, IL.[5] "Product Information. SSKI (potassium iodide)." Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] "Product Information. Potassium Chloride (potassium chloride)." Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67264, 'Potassium citrate', 'Mefenamic acid', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67351/', '[1] "Product Information. Potassium Chloride ER (potassium chloride)." Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. K-Phos Original (potassium acid phosphate)." Beach Pharmaceuticals, Tampa, FL.[4] "Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate)." Patrin Pharma, Skokie, IL.[5] "Product Information. SSKI (potassium iodide)." Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] "Product Information. Potassium Chloride (potassium chloride)." Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67265, 'Potassium citrate', 'Meloxicam', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67352/', '[1] "Product Information. Potassium Chloride ER (potassium chloride)." Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. K-Phos Original (potassium acid phosphate)." Beach Pharmaceuticals, Tampa, FL.[4] "Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate)." Patrin Pharma, Skokie, IL.[5] "Product Information. SSKI (potassium iodide)." Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] "Product Information. Potassium Chloride (potassium chloride)." Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67266, 'Potassium citrate', 'Memantine', 'Minor', 'The concomitant administration of memantine and drugs that alkalinize the urine may decrease the clearance of memantine, resulting in accumulation of memantine and possible increased adverse effects. Memantine clearance decreased by 80% at a urinary pH of 8. The clinical significance is unknown; however, the manufacturer recommends caution.', NULL, '-', NULL, '-', 'Excretion', 'Rivastigmine, Galantamine, Donepezil, Tacrine, Ginkgo biloba, Aducanumab', 'Potassium bicarbonate, Potassium gluconate', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67353/', '[1] "Product Information. Namenda (memantine)." Forest Pharmaceuticals, St. Louis, MO.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67267, 'Potassium citrate', 'Mepenzolate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Papaverine, Alosetron, Isometheptene', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67354/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67268, 'Potassium citrate', 'Mesoridazine', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67355/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67269, 'Potassium citrate', 'Methdilazine', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67356/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67270, 'Potassium citrate', 'Methotrexate', 'Minor', 'Alkalinization of the urine can increase the renal elimination of methotrexate. The pharmacologic effects of methotrexate may be decreased. No special clinical interventions appear to be necessary. In some cases of methotrexate toxicity, this interaction may prove beneficial.', NULL, '-', NULL, '-', 'Excretion', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 'Potassium bicarbonate, Potassium gluconate', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67357/', '[1] Sand TE, Jacobsen S "Effect of urine pH and flow on renal clearance of methotrexate." Eur J Clin Pharmacol 19 (1981): 453-6[2] Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA "Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity." N Engl J Med 297 (1977): 630-4[3] Nirenberg A, Mosende C, Mehta BM, Gisolfi AL, Rosen G "High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity." Cancer Treat Rep 61 (1977): 779-83[4] Nesher G, Mates M, Zevin S "Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis." Arthritis Rheum 48 (2003): 571-572', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67271, 'Potassium citrate', 'Methotrimeprazine', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67358/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67272, 'Potassium citrate', 'Mexiletine', 'Moderate', 'Agents that alkalinize the urine reduce the plasma clearance of mexiletine. The result may be increased plasma mexiletine levels and possible toxicity. The clinical significance is unknown.', NULL, 'It is recommended that such drugs be avoided during mexiletine therapy.', NULL, 'It is recommended that such drugs be avoided during mexiletine therapy.', 'Excretion', 'Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67359/', '[1] Mitchell BG, Clements JA, Pottage A, Prescott LF "Mexiletine disposition: individual variation in response to urine acidification and alkalinisation." Br J Clin Pharmacol 16 (1983): 281-4', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67273, 'Potassium citrate', 'Minocycline', 'Moderate', 'INTERVAL: Alkalinization of the urine may decrease the plasma concentration of some tetracyclines. The mechanism is not completely understood, but may involve increased renal elimination of tetracyclines when the urine becomes alkalinized.', NULL, 'If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).', NULL, 'If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).', 'Excretion', 'Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Methylprednisolone, Azelaic acid, More', 'Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67360/', '[1] Elliott GR "Sodium bicarbonate and oral tetracycline." Clin Pharmacol Ther 13 (1972): 459[2] Jaffe JM, Poust RI, Feld SL, Colaizzi JL "Influence of repetitive dosing and altered urinary pH on doxycycline excretion in humans." J Pharm Sci 63 (1974): 1256-60[3] Jaffe JM, Colaizzi JI, Poust RI, McDonald RH Jr "Effect of altered urinary pH on tetracycline and doxycycline excretion in humans." J Pharmacokinet Biopharm 1 (1973): 267-82[4] "Product Information. Achromycin (tetracycline)." Lederle Laboratories, Wayne, NJ.[5] "Product Information. Declomycin (demeclocycline)." Lederle Laboratories, Wayne, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67274, 'Potassium citrate', 'Moexipril', 'Major', 'Concomitant use of angiotensin converting enzyme (ACE) inhibitors and potassium salts may increase the risk of hyperkalemia. Inhibition of ACE results in decreased aldosterone secretion, which in turn causes potassium retention.', NULL, 'Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice.', NULL, 'Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67361/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Chan TY, Critchley JA "Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements." Drug Saf 7 (1992): 159-61[3] Warren SE, O''Connor DT "Hyperkalemia resulting from captopril administration." JAMA 244 (1980): 2551-2[4] Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association "Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association." Circulation 104 (2001): 1985-91[5] Large DM, Carr PH, Laing I, Davies M "Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism." Postgrad Med J 60 (1984): 370-3[6] Schuna AA, Schmidt GR, Pitterle ME "Serum potassium concentrations after initiation of captopril therapy." Clin Pharm 5 (1986): 920-3[7] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[8] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[9] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[10] Packer M, Lee WH "Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure." Am J Cardiol 57 (1986): 347-8[11] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[12] Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70[13] Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2[14] Speirs CJ, Dollery CT, Inman WH, et al "Postmarketing surveillance of enalapril II: investigation of the potential role of enalapril in deaths with renal failure." Br Med J 297 (1988): 830-2[15] Jarman PR, Kehely AM, Mather HM "Hyperkalaemia in diabetes: prevalence and associations." Postgrad Med J 71 (1995): 551-2[16] Obialo CI, Ofili EO, Mirza T "Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease." Am J Cardiol 90 (2002): 663-5[17] Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN "Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis." Hypertension 1 (1979): 279-80[18] Graves JW "Hyperkalemia due to a potassium-based water softener." N Engl J Med 339 (1998): 1790-1[19] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[20] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538[21] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12[22] Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812[23] Stoltz ML, Andrews CE Jr "Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use ." JAMA 264 (1990): 2737-8[24] Reardon LC, Macpherson DS "Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?" Arch Intern Med 158 (1998): 26-32[25] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[26] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[27] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67275, 'Potassium citrate', 'Molindone', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67362/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67276, 'Potassium citrate', 'Moxifloxacin', 'Moderate', 'Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.', NULL, 'Concomitant use should generally be avoided.', NULL, 'Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.', 'Excretion', 'Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More', 'Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67363/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67277, 'Potassium citrate', 'Nabumetone', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67364/', '[1] "Product Information. Potassium Chloride ER (potassium chloride)." Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. K-Phos Original (potassium acid phosphate)." Beach Pharmaceuticals, Tampa, FL.[4] "Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate)." Patrin Pharma, Skokie, IL.[5] "Product Information. SSKI (potassium iodide)." Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] "Product Information. Potassium Chloride (potassium chloride)." Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67278, 'Potassium citrate', 'Nalidixic acid', 'Moderate', 'Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.', NULL, 'Concomitant use should generally be avoided.', NULL, 'Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.', 'Excretion', 'Delafloxacin', 'Potassium chloride, Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67365/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67279, 'Potassium citrate', 'Naproxen', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67366/', '[1] "Product Information. Potassium Chloride ER (potassium chloride)." Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. K-Phos Original (potassium acid phosphate)." Beach Pharmaceuticals, Tampa, FL.[4] "Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate)." Patrin Pharma, Skokie, IL.[5] "Product Information. SSKI (potassium iodide)." Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] "Product Information. Potassium Chloride (potassium chloride)." Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67280, 'Potassium citrate', 'Norfloxacin', 'Moderate', 'Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.', NULL, 'Concomitant use should generally be avoided.', NULL, 'Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.', 'Excretion', 'Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More', 'Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67367/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67281, 'Potassium citrate', 'Nortriptyline', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Citalopram, Sertraline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67368/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67282, 'Potassium citrate', 'Ofloxacin', 'Moderate', 'Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.', NULL, 'Concomitant use should generally be avoided.', NULL, 'Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.', 'Excretion', 'Delafloxacin, Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More', 'Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67369/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67283, 'Potassium citrate', 'Olanzapine', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67370/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67284, 'Potassium citrate', 'Orphenadrine', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Carisoprodol, Chlorzoxazone, Tizanidine, Baclofen, Methocarbamol, Chlormezanone', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67371/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67285, 'Potassium citrate', 'Oxaprozin', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67372/', '[1] "Product Information. Potassium Chloride ER (potassium chloride)." Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. K-Phos Original (potassium acid phosphate)." Beach Pharmaceuticals, Tampa, FL.[4] "Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate)." Patrin Pharma, Skokie, IL.[5] "Product Information. SSKI (potassium iodide)." Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] "Product Information. Potassium Chloride (potassium chloride)." Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67286, 'Potassium citrate', 'Oxybutynin', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67373/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67287, 'Potassium citrate', 'Oxytetracycline', 'Moderate', 'INTERVAL: Alkalinization of the urine may decrease the plasma concentration of some tetracyclines. The mechanism is not completely understood, but may involve increased renal elimination of tetracyclines when the urine becomes alkalinized.', NULL, 'If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).', NULL, 'If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).', 'Excretion', 'Tigecycline, Sarecycline, Omadacycline, Eravacycline, Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, More', 'Potassium chloride, Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67374/', '[1] Elliott GR "Sodium bicarbonate and oral tetracycline." Clin Pharmacol Ther 13 (1972): 459[2] Jaffe JM, Poust RI, Feld SL, Colaizzi JL "Influence of repetitive dosing and altered urinary pH on doxycycline excretion in humans." J Pharm Sci 63 (1974): 1256-60[3] Jaffe JM, Colaizzi JI, Poust RI, McDonald RH Jr "Effect of altered urinary pH on tetracycline and doxycycline excretion in humans." J Pharmacokinet Biopharm 1 (1973): 267-82[4] "Product Information. Achromycin (tetracycline)." Lederle Laboratories, Wayne, NJ.[5] "Product Information. Declomycin (demeclocycline)." Lederle Laboratories, Wayne, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67288, 'Potassium citrate', 'Perindopril', 'Major', 'Concomitant use of angiotensin converting enzyme (ACE) inhibitors and potassium salts may increase the risk of hyperkalemia. Inhibition of ACE results in decreased aldosterone secretion, which in turn causes potassium retention.', NULL, 'Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice.', NULL, 'Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67375/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Chan TY, Critchley JA "Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements." Drug Saf 7 (1992): 159-61[3] Warren SE, O''Connor DT "Hyperkalemia resulting from captopril administration." JAMA 244 (1980): 2551-2[4] Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association "Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association." Circulation 104 (2001): 1985-91[5] Large DM, Carr PH, Laing I, Davies M "Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism." Postgrad Med J 60 (1984): 370-3[6] Schuna AA, Schmidt GR, Pitterle ME "Serum potassium concentrations after initiation of captopril therapy." Clin Pharm 5 (1986): 920-3[7] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[8] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[9] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[10] Packer M, Lee WH "Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure." Am J Cardiol 57 (1986): 347-8[11] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[12] Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70[13] Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2[14] Speirs CJ, Dollery CT, Inman WH, et al "Postmarketing surveillance of enalapril II: investigation of the potential role of enalapril in deaths with renal failure." Br Med J 297 (1988): 830-2[15] Jarman PR, Kehely AM, Mather HM "Hyperkalaemia in diabetes: prevalence and associations." Postgrad Med J 71 (1995): 551-2[16] Obialo CI, Ofili EO, Mirza T "Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease." Am J Cardiol 90 (2002): 663-5[17] Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN "Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis." Hypertension 1 (1979): 279-80[18] Graves JW "Hyperkalemia due to a potassium-based water softener." N Engl J Med 339 (1998): 1790-1[19] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[20] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538[21] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12[22] Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812[23] Stoltz ML, Andrews CE Jr "Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use ." JAMA 264 (1990): 2737-8[24] Reardon LC, Macpherson DS "Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?" Arch Intern Med 158 (1998): 26-32[25] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[26] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[27] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67289, 'Potassium citrate', 'Perphenazine', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67376/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67290, 'Potassium citrate', 'Phenindamine', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67377/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67291, 'Potassium citrate', 'Phenylbutazone', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib, Tolazoline, Rabeprazole, Dimethyl sulfoxide', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67378/', '[1] "Product Information. Potassium Chloride ER (potassium chloride)." Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. K-Phos Original (potassium acid phosphate)." Beach Pharmaceuticals, Tampa, FL.[4] "Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate)." Patrin Pharma, Skokie, IL.[5] "Product Information. SSKI (potassium iodide)." Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] "Product Information. Potassium Chloride (potassium chloride)." Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67292, 'Potassium citrate', 'Pimozide', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67379/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67293, 'Potassium citrate', 'Piroxicam', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib, Tolazoline, Rabeprazole, Dimethyl sulfoxide, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67380/', '[1] "Product Information. Potassium Chloride ER (potassium chloride)." Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. K-Phos Original (potassium acid phosphate)." Beach Pharmaceuticals, Tampa, FL.[4] "Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate)." Patrin Pharma, Skokie, IL.[5] "Product Information. SSKI (potassium iodide)." Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] "Product Information. Potassium Chloride (potassium chloride)." Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67294, 'Prochlorperazine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67381/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67295, 'Procyclidine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Potassium bicarbonate, Potassium gluconate', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67382/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67296, 'Promazine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67383/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67297, 'Promethazine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67384/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67298, 'Propantheline', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Papaverine, Alosetron, Isometheptene', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67385/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67299, 'Propiomazine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67386/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67300, 'Protriptyline', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Citalopram, Sertraline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67387/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67301, 'Potassium citrate', 'Mepyramine', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67388/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67302, 'Quinapril', 'Potassium citrate', 'Major', 'Concomitant use of angiotensin converting enzyme (ACE) inhibitors and potassium salts may increase the risk of hyperkalemia. Inhibition of ACE results in decreased aldosterone secretion, which in turn causes potassium retention.', NULL, 'Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice.', NULL, 'Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67389/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Chan TY, Critchley JA "Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements." Drug Saf 7 (1992): 159-61[3] Warren SE, O''Connor DT "Hyperkalemia resulting from captopril administration." JAMA 244 (1980): 2551-2[4] Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association "Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association." Circulation 104 (2001): 1985-91[5] Large DM, Carr PH, Laing I, Davies M "Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism." Postgrad Med J 60 (1984): 370-3[6] Schuna AA, Schmidt GR, Pitterle ME "Serum potassium concentrations after initiation of captopril therapy." Clin Pharm 5 (1986): 920-3[7] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[8] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[9] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[10] Packer M, Lee WH "Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure." Am J Cardiol 57 (1986): 347-8[11] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[12] Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70[13] Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2[14] Speirs CJ, Dollery CT, Inman WH, et al "Postmarketing surveillance of enalapril II: investigation of the potential role of enalapril in deaths with renal failure." Br Med J 297 (1988): 830-2[15] Jarman PR, Kehely AM, Mather HM "Hyperkalaemia in diabetes: prevalence and associations." Postgrad Med J 71 (1995): 551-2[16] Obialo CI, Ofili EO, Mirza T "Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease." Am J Cardiol 90 (2002): 663-5[17] Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN "Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis." Hypertension 1 (1979): 279-80[18] Graves JW "Hyperkalemia due to a potassium-based water softener." N Engl J Med 339 (1998): 1790-1[19] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[20] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538[21] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12[22] Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812[23] Stoltz ML, Andrews CE Jr "Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use ." JAMA 264 (1990): 2737-8[24] Reardon LC, Macpherson DS "Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?" Arch Intern Med 158 (1998): 26-32[25] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[26] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[27] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67303, 'Quinidine', 'Potassium citrate', 'Moderate', 'Coadministration with drugs that can increase urinary pH such as antacids, carbonic anhydrase inhibitors, or urinary alkalinizers may decrease the urinary excretion of quinidine. The proposed mechanism is increased renal tubular reabsorption due to reduced ionization of quinidine in alkaline urine.', NULL, 'Caution is advised if quinidine is used with agents that can increase urinary pH.', NULL, 'Caution is advised if quinidine is used with agents that can increase urinary pH. Quinidine levels may need to be monitored more closely following addition or discontinuation of these agents, and the quinidine dosage adjusted as necessary. Patients should be advised to seek medical attention if they experience symptoms that could indicate quinidine toxicity such as tinnitus, hearing loss, visual disturbances, diarrhea, headache, dizziness, palpitations, syncope, or irregular heartbeats.', 'Excretion', 'Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67390/', '[1] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[2] Mauro VF, Mauro LS, Fraker TD Jr, Temesy-Armos PN, Somani P "Effect of aluminum hydroxide gel on quinidine gluconate absorption." DICP 24 (1990): 252-4[3] Romankiewicz JA, Reidenberg M, Drayer D, Franklin JE "The noninterference of aluminum hydroxide gel with quinidine sulfate absorption: An approach to control quinidine-induced diarrhea." Am Heart J 96 (1978): 518-20[4] Gerhardt RE, Knouss RF, Thyrum PT, et al "Quinidine excretion in aciduria and alkaluria." Ann Intern Med 71 (1969): 927-33[5] Zinn MB "Quinidine intoxication from alkali ingestion." Tex Med 66 (1970): 64-6[6] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[7] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[8] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[9] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67304, 'Ramipril', 'Potassium citrate', 'Major', 'Concomitant use of angiotensin converting enzyme (ACE) inhibitors and potassium salts may increase the risk of hyperkalemia. Inhibition of ACE results in decreased aldosterone secretion, which in turn causes potassium retention.', NULL, 'Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice.', NULL, 'Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67391/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Chan TY, Critchley JA "Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements." Drug Saf 7 (1992): 159-61[3] Warren SE, O''Connor DT "Hyperkalemia resulting from captopril administration." JAMA 244 (1980): 2551-2[4] Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association "Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association." Circulation 104 (2001): 1985-91[5] Large DM, Carr PH, Laing I, Davies M "Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism." Postgrad Med J 60 (1984): 370-3[6] Schuna AA, Schmidt GR, Pitterle ME "Serum potassium concentrations after initiation of captopril therapy." Clin Pharm 5 (1986): 920-3[7] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[8] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[9] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[10] Packer M, Lee WH "Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure." Am J Cardiol 57 (1986): 347-8[11] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[12] Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70[13] Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2[14] Speirs CJ, Dollery CT, Inman WH, et al "Postmarketing surveillance of enalapril II: investigation of the potential role of enalapril in deaths with renal failure." Br Med J 297 (1988): 830-2[15] Jarman PR, Kehely AM, Mather HM "Hyperkalaemia in diabetes: prevalence and associations." Postgrad Med J 71 (1995): 551-2[16] Obialo CI, Ofili EO, Mirza T "Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease." Am J Cardiol 90 (2002): 663-5[17] Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN "Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis." Hypertension 1 (1979): 279-80[18] Graves JW "Hyperkalemia due to a potassium-based water softener." N Engl J Med 339 (1998): 1790-1[19] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[20] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538[21] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12[22] Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812[23] Stoltz ML, Andrews CE Jr "Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use ." JAMA 264 (1990): 2737-8[24] Reardon LC, Macpherson DS "Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?" Arch Intern Med 158 (1998): 26-32[25] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[26] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[27] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67305, 'Salsalate', 'Potassium citrate', 'Moderate', 'Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other salicylates. The mechanism involves reduction in salicylate renal tubular reabsorption due to increased urinary pH, resulting in increased renal salicylate clearance especially above urine pH of 7. This interaction is sometimes exploited in the treatment of salicylate toxicity.', NULL, 'Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.', NULL, 'Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.', 'Excretion', 'Acetaminophen, Ziconotide, Methoxyflurane', 'Potassium chloride, Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67392/', '[1] Prescott LF, Balali-Mood M, Critchley JA, Johnstone AF, Proudfoot AT "Diuresis or urinary alkalinisation for salicylate poisoning?" Br Med J (Clin Res Ed) 285 (1982): 1383-6[2] Brouwers JRBJ, Desmet PAGM "Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs." Clin Pharmacokinet 27 (1994): 462-85[3] Berg KJ "Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency." Eur J Clin Pharmacol 11 (1977): 111-6[4] Balali-Mood M, Prescott LF "Failure of alkaline diuresis to enhance diflunisal elimination." Br J Clin Pharmacol 10 (1980): 163-5[5] Berg KJ "Acute acetylsalicylic acid poisoning: treatment with forced alkaline diuresis and diuretics." Eur J Clin Pharmacol 12 (1977): 111-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67306, 'Scopolamine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67393/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67307, 'Solifenacin', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67394/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67308, 'Sparfloxacin', 'Potassium citrate', 'Moderate', 'Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.', NULL, 'Concomitant use should generally be avoided.', NULL, 'Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.', 'Excretion', 'Delafloxacin', 'Potassium chloride, Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67395/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67309, 'Sulindac', 'Potassium citrate', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67396/', '[1] "Product Information. Potassium Chloride ER (potassium chloride)." Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. K-Phos Original (potassium acid phosphate)." Beach Pharmaceuticals, Tampa, FL.[4] "Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate)." Patrin Pharma, Skokie, IL.[5] "Product Information. SSKI (potassium iodide)." Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] "Product Information. Potassium Chloride (potassium chloride)." Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67310, 'Telmisartan', 'Potassium citrate', 'Major', 'Concomitant use of angiotensin II receptor blockers (ARBs) and potassium salts may increase the risk of hyperkalemia. Inhibition of angiotensin II results in decreased aldosterone secretion, which in turn causes potassium retention. Risk factors for developing severe or life-threatening hyperkalemia may include renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, and concomitant use of other agents that block the renin-angiotensin-aldosterone system or otherwise increase serum potassium levels.', NULL, 'Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.', NULL, 'Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67397/', '[1] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12[2] Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812[3] Obialo CI, Ofili EO, Mirza T "Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease." Am J Cardiol 90 (2002): 663-5[4] Jarman PR, Kehely AM, Mather HM "Hyperkalaemia in diabetes: prevalence and associations." Postgrad Med J 71 (1995): 551-2[5] "Product Information. Cozaar (losartan)." Merck & Co, Inc, West Point, PA.[6] Large DM, Carr PH, Laing I, Davies M "Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism." Postgrad Med J 60 (1984): 370-3[7] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[8] "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals, East Hanover, NJ.[9] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[10] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[11] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[12] "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals, East Hanover, NJ.[13] "Product Information. Cozaar (losartan)." Merck & Co, Inc, West Point, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67311, 'Thiethylperazine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67398/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67312, 'Thioridazine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67399/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67313, 'Thiothixene', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67400/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67314, 'Tolazamide', 'Potassium citrate', 'Minor', 'Alkalinization of the urine may increase the renal clearance of some sulfonylureas for which renal elimination is pH dependent. The clinical significance of this interaction is unknown. Management consists of monitoring blood glucose frequently during the initial period of coadministration. The sulfonylurea dosage should be adjusted as needed and appropriate.', NULL, '-', NULL, '-', 'Excretion', 'Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Glimepiride, Albiglutide, Rosiglitazone, More', 'Potassium chloride, Potassium bicarbonate, Potassium gluconate', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67401/', '[1] Neuvonen PJ, Karkkainen S "Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics." Clin Pharmacol Ther 33 (1983): 386-93[2] Kivisto KT, Neuvonen PJ "Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide." Eur J Clin Pharmacol 40 (1991): 383-6[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[5] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[6] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[7] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[8] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[9] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[10] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[11] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67315, 'Tolbutamide', 'Potassium citrate', 'Minor', 'Alkalinization of the urine may increase the renal clearance of some sulfonylureas for which renal elimination is pH dependent. The clinical significance of this interaction is unknown. Management consists of monitoring blood glucose frequently during the initial period of coadministration. The sulfonylurea dosage should be adjusted as needed and appropriate.', NULL, '-', NULL, '-', 'Excretion', 'Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Macimorelin, Methacholine, More', 'Potassium bicarbonate, Potassium gluconate', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67402/', '[1] Neuvonen PJ, Karkkainen S "Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics." Clin Pharmacol Ther 33 (1983): 386-93[2] Kivisto KT, Neuvonen PJ "Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide." Eur J Clin Pharmacol 40 (1991): 383-6[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[5] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[6] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[7] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[8] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[9] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[10] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[11] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67316, 'Tolmetin', 'Potassium citrate', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib, Tolazoline, Rabeprazole, Dimethyl sulfoxide', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67403/', '[1] "Product Information. Potassium Chloride ER (potassium chloride)." Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. K-Phos Original (potassium acid phosphate)." Beach Pharmaceuticals, Tampa, FL.[4] "Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate)." Patrin Pharma, Skokie, IL.[5] "Product Information. SSKI (potassium iodide)." Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] "Product Information. Potassium Chloride (potassium chloride)." Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67317, 'Tolterodine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67404/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67318, 'Tolvaptan', 'Potassium citrate', 'Moderate', 'Coadministration with tolvaptan can potentiate the risk of hyperkalemia in patients treated with other drugs that are known to increase serum potassium. Tolvaptan alone can increase serum potassium by causing an acute reduction of the extracellular fluid volume.', NULL, 'Serum potassium levels should be checked regularly during concomitant therapy with tolvaptan and other agents that can increase serum potassium such as ACE inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, and miscellaneous agents like cyclosporin, heparin, tacrolimus, and trimethoprim.', NULL, 'Serum potassium levels should be checked regularly during concomitant therapy with tolvaptan and other agents that can increase serum potassium such as ACE inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, and miscellaneous agents like cyclosporin, heparin, tacrolimus, and trimethoprim. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Conivaptan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67405/', '[1] "Product Information. Samsca (tolvaptan)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[2] "Product Information. Samsca (tolvaptan)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67319, 'Trandolapril', 'Potassium citrate', 'Major', 'Concomitant use of angiotensin converting enzyme (ACE) inhibitors and potassium salts may increase the risk of hyperkalemia. Inhibition of ACE results in decreased aldosterone secretion, which in turn causes potassium retention.', NULL, 'Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice.', NULL, 'Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67406/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Chan TY, Critchley JA "Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements." Drug Saf 7 (1992): 159-61[3] Warren SE, O''Connor DT "Hyperkalemia resulting from captopril administration." JAMA 244 (1980): 2551-2[4] Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association "Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association." Circulation 104 (2001): 1985-91[5] Large DM, Carr PH, Laing I, Davies M "Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism." Postgrad Med J 60 (1984): 370-3[6] Schuna AA, Schmidt GR, Pitterle ME "Serum potassium concentrations after initiation of captopril therapy." Clin Pharm 5 (1986): 920-3[7] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[8] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[9] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[10] Packer M, Lee WH "Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure." Am J Cardiol 57 (1986): 347-8[11] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[12] Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70[13] Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2[14] Speirs CJ, Dollery CT, Inman WH, et al "Postmarketing surveillance of enalapril II: investigation of the potential role of enalapril in deaths with renal failure." Br Med J 297 (1988): 830-2[15] Jarman PR, Kehely AM, Mather HM "Hyperkalaemia in diabetes: prevalence and associations." Postgrad Med J 71 (1995): 551-2[16] Obialo CI, Ofili EO, Mirza T "Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease." Am J Cardiol 90 (2002): 663-5[17] Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN "Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis." Hypertension 1 (1979): 279-80[18] Graves JW "Hyperkalemia due to a potassium-based water softener." N Engl J Med 339 (1998): 1790-1[19] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[20] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538[21] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12[22] Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812[23] Stoltz ML, Andrews CE Jr "Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use ." JAMA 264 (1990): 2737-8[24] Reardon LC, Macpherson DS "Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?" Arch Intern Med 158 (1998): 26-32[25] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[26] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[27] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67320, 'Triamterene', 'Potassium citrate', 'Major', 'The concomitant use of potassium-sparing diuretics and potassium preparations may result in hyperkalemia.', NULL, 'The use of potassium preparations in patients treated with potassium-sparing diuretics is generally not recommended.', NULL, 'The use of potassium preparations in patients treated with potassium-sparing diuretics is generally not recommended. Caution is advised if coadministration is required, particularly in patients with renal impairment, diabetes, old age, worsening heart failure, and/or a risk for dehydration. Serum potassium and renal function should be checked regularly, and oral potassium supplementation should be avoided in patients with severe congestive heart failure who have serum potassium levels above 3.5 mEq/L. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as weakness, listlessness, confusion, tingling of the extremities, and irregular heartbeat.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67407/', '[1] Shapiro S, Slone D, Lewis GP, Jick H "Fatal drug reactions among medical inpatients." JAMA 216 (1971): 467-72[2] McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970): 58-70[3] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12[4] Jarman PR, Kehely AM, Mather HM "Hyperkalaemia in diabetes: prevalence and associations." Postgrad Med J 71 (1995): 551-2[5] Berry C, McMurray JJ "Serious adverse events experienced by patients with chronic heart failure taking spironolactone." Heart 85 (2001): E8[6] Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006): 49-58[7] "Product Information. Aldactone (spironolactone)." Searle, Skokie, IL.[8] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[9] Masoudi FA, Gross CP, Wang Y, et al. "Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001." Circulation 112 (2005): 39-47[10] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[11] O''Reilly MV, Murnaghan DP, Williams MB "Transvenous pacemaker failure induced by hyperkalemia." JAMA 228 (1974): 336-7[12] Greenblatt DJ, Koch-Weser J "Adverse reactions to spironolactone: a report from the Boston Collaborative Drug Surveillance Program." JAMA 225 (1973): 40-3[13] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[14] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[15] Walker BR, Hoppe RC, Alexander F "Effect of triamterene on the renal clearance of calcium, magnesium, phosphate, and uric acid in man." Clin Pharmacol Ther 13 (1972): 245-50[16] Mashford ML, Robertson MB "Spironolactone and ammonium and potassium chloride." Br Med J 4 (1972): 298-9[17] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[18] Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812[19] Martin J, Mourton S, Nicholls G "Severe hyperkalaemia with prescription of potassium-retaining agents in an elderly patient." N Z Med J 116 (2003): U542[20] Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70[21] Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D "Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study." BMJ 327 (2003): 1141-2[22] Bozkurt B, Agoston I, Knowlton AA "Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines." J Am Coll Cardiol 41 (2003): 211-4', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67321, 'Trifluoperazine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67408/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67322, 'Triflupromazine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67409/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67323, 'Trihexyphenidyl', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Potassium bicarbonate, Potassium gluconate', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67410/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67324, 'Alimemazine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67411/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67325, 'Trimethoprim', 'Potassium citrate', 'Major', 'The use of trimethoprim in combination with other potassium-sparing drugs or potassium salts may increase the risk of hyperkalemia. Trimethoprim inhibits sodium reabsorption and potassium excretion by blocking sodium channels in the renal distal tubules.', NULL, 'Serum potassium and sodium levels as well as renal function should be closely monitored during coadministration of trimethoprim with other potassium-sparing drugs or potassium salts, particularly in patients receiving high-dose or long-term trimethoprim treatment and in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration.', NULL, 'Serum potassium and sodium levels as well as renal function should be closely monitored during coadministration of trimethoprim with other potassium-sparing drugs or potassium salts, particularly in patients receiving high-dose or long-term trimethoprim treatment and in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. A dosage reduction of trimethoprim is recommended in renal dysfunction (50% reduction for CrCl between 15 and 30 mL/min). Patients should be given dietary counseling to avoid excessive intake of potassium-rich foods and salt substitutes, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat. Trimethoprim should be discontinued if hyperkalemia occurs.', 'Excretion', 'Sulfadiazine, Sulfamethoxazole, Sulfamethizole, Sulfisoxazole, Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67412/', '[1] Witt JM, Koo JM, Danielson BD "Effect of standard-dose trimethoprim/sulfamethoxazole on the serum potassium concentration in elderly men." Ann Pharmacother 30 (1996): 347-50[2] Canaday DH, Johnson JR "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 438[3] Noto H, Kaneko Y, Takano T, Kurokawa K "Severe hyponatremia and hyperkalemia induced by trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia." Intern Med 34 (1995): 96-9[4] Perazella MA, Mahnensmith RL "Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose." Clin Nephrol 46 (1996): 187-92[5] Velazquez H, Perazella MA, Wright FS, Ellison DH "Renal mechanism of trimethoprim-induced hyperkalemia." Ann Intern Med 119 (1993): 296-301[6] Marinella MA "Reversible hyperkalemia associated with trimethoprim-sulfamethoxazole." Am J Med Sci 310 (1995): 115-7[7] Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006): 49-58[8] Koc M, Bihorac A, Ozener CI, Kantarci G, Akoglu E "Severe hyperkalemia in two renal transplant recipients treated with standard dose of trimethoprim-sulfamethoxazole." Am J Kidney Dis 36 (2000): u59-64[9] Bugge JF "Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs." J Intern Med 240 (1996): 249-51[10] Choi MJ, Fernandez PC, Patnaik A, Coupaye-Gerard B, D''Andrea D, Szerlip H, Kleyman TR "Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS." N Engl J Med 328 (1993): 703-6[11] Thomas RJ "Severe hyperkalemia with trimethoprim-quinapril." Ann Pharmacother 30 (1996): 413-4[12] Marinella MA "Severe hyperkalemia associated with trimethoprim-sulfamethoxazole and spironolactone." Infect Dis Clin Pract 6 (1997): 256-8[13] Smith GW, Cohen SB "Hyperkalaemia and non-oliguric renal failure associated with trimethoprim." Br Med J 308 (1994): 454[14] Eiam-Ong S, Kurtzman NA, Sabatini S "Studies on the mechanism of trimethoprim-induced hyperkalemia." Kidney Int 49 (1996): 1372-8[15] Fouche R, Bernardin G, Roger PM, Corcelle P, Simler JM, Mattei M "Hyperkaliemia in a patient given high-dose trimethoprim-sulfamethoxazole." Presse Med 25 (1996): 2044[16] "Prevent-ERR: sulfamethoxazole and trimethoprim-induced hyperkalemia." ISMP Medication Safety Alert! 13(Dec 4) (2008): 3[17] Pennypacker LC, Mintzer J, Pitner J "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 437[18] Modest GA, Price B, Mascoli N "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 437[19] Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14[20] Martin J, Mourton S, Nicholls G "Severe hyperkalaemia with prescription of potassium-retaining agents in an elderly patient." N Z Med J 116 (2003): U542[21] Greenberg S, Reiser IW, Chou SY "Hyperkalemia with high-dose trimethoprim-sulfamethoxazole therapy." Am J Kidney Dis 22 (1993): 603-6[22] Mori H, Kuroda Y, Imamura S, et al "Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole." Intern Med 42 (2003): 665-9[23] Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56[24] Alappan R, Perazella MA, Buller GK "Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole." Ann Intern Med 124 (1996): 316-20[25] Perlmutter EP, Sweeney D, Herskovits G, Kleiner M "Case report: severe hyperkalemia in a geriatric patient receiving standard doses of trimethoprim-sulfamethoxazole." Am J Med Sci 311 (1996): 84-5[26] Marinella MA "Trimethoprim-sulfamethoxazole associated with hyperkalemia." West J Med 167 (1997): 356-8[27] Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM "Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study." Arch Intern Med 170 (2010): 1045-9[28] Hsu I, Wordell CJ "Hyperkalemia and high-dose trimethoprim/sulfamethoxazole." Ann Pharmacother 29 (1995): 427-9[29] Lin SH, Kuo AA, Yu FC, Lin YF "Reversible voltage-dependent distal renal tubular acidosis in a patient receiving standaard doses of trimethoprim-sulphamethoxazole." Nephrol Dial Transplant 12 (1997): 1031-33[30] Lawson DH, O''Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5[31] Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40[32] Perazella MA, Alappan R, Buller GK "Hyperkalemia and trimethoprim-sulfamethoxazole." Ann Intern Med 125 (1996): 1015[33] "Product Information. Bactrim (trimethoprim-sulfamethoxazole)." Roche Laboratories, Nutley, NJ.[34] Mihm LB, Rathbun RC, Resmantargoff BH "Hyperkalemia associated with high-dose trimethoprim-sulfamethoxazole in a patient with the acquired immunodeficiency syndrome." Pharmacotherapy 15 (1995): 793-7[35] Lee SW, Park SW, Kang JM "Intraoperative hyperkalemia induced by administration of trimethoprim-sulfamethoxazole in a patient receiving angiotensin receptor blockers." J Clin Anesth 26 (2014): 427-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67326, 'Trimipramine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Citalopram, Sertraline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67413/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67327, 'Tripelennamine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, Tetracaine', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67414/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67328, 'Triprolidine', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67415/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67329, 'Trospium', 'Potassium citrate', 'Major', 'Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.', NULL, 'The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.', 'Synergism', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, More', 'Potassium bicarbonate, Potassium gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67416/', '[1] "Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.[2] Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ "Ulceration of small intestine and slow-release potassium tablets." Br Med J 2 (1975): 746[8] Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2[11] "Product Information. Urocit (potassium citrate)." Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Sanctura (trospium chloride)." Odyssey Pharmaceutical, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67330, 'Trovafloxacin', 'Potassium citrate', 'Moderate', 'Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.', NULL, 'Concomitant use should generally be avoided.', NULL, 'Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.', 'Excretion', 'Delafloxacin', 'Potassium chloride, Potassium bicarbonate, Potassium gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67417/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67331, 'Cladribine', 'Acetohydroxamic acid', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Ravulizumab, Diroximel fumarate, Methotrexate, Inebilizumab, Belumosudil, Ozanimod, Emapalumab, Natalizumab, More', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67418/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67332, 'Human adenovirus e serotype 4 strain cl-68578 antigen', 'Cladribine', 'Moderate', 'There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.', NULL, 'The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies.', NULL, 'The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies. Caution is advised.', 'Others', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67419/', '[1] "Product Information. Adenovirus Vaccine Type 4 and Type 7 (adenovirus vaccine, live)." Teva Pharmaceuticals USA, North Wales, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67333, 'Cladribine', 'Aurothioglucose', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67420/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67334, 'Cladribine', 'Axicabtagene ciloleucel', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', 'Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67421/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67335, 'Cladribine', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67422/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.[3] "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67336, 'Cladribine', 'Belinostat', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', 'Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67423/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67337, 'Cladribine', 'Bifidobacterium longum infantis', 'Moderate', 'Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.', 'Others', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67424/', '[1] Borriello SP, Hammes WP, Holzapfel W, et.al "Safety of probiotics that contain lactobacilli or bifidobacteria." Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. "Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland." Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P "Lactobacillus species as opportunistic pathogens in immunocompromised patients." Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. "Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG." Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL "Lactobacillus bacteremia and endocarditis: review of 45 cases." Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML "Probiotic use in clinical practice: what are the risks?" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al "Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin." Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. "Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG." Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al "Lactobacilli and bacteremia in southern Finland, 1989-1992" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C "Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis." J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM "Lactobacillus endocarditis caused by a probiotic organism." Clin Microbiol Infect 5 (1999): 290-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67338, 'Cladribine', 'Brexucabtagene autoleucel', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67425/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67339, 'Cladribine', 'Candida albicans', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67426/', '[1] "Product Information. Spherulin (coccidioidin skin test)." ALK Laboratories Inc, Wallingford, CT.[2] "Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative)." Connaught Laboratories Ltd, Toronto, ON.[3] "Product Information. Candin (candida albicans extract)." Nielsen Biosciences Inc, San Diego, CA.[4] "Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen)." Aventis Pharmaceuticals, Swiftwater, PA.[5] "Product Information. Multitest CMI (skin test antigens, multiple)." Aventis Pharmaceuticals, Swiftwater, PA.[6] "Product Information. Histolyn-Cyl (histoplasmin)." ALK Laboratories Inc, Wallingford, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67340, 'Cladribine', 'Vibrio cholerae CVD 103-HgR strain live antigen', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67427/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67341, 'Clofarabine', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More', 'Cladribine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67428/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67342, 'Clozapine', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Ustekinumab, Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, Apremilast, Inebilizumab, More', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67429/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67343, 'Cobimetinib', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More', 'Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67430/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67344, 'Coccidioides immitis spherule', 'Cladribine', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67431/', '[1] "Product Information. Spherulin (coccidioidin skin test)." ALK Laboratories Inc, Wallingford, CT.[2] "Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative)." Connaught Laboratories Ltd, Toronto, ON.[3] "Product Information. Candin (candida albicans extract)." Nielsen Biosciences Inc, San Diego, CA.[4] "Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen)." Aventis Pharmaceuticals, Swiftwater, PA.[5] "Product Information. Multitest CMI (skin test antigens, multiple)." Aventis Pharmaceuticals, Swiftwater, PA.[6] "Product Information. Histolyn-Cyl (histoplasmin)." ALK Laboratories Inc, Wallingford, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67345, 'Colchicine', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Anakinra, More', 'Lesinurad, Febuxostat, Pegloticase, Sulfinpyrazone, Rasburicase, Probenecid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67432/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67346, 'Copanlisib', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', 'Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67433/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67347, 'Corticotropin', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', 'Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67434/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67348, 'Cladribine', 'Tetracosactide', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', 'Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67435/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67349, 'Cyclophosphamide', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67436/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67350, 'Cyclosporine', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67437/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67351, 'Cytarabine', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Cladribine, Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67438/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67352, 'Cytarabine (liposomal)', 'Cladribine', 'Moderate', 'The use of cladribine with medications that undergo intracellular phosphorylation may reduce its efficacy by inhibiting its phosphorylation to its active form. The clinical significance of this interaction is unknown.', NULL, 'Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.', NULL, 'Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.', 'Antagonism', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 'Cladribine, Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67439/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[4] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67353, 'Dacarbazine', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67440/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67354, 'Dactinomycin', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67441/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67355, 'Dapsone', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, More', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Erythromycin, Azelaic acid, Adapalene, Clofazimine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67442/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67356, 'Daratumumab', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67443/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67357, 'Darolutamide', 'Cladribine', 'Moderate', 'Coadministration with darolutamide may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The proposed mechanism is decreased clearance due to inhibition of BCRP-mediated intestinal and hepatobiliary efflux by darolutamide.', NULL, 'Concomitant use of darolutamide with drugs that are BCRP substrates should be avoided when possible.', NULL, 'Concomitant use of darolutamide with drugs that are BCRP substrates should be avoided when possible. If coadministration is required, patients should be monitored carefully for increased adverse reactions of these drugs and dosing adjusted as necessary.', 'Metabolism', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 'Tamoxifen, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67444/', '[1] "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.[2] "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.[3] "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67358, 'Dasatinib', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67445/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67359, 'Daunorubicin', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67446/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67360, 'Daunorubicin (liposomal)', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67447/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67361, 'Decitabine', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', 'Cladribine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67448/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67362, 'Deferiprone', 'Cladribine', 'Major', 'Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Deferiprone alone can cause agranulocytosis, which may be preceded by neutropenia.', NULL, 'Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided.', NULL, 'Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided. Otherwise, close monitoring of absolute neutrophil count (ANC) is recommended if coadministration is required.', 'Synergism', 'Cyclosporine, Ustekinumab, Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Tacrolimus, Abatacept, Siponimod, Apremilast, More', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67449/', '[1] "Product Information. Ferriprox (deferiprone)." ApoPharma USA Inc, Rockville, MD.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67363, 'Deflazacort', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67450/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67364, 'Denileukin diftitox', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67451/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67365, 'Denosumab', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Voclosporin, Pegcetacoplan, Eculizumab, Sutimlimab', 'Tiludronic acid, Alendronic acid, Vosoritide, Etidronic acid, Ibandronate, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab, Zoledronic acid, Pamidronic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67452/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67366, 'Didanosine', 'Cladribine', 'Moderate', 'The use of cladribine with medications that undergo intracellular phosphorylation may reduce its efficacy by inhibiting its phosphorylation to its active form. The clinical significance of this interaction is unknown.', NULL, 'Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.', NULL, 'Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.', 'Antagonism', 'Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Tacrolimus, Abatacept, Upadacitinib, More', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67453/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[4] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67367, 'Dimethyl fumarate', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Dimethyl fumarate, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67454/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67368, 'Dinutuximab', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67455/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67369, 'Diroximel fumarate', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Diroximel fumarate, Sutimlimab', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67456/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67370, 'Docetaxel', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67457/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67371, 'Doxorubicin', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67458/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67372, 'Doxorubicin (liposomal)', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67459/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67373, 'Drospirenone', 'Cladribine', 'Moderate', 'RECOMMENDED: Coadministration with cladribine may reduce the efficacy of hormonal contraceptives. The mechanism has not been established. There are no clinical data regarding the use of cladribine with hormonal contraceptives.', NULL, 'Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm.', NULL, 'Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course. Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle. In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course.', 'Others', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More', 'Megestrol acetate, Estetrol, Ulipristal, Estradiol, Megestrol acetate, Progesterone, Estradiol', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67460/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[8] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[11] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[12] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[13] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[14] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[15] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[16] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[17] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[18] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[19] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[20] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[21] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[22] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[23] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[24] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[25] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[26] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[29] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[30] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[31] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[32] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[33] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[34] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[35] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[36] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[37] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[38] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[39] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[40] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67374, 'Dupilumab', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', 'Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Ivermectin, Caffeine, Diclofenac, Cromoglicic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67461/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67375, 'Durvalumab', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67462/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67376, 'Duvelisib', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More', 'Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67463/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67377, 'Efalizumab', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Efalizumab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67464/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67378, 'Elotuzumab', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67465/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67379, 'Eltrombopag', 'Cladribine', 'Moderate', 'Oral bioavailability and systemic exposure of cladribine may be increased by potent inhibitors of breast cancer resistance protein (BCRP) while intracellular distribution and renal elimination of cladribine may be altered by potent inhibitors of equilibrative nucleoside transporter 1 (ENT1) and concentrative nucleoside transporter 3 (CNT3). The mechanism involves inhibition of ENT1, CNT3, and/or BCRP as cladribine is a substrate of each of these transporter systems.', NULL, 'Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles.', NULL, 'Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles. If coadministration is required, consider concomitant alternatives that exhibit no or minimal inhibition of ENT1, CNT3, or BCRP. If this is not possible, dose reduction to the minimum mandatory dose, separation in the timing of administration, and careful patient monitoring is recommended.', 'Absorption, Distribution, Excretion', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More', 'Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67466/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67380, 'Emtricitabine', 'Cladribine', 'Moderate', 'The use of cladribine with medications that undergo intracellular phosphorylation may reduce its efficacy by inhibiting its phosphorylation to its active form. The clinical significance of this interaction is unknown.', NULL, 'Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.', NULL, 'Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.', 'Antagonism', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67467/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[4] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67381, 'Enasidenib', 'Cladribine', 'Moderate', 'Based on in vitro data, coadministration with enasidenib may increase the plasma concentrations of drugs that are substrates of the transporters, organic anion transporting polypeptides (OATP) 1B1/1B3 and breast cancer resistance protein (BCRP). The proposed mechanism is decreased clearance due to enasidenib -mediated inhibition of OATP1B1/1B3 and BCRP transporters.', NULL, 'Caution is advised when enasidenib is used concurrently with medications that are substrates of OATP 1B1/1B3 and/or BCRP, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when enasidenib is used concurrently with medications that are substrates of OATP 1B1/1B3 and/or BCRP, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever enasidenib is added to or withdrawn from therapy.', 'Distribution', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 'Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67468/', '[1] "Product Information. Idhifa (enasidenib)." Celgene Corporation, Summit, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67382, 'Enfortumab vedotin', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67469/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67383, 'Entecavir', 'Cladribine', 'Moderate', 'The use of cladribine with medications that undergo intracellular phosphorylation may reduce its efficacy by inhibiting its phosphorylation to its active form. The clinical significance of this interaction is unknown.', NULL, 'Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.', NULL, 'Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.', 'Antagonism', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67470/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[4] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67384, 'Entrectinib', 'Cladribine', 'Moderate', 'Coadministration with entrectinib may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The proposed mechanisms, based on in vitro data, is decreased clearance due to entrectinib-mediated inhibition of BCRP transport protein.', NULL, 'Caution is advised when entrectinib is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, mitoxantrone, topotecan, and lapatinib.', NULL, 'Caution is advised when entrectinib is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, mitoxantrone, topotecan, and lapatinib. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever entrectinib is added to or withdrawn from therapy.', 'Others', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67471/', '[1] "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67385, 'Enzalutamide', 'Cladribine', 'Moderate', 'Cladribine exposure may be decreased by potent inducers of breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp). The mechanism involves induction of BCRP and/or P-gp as cladribine is a substrate of each of these transporter systems. The clinical relevance remains unknown.', NULL, 'Possible decreases in cladribine exposure and efficacy should be considered if potent inducers of BCRP or P-gp are coadministered.', NULL, 'Possible decreases in cladribine exposure and efficacy should be considered if potent inducers of BCRP or P-gp are coadministered.', 'Others', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Tamoxifen, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67472/', '[1] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[5] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67386, 'Epirubicin', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67473/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67387, 'Eribulin', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67474/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67388, 'Etanercept', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Etanercept, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67475/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67389, 'Ethotoin', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Golimumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Tacrolimus, Abatacept, Upadacitinib, More', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67476/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67390, 'Etonogestrel', 'Cladribine', 'Moderate', 'RECOMMENDED: Coadministration with cladribine may reduce the efficacy of hormonal contraceptives. The mechanism has not been established. There are no clinical data regarding the use of cladribine with hormonal contraceptives.', NULL, 'Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm.', NULL, 'Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course. Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle. In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course.', 'Others', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More', 'Megestrol acetate, Estetrol, Ulipristal, Estradiol', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67477/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[8] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[11] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[12] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[13] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[14] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[15] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[16] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[17] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[18] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[19] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[20] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[21] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[22] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[23] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[24] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[25] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[26] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[29] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[30] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[31] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[32] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[33] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[34] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[35] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[36] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[37] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[38] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[39] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[40] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67391, 'Etoposide', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67478/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67392, 'Everolimus', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More', 'Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67479/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67393, 'Cladribine', 'Trastuzumab deruxtecan', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67480/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67394, 'Famciclovir', 'Cladribine', 'Moderate', 'The use of cladribine with medications that undergo intracellular phosphorylation may reduce its efficacy by inhibiting its phosphorylation to its active form. The clinical significance of this interaction is unknown.', NULL, 'Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.', NULL, 'Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.', 'Antagonism', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67481/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[4] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67395, 'Felbamate', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67482/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67396, 'Filgrastim', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67483/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67397, 'Fingolimod', 'Cladribine', 'Major', 'Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.', NULL, 'The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', NULL, 'The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.', 'Synergism', 'Pegcetacoplan, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Fingolimod, Eculizumab, Sutimlimab', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67484/', '[1] "Product Information. Gilenya (fingolimod)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67398, 'Floxuridine', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', 'Cladribine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67485/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67399, 'Flucytosine', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Golimumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More', 'Fluconazole, Caspofungin, Amphotericin B, Itraconazole, Miconazole, Micafungin, Posaconazole, Ketoconazole, Anidulafungin, Voriconazole, Salicylic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67486/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67400, 'Fludarabine', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Cladribine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67487/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67401, 'Fludrocortisone', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More', 'Fluocinolone acetonide, Fluorometholone, Indomethacin, Fluocinolone acetonide, Diclofenac', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67488/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67402, 'Fluorouracil', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', 'Cladribine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67489/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67403, 'Fluticasone', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Ipratropium, Cromoglicic acid, Revefenacin, Nedocromil, Tiotropium, Beclomethasone dipropionate, Mometasone furoate, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67490/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67404, 'Glasdegib', 'Cladribine', 'Moderate', 'Coadministration with glasdegib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) efflux transporters.', NULL, 'Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range. Clinical and laboratory monitoring should be considered whenever glasdegib is added to or withdrawn from therapy with these drugs, and dosages adjusted as necessary. Patients should be monitored for the development of adverse effects.', 'Absorption', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67491/', '[1] "Product Information. Daurismo (glasdegib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Daurismo (glasdegib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67405, 'Cladribine', 'Sodium aurothiomalate', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67492/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67406, 'Golimumab', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Golimumab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67493/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67407, 'Guanidine', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67494/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67408, 'Guselkumab', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67495/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67409, 'Hepatitis A Vaccine', 'Cladribine', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67496/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67410, 'Hepatitis B Vaccine (Recombinant)', 'Cladribine', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67497/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67411, 'Human papillomavirus type 11 L1 capsid protein antigen', 'Cladribine', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67498/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67412, 'Hydroxyurea', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', 'Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67499/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67413, 'Ibritumomab tiuxetan', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Iodide I-131', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67500/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67414, 'Ibrutinib', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More', 'Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67501/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67415, 'Idarubicin', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67502/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67416, 'Idelalisib', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, Emapalumab, More', 'Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67503/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67417, 'Ifosfamide', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67504/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67418, 'Imatinib', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Ozanimod, More', 'Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67505/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67419, 'Inebilizumab', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67506/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67420, 'Infliximab', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Infliximab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67507/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67421, 'Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)', 'Cladribine', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67508/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67422, 'Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)', 'Cladribine', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67509/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67423, 'Inotuzumab ozogamicin', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67510/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67424, 'Interferon alfa-2a, Recombinant', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67511/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67425, 'Interferon alfa-2b', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67512/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67426, 'Interferon alfa-n1', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67513/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67427, 'Interferon alfa-n3', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67514/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67428, 'Interferon alfacon-1', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67515/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67429, 'Interferon beta-1a', 'Cladribine', 'Moderate', 'The use of cladribine with beta interferons may increase the risk of lymphopenia. The mechanism involves additive risk of lymphopenia.', NULL, 'Concomitant use of cladribine and beta interferons is not recommended.', NULL, 'Concomitant use of cladribine and beta interferons is not recommended.', 'Synergism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Upadacitinib, Anakinra, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67516/', '[1] Montalban X, Leist TP, Cohen BA, et.al "Cladribine tablets added to IFN- in active relapsing MS: The ONWARD study." Neurol Neruroimmunol Neuroinflamm 11 (2018): e477[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67430, 'Interferon beta-1b', 'Cladribine', 'Moderate', 'The use of cladribine with beta interferons may increase the risk of lymphopenia. The mechanism involves additive risk of lymphopenia.', NULL, 'Concomitant use of cladribine and beta interferons is not recommended.', NULL, 'Concomitant use of cladribine and beta interferons is not recommended.', 'Synergism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Upadacitinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67517/', '[1] Montalban X, Leist TP, Cohen BA, et.al "Cladribine tablets added to IFN- in active relapsing MS: The ONWARD study." Neurol Neruroimmunol Neuroinflamm 11 (2018): e477[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67431, 'Interferon gamma-1b', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67518/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67432, 'Iobenguane (I-131)', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67519/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67433, 'Cladribine', 'Tositumomab (I-131)', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67520/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67434, 'Irinotecan', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67521/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67435, 'Irinotecan (liposomal)', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67522/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67436, 'Isatuximab', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67523/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67437, 'Cladribine', 'Ixabepilone', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67524/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67438, 'Cladribine', 'Ixazomib', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67525/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67439, 'Cladribine', 'Ixekizumab', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67526/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67440, 'Cladribine', 'Lactobacillus acidophilus', 'Moderate', 'Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.', 'Others', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67527/', '[1] Borriello SP, Hammes WP, Holzapfel W, et.al "Safety of probiotics that contain lactobacilli or bifidobacteria." Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. "Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland." Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P "Lactobacillus species as opportunistic pathogens in immunocompromised patients." Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. "Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG." Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL "Lactobacillus bacteremia and endocarditis: review of 45 cases." Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML "Probiotic use in clinical practice: what are the risks?" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al "Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin." Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. "Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG." Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al "Lactobacilli and bacteremia in southern Finland, 1989-1992" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C "Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis." J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM "Lactobacillus endocarditis caused by a probiotic organism." Clin Microbiol Infect 5 (1999): 290-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67441, 'Cladribine', 'Lasmiditan', 'Moderate', 'Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan.', NULL, 'Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible.', NULL, 'Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible. If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary.', 'Distribution', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More', 'Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Ergotamine, Clonidine, Naratriptan, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67528/', '[1] "Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company, Indianapolis, IN.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67442, 'Cladribine', 'Leflunomide', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Apremilast, Belumosudil, Leflunomide, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67529/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67443, 'Cladribine', 'Lenalidomide', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67530/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67444, 'Cladribine', 'Levamisole', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', 'Thiabendazole, Pyrantel, Ivermectin, Piperazine, Mebendazole', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67531/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67445, 'Cladribine', 'Linezolid', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Tinidazole, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67532/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67446, 'Cladribine', 'Lomustine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67533/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67447, 'Cladribine', 'Lonafarnib', 'Moderate', 'Coadministration with lonafarnib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter.', NULL, 'Caution is advised when lonafarnib is used concomitantly with drugs that are sensitive P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when lonafarnib is used concomitantly with drugs that are sensitive P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lonafarnib is added to or withdrawn from therapy.', 'Metabolism', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67534/', '[1] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.[2] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67448, 'Cladribine', 'Lorlatinib', 'Moderate', 'Coadministration of lorlatinib with drugs that are P-glycoprotein (P-gp) substrates may decrease the plasma concentration and pharmacologic effect of the P-gp substrate. The proposed mechanism is induction of P-gp mediated drug efflux by lorlatinib.', NULL, 'Concomitant use of lorlatinib with drugs that are P-gp substrates should generally be avoided, especially those P-gp substrates for which minimal concentration changes may lead to serious therapeutic failures.', NULL, 'Concomitant use of lorlatinib with drugs that are P-gp substrates should generally be avoided, especially those P-gp substrates for which minimal concentration changes may lead to serious therapeutic failures. If coadministration is required, consider dosage adjustments and clinical and laboratory monitoring whenever lorlatinib is added to or withdrawn from therapy.', 'Excretion', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, More', 'Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67535/', '[1] "Product Information. Lorbrena (lorlatinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Lorbrena (lorlatinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67449, 'Cladribine', 'Lurbinectedin', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More', 'Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67536/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67450, 'Cladribine', 'Lutetium Lu 177 dotatate', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67537/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67451, 'Cladribine', 'Lyme disease vaccine (recombinant OspA)', 'Moderate', 'The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy.', NULL, 'The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Spesolimab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Daclizumab, Emapalumab, Eculizumab, Anifrolumab, Deucravacitinib, Ponesimod, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67538/', '[1] "Product Information. Lymerix (Lyme disease vaccine)." SmithKline Beecham, Philadelphia, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67452, 'Cladribine', 'Measles virus vaccine live attenuated', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67539/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.[3] "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67453, 'Cladribine', 'Mechlorethamine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67540/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67454, 'Cladribine', 'Medroxyprogesterone acetate', 'Moderate', 'RECOMMENDED: Coadministration with cladribine may reduce the efficacy of hormonal contraceptives. The mechanism has not been established. There are no clinical data regarding the use of cladribine with hormonal contraceptives.', NULL, 'Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm.', NULL, 'Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course. Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle. In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course.', 'Others', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More', 'Megestrol acetate, Estetrol, Ulipristal, Estradiol, Megestrol acetate, Progesterone, Megestrol acetate, Progesterone, Estradiol, Diethylstilbestrol, Histrelin, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67541/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[8] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[11] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[12] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[13] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[14] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[15] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[16] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[17] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[18] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[19] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[20] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[21] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[22] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[23] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[24] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[25] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[26] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[29] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[30] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[31] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[32] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[33] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[34] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[35] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[36] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[37] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[38] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[39] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[40] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67455, 'Cladribine', 'Melphalan', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67542/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67456, 'Cladribine', 'Meningococcal polysaccharide vaccine group C', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Spesolimab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Daclizumab, Emapalumab, Anifrolumab, Deucravacitinib, Ponesimod, Ravulizumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67543/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67457, 'Cladribine', 'Mephenytoin', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67544/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67458, 'Cladribine', 'Mercaptopurine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Cladribine, Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67545/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67459, 'Cladribine', 'Methotrexate', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Cladribine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67546/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67460, 'Cladribine', 'Methylprednisolone', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Erythromycin, Azelaic acid, Adapalene, Fluocinolone acetonide, Fluocinonide, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67547/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67461, 'Cladribine', 'Midostaurin', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', 'Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67548/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67462, 'Cladribine', 'Mitomycin', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67549/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67463, 'Cladribine', 'Mitoxantrone', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67550/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67464, 'Cladribine', 'Mogamulizumab', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67551/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67465, 'Cladribine', 'Monomethyl fumarate', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67552/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67466, 'Cladribine', 'Mumps virus strain B level jeryl lynn live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67553/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.[3] "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67467, 'Cladribine', 'Muromonab', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67554/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67468, 'Cladribine', 'Mycophenolate mofetil', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67555/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67469, 'Cladribine', 'Mycophenolic acid', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67556/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67470, 'Cladribine', 'Natalizumab', 'Major', 'Concomitant or recent use of immunosuppressant, immunomodulating, or antineoplastic agents in patients treated with natalizumab may increase the risk of infections including progressive multifocal leukoencephalopathy (PML), a severely disabling, potentially fatal opportunistic viral infection of the brain.', NULL, 'The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established.', NULL, 'The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established. In general, patients receiving chronic therapy with such agents should not be treated with natalizumab due to potentially increased risk of PML and other serious infections. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. Due to the long half-life of natalizumab, immune effects are possible for up to 2 to 3 months following its discontinuation.', 'Synergism', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Natalizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67557/', '[1] "Product Information. Tysabri (natalizumab)." Elan Pharmaceutical/Athena Neurosciences Inc, South San Francisco, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67471, 'Cladribine', 'Naxitamab', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67558/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67472, 'Cladribine', 'Nelarabine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', 'Cladribine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67559/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67473, 'Cladribine', 'Nilotinib', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67560/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67474, 'Cladribine', 'Nimodipine', 'Moderate', 'Oral bioavailability and systemic exposure of cladribine may be increased by potent inhibitors of breast cancer resistance protein (BCRP) while intracellular distribution and renal elimination of cladribine may be altered by potent inhibitors of equilibrative nucleoside transporter 1 (ENT1) and concentrative nucleoside transporter 3 (CNT3). The mechanism involves inhibition of ENT1, CNT3, and/or BCRP as cladribine is a substrate of each of these transporter systems.', NULL, 'Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles.', NULL, 'Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles. If coadministration is required, consider concomitant alternatives that exhibit no or minimal inhibition of ENT1, CNT3, or BCRP. If this is not possible, dose reduction to the minimum mandatory dose, separation in the timing of administration, and careful patient monitoring is recommended.', 'Absorption, Distribution, Excretion', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Belumosudil, More', 'Felodipine, Amlodipine, Nisoldipine, Nicardipine, Isradipine, Clevidipine, Levamlodipine, Celecoxib, Mibefradil', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67561/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67475, 'Cladribine', 'Niraparib', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More', 'Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67562/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67476, 'Cladribine', 'Norgestrel', 'Moderate', 'RECOMMENDED: Coadministration with cladribine may reduce the efficacy of hormonal contraceptives. The mechanism has not been established. There are no clinical data regarding the use of cladribine with hormonal contraceptives.', NULL, 'Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm.', NULL, 'Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course. Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle. In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course.', 'Others', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More', 'Megestrol acetate, Progesterone, Estradiol, Megestrol acetate, Estetrol, Ulipristal, Estradiol', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67563/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[8] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[11] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[12] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[13] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[14] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[15] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[16] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[17] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[18] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[19] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[20] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[21] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[22] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[23] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[24] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[25] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[26] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[29] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[30] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[31] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[32] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[33] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[34] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[35] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[36] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[37] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[38] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[39] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[40] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67477, 'Cladribine', 'Obinutuzumab', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67564/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67478, 'Cladribine', 'Ocrelizumab', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67565/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67479, 'Cladribine', 'Ofatumumab', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67566/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67480, 'Cladribine', 'Olaparib', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More', 'Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67567/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67481, 'Cladribine', 'Olaratumab', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67568/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67482, 'Cladribine', 'Omacetaxine mepesuccinate', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67569/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67483, 'Cladribine', 'Osimertinib', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67570/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67484, 'Cladribine', 'Oxaliplatin', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More', 'Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67571/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67485, 'Cladribine', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', NULL, 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', NULL, 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Apremilast, Pirfenidone, Belumosudil, Ozanimod, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67572/', '[1] "Product Information. Zeposia (ozanimod)." Celgene Corporation, Summit, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Zeposia (ozanimod)." Celgene Corporation, Summit, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67486, 'Cladribine', 'Paclitaxel (protein-bound)', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67573/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67487, 'Cladribine', 'Palbociclib', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', 'Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67574/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67488, 'Cladribine', 'Palifermin', 'Moderate', 'INTERVAL: In a clinical trial, administration of palifermin within 24 hours of chemotherapy resulted in increased severity and duration of oral mucositis, presumably due to increased sensitivity of the rapidly dividing epithelial cells in the immediate post-chemotherapy period.', NULL, 'Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.', NULL, 'Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.', 'Others', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67575/', '[1] "Product Information. Kepivance (palifermin)." Shire US Inc, Florence, KY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67489, 'Cladribine', 'Panobinostat', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More', 'Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67576/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67490, 'Cladribine', 'Paramethadione', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67577/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67491, 'Cladribine', 'Pazopanib', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67578/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67492, 'Cladribine', 'Pegfilgrastim', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67579/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67493, 'Cladribine', 'Peginterferon alfa-2a', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67580/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67494, 'Cladribine', 'Peginterferon alfa-2b', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67581/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67495, 'Cladribine', 'Peginterferon beta-1a', 'Moderate', 'The use of cladribine with beta interferons may increase the risk of lymphopenia. The mechanism involves additive risk of lymphopenia.', NULL, 'Concomitant use of cladribine and beta interferons is not recommended.', NULL, 'Concomitant use of cladribine and beta interferons is not recommended.', 'Synergism', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Upadacitinib, Anakinra, More', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67582/', '[1] Montalban X, Leist TP, Cohen BA, et.al "Cladribine tablets added to IFN- in active relapsing MS: The ONWARD study." Neurol Neruroimmunol Neuroinflamm 11 (2018): e477[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67496, 'Cladribine', 'Pemetrexed', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More', 'Cladribine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67583/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67497, 'Cladribine', 'Penicillamine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Golimumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, Abatacept, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67584/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67498, 'Cladribine', 'Pentamidine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Miltefosine, Nifurtimox, Benznidazole', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67585/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67499, 'Cladribine', 'Pentostatin', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', 'Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67586/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (67500, 'Cladribine', 'Phenylbutazone', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Golimumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More', 'Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, Glucosamine, Oxaprozin, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/67587/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
